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Summary 
Background- Coronary artery disease (CAD) is one of the leading causes of death in 
affluent societies. Atherosclerosis, which is the pathological basis of CAD, is now 
regarded as a chronic inflammatory disease of the vascular wall. Many inflammatory 
proteins are elevated in CAD and correlated with future coronary events.
 
One of such 
inflammatory proteins is serum amyloid A (SAA). SAA is well known as an acute 
phase protein and as a useful biomarker of CAD. However, its direct role in 
atherogenesis is obscure. This study investigated the impact of SAA on the gene 
expression profile in human endothelial cells and focused on the genes that are of 
potential clinical relevance. The likely signaling pathways which mediate SAA 
effects were also examined.  
Methods and Results- Using the microarray method, SAA was shown to have wide 
effects on gene expression profile in cultured human umbilical vein endothelial cells 
(HUVECs), including the genes involved in endothelial proinflammation, dysfunction, 
procoagulation and plaque instability. These genes were further studied in HUVECs 
and human coronary artery endothelial cells (HCAECs) for their mRNA, protein and 
activity levels. Firstly, SAA was found to cause endothelial proinflammation by 
markedly inducing expression of cellular adhesion molecules (CAMs). Furthermore, 
SAA-dependent CAM induction was mediated through nuclear translocation and 
activation of NFκB. Secondly, SAA was shown to lead to endothelial dysfunction by 
significantly inhibiting the expression and bioactivity of endothelial nitric oxide 
synthase (eNOS). The nitric oxide (NO) production and NO-mediated cell 
proliferation were correspondingly impaired. Thirdly, SAA was found to disturb the 
 vi 
balance of tissue factor (TF) and tissue factor pathway inhibitor (TFPI) expression 
and activity in human endothelial cells. The inducing effect of SAA on TF was faster 
acting (4-8 h), while its inhibitory effect on TFPI required a longer exposure (24-48 
h). The SAA-dependent TF induction was mediated through mitogen-activated 
protein (MAP) kinase pathway. Finally, SAA was demonstrated to exert very 
significant effect on the expression and activation of matrix metalloproteinase-10 
(MMP-10) and the induction lasted for at least 48 h. Because SAA also led to 
inflammatory cyclooxygenase-2 (COX-2) induction, a COX-2 inhibitor celecoxib 
was applied to inhibit such inflammatory response. Interestingly, celecoxib has been 
shown to suppress not only the SAA-induced prostaglandin E2 (PGE2) production but 
also the SAA-induced MMP-10 secretion. 
Conclusions- This study investigated the direct impact of SAA on atherosclerosis. 
SAA led to endothelial proinflammation, dysfunction, procoagulation and MMP 
induction in cultured human endothelial cells. These findings may pave the way for 
future studies to elucidate the novel mechanism of how the inflammatory protein 
SAA plays an important role in atherosclerosis. This may also lead to SAA being a 
potential novel target for the prevention and therapy of CAD.  
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Coronary artery disease (CAD) is the leading cause of death in affluent societies. 
Atherosclerosis, characterized as accumulation of lipids in vascular wall, is the 
pathological basis of CAD. To better manage and treat atherosclerosis, it is 
imperative that the process of atherogenesis be well understood. Over the years, 
studies have shown that inflammatory factors are involved in all stages of 
atherogenesis, and hence, atherosclerosis is now regarded as a chronic inflammatory 
disease and not merely due to dysfunctional lipid metabolism. We believe that Serum 
Amyloid A (SAA), which is a highly conserved inflammatory protein, may directly 
contribute to atherogenesis.  
 
1.1 Overview of Atherosclerosis 
1.1.1 Development of views on atherosclerosis 
For a while, atherosclerosis is defined as a progressive disease with the accumulation 
of lipids and fibrous elements in the middle to large arteries. Before the 1970s, lipids 
were considered as a dominant factor contributing to atherosclerosis and this was 
corroborated by both clinical trials and experimental data. In essence, clinical trials 
showed a strong link between hypercholesterolemia or hyperlipidemia and CAD. 
Animal experiments have also proven that high-fat diets lead to atherosclerosis in 
rabbits or mice.  With the rapid development of vascular biology in the 1970s and 
1980s, growth factors and the proliferation of smooth muscle cells (SMCs) were 
found to play important roles in atherosclerosis. Smooth muscle cells were found to 
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proliferate in atherosclerotic lesion (atheroma) under microscopy and the clinical 
problem of restenosis following arterial intervention was found to be caused by 
uncontrolled vascular growth. A fusion of the above views led to the ‘response-to-
injury’ theory, which seeks to explain the fibroproliferation of the vascular wall after 
initial lipid invasion.
1
    
    More recently, a prominent role of inflammation was discovered for atherosclerosis 
and its complications.
 2-4
 Atherosclerosis is not merely a disease due to excessive lipid 
deposition but inflammation and immune response were found at the atherosclerotic 
site. In vitro and in vivo studies showed that effectors of the immune system are 
involved directly in all stages of atherogenesis, from endothelial dysfunction to the 
final focal necrosis and fibrous cap rapture which leads to acute clinical events. More 
specifically, inflammatory factors initially trigger endothelial dysfunction. Once the 
vessels are impaired by lipids, smoking, free radicals, and diabetes, they highly 
express cytokines and adhesion molecules and enter into a “proinflammatory” state, 
which is ready for recruitment of leukocytes. Simultaneously, the endothelium loses 
its function to dilate and constrict normally because of a resulting impaired nitric 
oxide (NO) production. Nitric oxide is a key endothelium-derived relaxing factor 
(EDRF) which promotes vasodilatation. With the progression of atherosclerosis, 
SMCs proliferate under the stimulation of growth factors and cytokines. Finally, 
severe thrombosis and plaque rupture are notable complications of advanced lesions 
that lead to deadly, unstable coronary artery syndromes or acute myocardial infarction. 
Mural thrombosis is also ubiquitous in the initiation and the progression of 
atherogenesis. Thrombosis is basically caused by a hypercoagulable state or the 
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unbalance of coagulation and fibrinolysis, including the induction of tissue factor (TF) 
and the inhibition of tissue factor pathway inhibitor (TFPI). Plaque rupture is 
commonly caused by degradation of the fibrous cap at the thinnest shoulders of the 
lesion.  
1.1.2 Inflammatory factors in atherosclerosis 
In the past decades, an increasing number of inflammatory factors were revealed to 
play a role in atherogenesis.
1
 The effectors of the immune system are involved 
directly in all stages of atherogenesis.
 2
 The earliest changes that precede the 
formation of atheroma take place in the endothelium, leading to endothelial 
dysfunction. The endothelial permeability is increased, which is mediated by NO, 
prostacyclin, platelet-derived growth factor (PDGF), angiotensin II, and endothelin. 
The leukocyte adhesion molecules are upregulated, including L-selectin, integrins, 
and platelet–endothelial-cell adhesion molecule 1 (PECAM-1). The endothelium-
derived cellular adhesion molecules (CAMs) are also upregulated, which include 
endothelial cell-derived selectin (E-selectin), intercellular adhesion molecule 1 
(ICAM-1), and vascular-cell adhesion molecule 1 (VCAM-1). The leukocytes finally 
enter into the artery wall, which is mediated by oxidized low-density lipoprotein 
(oxidized LDL), monocyte chemotactic protein 1 (MCP-1), interleukin-8 (IL-8), 
PDGF, macrophage colony-stimulating factor (CSF), and osteopontin. Subsequently, 
the formation of fatty streaks begins, which consist of lipid-laden monocytes and 
macrophages (foam cells) together with T lymphocytes. Later they are joined by 
various numbers of SMCs. The steps involved in this process include smooth-muscle 
migration, T-cell activation, foam cell formation, and platelet adherence and 
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aggregation. The fatty streak formation is mediated by PDGF, fibroblast growth 
factor 2 (FGF-2), transforming growth factor betta (TGF-β), tumor necrosis factor α 
(TNFα), IL-1, IL-2, granulocyte–macrophage CSF, macrophage CSF, integrins, P-
selectin, fibrin, thromboxane A2 (TXA2) and TF. As fatty streaks progress to 
advanced lesions, they tend to form a fibrous cap that walls off the lesion from the 
lumen. The fibrous cap covers a necrotic core which is a mixture leukocytes, lipid, 
and debris. These lesions expand at their shoulders by means of continued leukocyte 
adhesion and entry caused by the same factors listed before. Finally, rupture of the 
fibrous cap can rapidly lead to thrombosis and occlusion of the artery. It usually  
 Table 1. A summary of the contributing factors to atherogenesis. Most materials are 
taken from “Atherosclerosis--an inflammatory disease” (Ross R. N Engl J Med. 
1999;340:115-26). 2  
Progress Characteristics Contributing factors 








Leukocytes entry into the 
artery wall 
NO, prostacyclin, PDGF, angiotensin 
II, endothelin 
 
Leukocyte adhesion molecules: L-








Smooth-muscle migration  
T-cell activation  
Foam cell formation  
Platelet adherence and 
aggregation 
PDGF, FGF-2, TGF-β, TNFα, IL-1, 
IL-2, granulocyte–macrophage CSF, 
macrophage CSF, integrins, P-





adhesion and entry 
CAMs, selectins, integrins, PDGF, 








Thinning or rupture of the 
fibrous cap 
matrix metalloproteinases (MMPs), 
other proteolytic enzymes 
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occurs at sites of thinning of the fibrous cap. Thinning of the fibrous cap is apparently 
due to matrix metalloproteinases (MMPs) and other proteolytic enzymes released 
from vaso-related cells at these sites. These enzymes can cause matrix degradation 
and plaque rupture, and eventually result in acute coronary events. The contributing 
factors in atherogenesis are summarized in Table 1.   In the past decades, histological 
studies have shown immune cells accumulating in the atherosclerotic lesions, 
including mononuclear phagocytes, lymphocytes and mast cells. Inflammatory 
proteins, such as cytokines, chemokines, adhesion molecules, and acute phase 
proteins have been found to be highly expressed in atheroma as well. In addition, 
many inflammatory proteins have also been shown to be elevated in CAD.5 The 
Women’s Health Study showed that 4 inflammatory markers, C-reactive protein 
(CRP), serum amyloid a (SAA), interleukin-6 (IL-6) and ICAM-1, were significant 
predictors of CAD risk.
 6,7
Among them, CRP and SAA were the strongest predictors 
of CAD risk. Interestingly, both CRP and SAA are major acute phase proteins which 
can be induced 100-1000 folds under acute inflammation stimuli.  
    Emerging clinical data have shifted the emphasis of research by investigators 
considerably. In vitro studies have shown that CRP activates the entire recruitment 
cascade of white blood cells via inducing the release of ICAM-1, VCAM-1, selectin 
E, and MCP-1.
 8,9
 In such a case, the endothelium enters into a “proinflammatory” 
state and initiates atherogenesis. In another study, CRP was implicated in endothelial 
dysfunction, characterized by impaired NO production and vasoreactivity.
 10
 In 
addition, CRP could also induce TF expression which is the key molecule in the 
coagulation cascade.
 11
 Furthermore, CRP was recently reported to induce matrix 
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MMP-1 and MMP-10 causing plaque instability.
 12
 To date, CRP is accepted as a 
direct risk factor of CAD because of its wide effects on atherogenesis. As another 
acute phase protein, SAA shares many characters with CRP. Both of them could be 
highly induced under inflammatory stimuli and in acute myocardial infarction (AMI) 
patients.
6
  However, compared to CRP, SAA is much less studied, especially its direct 
effects on atherogenesis.  
 
1.2 Overview of SAA 
1.2.1 Biological characters of SAA 
SAA is a major acute phase protein that is produced following inflammatory stimuli 
in vertebrates. 13 An acute phase protein is defined as one whose plasma concentration 
increases or decreases by at least 25 percent during inflammatory disorders.
 14
 The 
two major human acute phase proteins are CRP and SAA. The genes and proteins of 
SAA have high degree of conservation in various species, including human, mouse, 
rabbit, dog, cow, sheep, horse and even marsupials and fish.
 13
 All SAA genes 
described to date share an identical four-exon three-intron organization which is 
characteristic of many other apolipoproteins, such as apoA-I. Human SAA is a 12.5-
kDa protein whose levels increase up to 1,000- fold in the serum 24–36 hr after 
infection or injury, and decline after 4-5 days, and return to baseline after 10-14 days.
 
16
 At normal levels, SAA associates with high-density lipoprotein (HDL) forming a 
heterogeneous HDL fraction containing SAA and predominantly apoA-I. At elevated 
concentrations, SAA displaces apoA-I to bind HDL predominantly or exists in 
circulation as lipid-free form.
 13
 HDL itself is anti-inflammation. However, once it is 
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binding with SAA under acute inflammation, its an-inflammatory function could be 
reduced. 15 
1.2.2 A biomarker of atherosclerosis  
The characterization of SAA as both an inflammatory protein and an apolipoprotein 
generate increased interest in CAD research as both are involved in atherogenesis.  
Accumulating clinical evidence shows that SAA is associated with CAD. Elevated 
circulation SAA levels were found in unstable angina and AMI.
 16
 In 1994, the 
prognostic value of SAA protein was first examined.
 16
 The levels of CRP and SAA 
were ≥ 0.3 mg/dl (exceeding the 90th percentile of the normal distribution) in 4 of the 
patients with stable angina (13%), 20 of the patients with unstable angina (65%), and 
22 of the patients with AMI (76%). The 20 patients with unstable angina who had 
higher levels of CRP and SAA had more ischemic episodes in the hospital than those 
with lower levels (4.8 +/- 2.5 vs. 1.8 +/- 2.4; P = 0.004). Among the patients admitted 
with AMI, unstable angina preceded infarction in 14 of the 22 patients (64%) with 
higher levels of CRP and SAA but in none of the 7 patients with lower levels.
 16
 SAA 
was also found to be a significant predictor of CAD risk and future coronary events in 
a prospective case–control study among 28,263 apparently healthy postmenopausal 
women over a mean follow-up period of three years. 6 They found that the relative 
risk of events for women in the highest as compared with the lowest quartile for this 
marker was 3.0 (95 percent confidence interval (CI), 1.5–6.0). In the 2004 WISE 
study, a total of 705 women referred for coronary angiography for suspected 
myocardial ischemia underwent plasma assays for SAA and CRP. SAA levels were 
independently associated with angiographic CAD (P=0.004) and highly predictive of 
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3-year cardiovascular events (death, myocardial infarction, congestive heart failure, 
stroke, and other vascular events) (P<0.0001). 17 From the WISE study, 580 women 
with fasting plasma samples of inflammatory markers (IL-6, CRP and SAA) were 
further analyzed as a “proinflammation” factor (cluster) over a median of 4.7 years 
follow-up. Quartile increases of the "proinflammation" cluster (IL-6, CRP, and SAA) 
yielded death rates of 2.6%, 7.2%, 13.1%, 26.6%, respectively (P < .0001). Women 
with ≥ 2 of 3 proinflammation markers in the upper quartile had an adjusted relative 
risk of death of 4.21 (95% CI 1.91-9.25). The risk of combined markers was higher 
than any single marker alone, all of which were roughly equally predictive. 
18
 The 
prognostic value of SAA in patients with stable CAD was also investigated in 2004. 
A prospective cohort study was conducted in 140 consecutive patients with stable 
CAD who had at least one coronary stenosis more than 50% in diameter confirmed by 
diagnostic coronary angiography (CAG).
 19
 They found that SAA/LDL complex (10 
µg/ml) (OR = 2.32, CI: 1.05-4.70) was independently related to the end events 
(cardiac death, AMI, cerebral infarction, and coronary revascularization) and the 
SAA/LDL complex was derived by oxidative interaction between SAA and 
lipoproteins. 19 In 2005, a Japanese group investigated the association between 
coronary sequelae late after Kawasaki disease (KD) and inflammatory markers. 20 
Their cross-sectional study supported the association between the persistence of 
coronary artery lesions and the levels of CRP and SAA.  In 2006, a cohort study of 
1117 consecutive patients (797 men and 320 women) recruited between 1993 and 
1995 was finished.
 21
 Comparison of living and deceased groups indicated that 
baseline levels of CRP, IL-6, SAA and homocysteine (Hcy) were elevated in the 
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deceased group (p < 0.001 in all cases). Patients who died of cardiovascular causes 
had higher levels of CRP, SAA, IL-6 and Hcy. Patients in the highest quartiles for IL-
6, SAA, CRP and Hcy levels had a significantly increased risk of death (2.01–2.57) 
compared with those in the lowest quartile with significant trends across quartiles.
 21
 
These clinical evidences suggest the potential of SAA as a biomarker of 
atherosclerosis and a determining factor in atherogenesis. Moreover, one group also 
investigated the association between SAA and endothelial dysfunction as indicated by 
reduced NO formation in 2003.
 22
 They found that the extent and severity of 
atherosclerosis of left coronary arteries correlated with the percentage changes of NO 
(r = -0.35, p < 0.05) and that of SAA (r = 0.43, p < 0.05) across coronary circulation, 
but not with changes in CRP. Moreover, the percentage changes of NO correlated 
with that of SAA (r = -0.36, p < 0.05). Their results indicated that the severity and 
extent of coronary atherosclerosis related to the degree of local inflammation which 
has a possible association with coronary endothelial dysfunction. 
1.2.3 Regulation of SAA expression 
SAA elevated in human atherosclerotic lesion  
Many laboratory experiments were carried out from 1990s following the hypothesis 
of SAA on atherosclerosis.  As with other acute-phase reactants, SAA is remarkably 
produced by the liver and released into the circulation under stimuli from IL-6, TNF 
and others. However, SAA is also expressed and accumulated in cells within human 
atherosclerotic lesions, including macrophages, macrophage-derived “foam cells,” 
adipocytes, endothelial cells, and smooth muscle cells.
 23
 In 1994, human 
atherosclerotic lesions of coronary and carotid arteries were examined for expression 
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of SAA mRNA by in situ hybridization.
 23
 SAA mRNA was found in most 
endothelial cells and some smooth muscle cells as well as macrophage-derived "foam 
cells," adventitial macrophages, and adipocytes. In addition, cultured smooth muscle 
cells expressed SAA mRNAs when treated with IL-1 or IL-6 in the presence of 
dexamethasone. In 2005, SAA expression was found elevated at the site of ruptured 
plaque in AMI patients.
 24 
Maier et al investigated the local and systemic levels of 
SAA in ruptured plaque in 42 patients with AMI.
 24
 In blood surrounding ruptured 
plaques, local levels of  SAA (24.3 mg/L; IQR, 16.3 to 44.0 mg/L) were significantly 
higher than at the systemic level (22.1 mg/L; 13.9 to 27.0 mg/L, P<0.0001). 
Harvested thrombus showed both extra- and intra- cellular positive staining for SAA. 
These results demonstrate that SAA is expressed and accumulated at the site of 
atheroma but not normal endothelium; this implies that SAA might have a role in 
atherogenesis. In 2006, Yang et al also reported that SAA was a proinflammatory 
adipokine in humans.
 25
 They found that SAA was highly and selectively expressed in 
human adipocytes. SAA mRNA levels and SAA secretion from adipose tissue were 
significantly correlated with body mass index (r = 0.47; p = 0.028 and r = 0.80; p = 
0.0002, respectively). They suggested that SAA could be the molecule that link 
obesity to chronic inflammation and CAD. 
SAA is induced by high-fat diets and reduced by anti-atherogenesis agents 
Recently, more and more evidences support the involvement of SAA in atherogenesis. 
A high-cholesterol diet, which is a traditional CAD risk factor, increases circulating 
SAA levels in mice associated with increased atherosclerosis, as well as in human 
beings.
 
Lewis et al fed female LDL-receptor–null (LDLR-/-) mice with high-fat diet 
 11 
(21%, wt/wt) for 10 weeks and plasma SAA levels were observed to be elevated.
 26
  
The addition of cholesterol in the diet further increased SAA levels by 2-fold. They 
also observed that plasma SAA levels correlated significantly with the extent of 
atherosclerosis at the aortic arch. Moreover, SAA levels obtained after 5 weeks on 
diet correlated significantly with 10-week lesion areas at the aortic sinus. Their results 
demonstrated that SAA levels could predict the extent of atherosclerosis in LDLR-/- 
mice and that SAA might be involved in lesion development.
 26
 In 2005, Tannock et 
al. compared CRP, SAA and lipoprotein levels in 201 healthy subjects on an 
American Heart Association-National Cholesterol Education Program step 1 diet at 
baseline and after addition of 4 eggs per day for 4 weeks. 27 Subjects were classified a 
priori into 3 groups: lean insulin sensitive (LIS), lean insulin resistant (LIR), or obese 
insulin resistant (OIR). Insulin resistance and obesity each were associated with 
increased baseline levels of both CRP (P <0.001) and SAA (P = 0.015). Egg feeding 
was associated with significant increases in both CRP and SAA in the LIS group 
(both P<0.01) but not in the LIR or OIR groups. Thus, a high-cholesterol diet leads to 
significant increases in SAA levels in LIS individuals. Taken together, these results 
hint on a possible new mechanism to explain atherogenesis, one that involves SAA. 
In brief, SAA might be the bridge between lipids and atherosclerosis. Other than its 
deposition on vascular wall, lipids may trigger SAA expression which leads to 
atherosclerosis. 
    Moreover, some protectors of cardiovascular system have been found to reduce 
SAA levels in mice and human beings. The 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase (HMGCR) inhibitor or statin is commonly used in medical practice to lower 
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cholesterol levels. Recently it has been reported to have anti-inflammatory effect 
beyond lipid-lowering effect. In the Myocardial Ischemia Reduction with Aggressive 
Cholesterol Lowering (MIRACL) study, 2402 subjects with unstable angina or non-
Q-wave myocardial infarction were randomized to atorvastatin 80 mg/d or placebo 
within 24 to 96 hours of hospital admission and treated for 16 weeks.
 28
 All 3 
inflammatory markers (CRP, SAA and IL-6) were markedly elevated at 
randomization and declined over the 16 weeks in both treatment groups. Compared 
with placebo, atorvastatin significantly reduced SAA -80% (95% CI, -82%, -78%) 
versus -77% (-79%, -75%) (P=0.0006). Reductions in CRP and SAA were observed 
in patients with unstable angina and non-Q-wave myocardial infarction. Hence, high-
dose atorvastatin promoted the decline in inflammation in patients with acute 
coronary syndromes.
 28
 In 2004, another study conducted in 515 patients with 
peripheral artery disease confirmed that patients receiving statin therapy (n=269, 52%) 
had a lower level of inflammation (CRP p<0.001, SAA p=0.001, fibrinogen p=0.007, 
albumin p<0.001, neutrophils p=0.049) and better survival (adjusted hazard ratio (HR) 
0.52, p=0.022) and event-free survival rates (adjusted HR 0.48, p=0.004) than 
patients without statin therapy. 29 Fish consumption has also been associated with 
reduced risk of coronary heart disease. In 2005, the ATTICA study, which enrolled 
1,514 men and 1,528 women, reported that those who consumed >300 g of fish per 
week had on average 28% lower SAA levels (p < 0.05) compared to non-fish 
consumers.
 30
 More recently, other protectors of cardiovascular system were also 
shown to lower circulating SAA levels, such as fenofibrate,
 31





 All these evidences suggested the possible 
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contribution of SAA to atherogenesis. It is thus important to investigate in depth the 
direct effects of SAA on vascular wall.  
1.2.4 Direct effects of SAA on vaso-related cells  
The above evidences imply that SAA may play a direct role in atherogenesis. Recent 
studies demonstrated some interesting functions of SAA on vaso-related cells, such as 
platelets, T lymphocytes, microphages,
 
neutrophils, SMCs and endothelial cells. On 
one hand, SAA has lipid-related functions; incorporation of SAA into HDL at 
concentrations equivalent to those found physiologically in moderate inflammation 
mediated a 1.5-fold increase in the binding of HDL to adherent peripheral blood 
mononuclear cells and an endothelial cell line, EA.hy.926. 34 SAA was also found to 
promote cholesterol efflux from lipid-loading macrophages via the ATP binding 
cassette transport system
35
 and mediated by Scavenger Receptor B-I (SR-BI).
 36
 SAA 
also inhibits cholesterol, phospholipids and triglyceride synthesis in rabbit aortic 
SMCs.
 37
 However, its lipid-related functions are still in debate. In 2005, Cai et al 
reported that SAA inhibited HDL binding and selective lipid uptake in Chinese 
hamster ovary cells (CHO) and the hepatocyte cell line, HepG2.
 38
 On the other hand, 
SAA may act as a cytokine and lead to vascular proinflammation on the facet of 
leukocytes. SAA was reported to induce TNF and IL-8 expression in neutrophils, as 
well as T lymphocyte migration and adhesion.
 39-41
 Xu et al showed that T cells 
pretreated with an optimal concentration of SAA exhibited enhanced adherence to 
human umbilical vein endothelial cell (HUVEC) monolayers.
 39
 The optimal 
concentrations of recombinant human SAA for the induction of T cell migration 
ranged from 0.8 to 4 µM (10 to 50 µg/ml), which was higher than the normal serum 
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level (<0.1 µM or 1.25 µg/ml) but well below the levels seen in inflammatory 
conditions (up to 80 µM or 1mg/ml). They also found that subcutaneous 
administration of a single 10 µg injection of SAA into mice caused the infiltration of 
human T lymphocytes at the injection sites by 4 h. In 2003, He et al found that SAA 
induced IL-8 secretion in neutrophils.
 40
 The induction of IL-8 by SAA involved both 
transcription and translation and mediated through the activation of nuclear factor 
kappa B (NFκB). In 2004, Hatanaka et al found that SAA stimulated the rapid 
expression and release of TNFα from cultured human blood neutrophils.
 41
 Monocytes 
also responded to SAA by releasing TNFα.
 41
 All these data suggested that SAA 
could modulate the inflammatory and immune responses, possibly contributing to 
vascular inflammation. The same group also demonstrated that the increased serum 
levels of SAA contributed to the sustained accumulation and activation of phagocytes 
from chronic granulomatous disease (CGD) patients.
 42
  
    To date, only a few of the SAA studies are focused on the endothelial cells (ECs), 
despite its important role in providing an anti-atherogenic barrier to protect vessels 
from harmful stimuli. Endothelial proinflammation and dysfunction lead to initiation 
of atherogenesis. To investigate the influence of SAA on atherogenesis, ECs should 
be the cell of choice. In 2006, Mullan et al reported that SAA induced ICAM-1, 
VCAM-1 and MMP-1 expression on human microvascular endothelial cells 
(HMVECs) and promoted peripheral blood mononuclear cell adhesion to HMVECs.
 
43
 They also found that SAA (10µg/ml) promoted the adhesion of peripheral blood 
mononuclear cells (PBMCs) to HMVECs. In addition, SAA at 10-50 µg/ml 
significantly increased endothelial cell tube formation. At 50-100 µg/ml, SAA 
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increased HMVEC migration. However, their study focused on rheumatoid arthritis 
(RA) and HMVECs are not used in atherosclerosis research because they are not 
derived from large vessels. For standard atherosclerosis research, human umbilical 
vein endothelial cells (HUVECs), human coronary artery endothelial cells (HCAECs), 
or human aortic endothelial cells (HAECs) should be used. Very recently, Yang et al 
found that SAA (0.47 and 2.34µg/ml) could induce IL-6, IL-8, TNFα, MCP-1 and 
plasminogen activator inhibitor-1 (PAI-1) in HCAECs. 
26 
However, they did not 
examine other inflammatory proteins, such as CAMs. Moreover, the previous studies 
of SAA effects were limited to a narrow range. Its lipid-related function has been 
studied in SMCs and macrophages but not in ECs; its proinflammatory function has 
been studied in vaso-related cells, including endothelial cells. However, even its 
proinflammtory function on ECs has not been systemically examined and only 
several inflammatory molecules have been found to be induced. Moreover, its other 
potential effects on endothelial dysfunction, coagulation, plaque instability or others 
have not been investigated at all.  
1.2.5 The mechanisms involved in SAA effects 
After some interesting effects of SAA were found in different cells, researchers are 
keen to finding its mechanism, including its intake by cells and the signaling 
transduction pathway involved.  
    As SAA is an apolipoprotein, the role of scavenger receptor B-I (SR-BI) in SAA 
intake has been well studied. SR-BI is an HDL receptor that mediates cellular uptake 
of cholesterol ester from HDL by a mechanism known as selective lipid uptake. In 
2005, SAA was reported as a substrate of CD36 and LIMPII Analogous-1 (CLA-1, 
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human orthologue of the SR-BI). 
44
 SAA was found to bind to CLA-1 and mediate 
IL-8 secretion in Hela cells. Flow cytometry experiments revealed a high increase of 
Alexa-488 SAA uptake in HeLa cells stably transfected with CLA-1. SAA was 
shown to directly bind to CLA-1 and co-internalize with transferrin to the endocytic 
recycling compartment which was a potential site of SAA metabolism. Alexa-488 
SAA uptake in the CLA-1-overexpressing HeLa cells and THP-1 monocyte cell line 
could be efficiently blocked by unlabeled SAA, HDL and other CLA-1 ligands. 
Meanwhile markedly enhanced phosphorylation of ERK1/2 and p38 were observed in 
cells stably transfected with CLA-1 cells following SAA stimulation when compared 
with mock transfected cells. The levels of the SAA-induced IL-8 secretion by CLA-1-
overexpressing cells also significantly exceeded those detected for control cells. 
Synthetic amphipathic peptides possessing a structural alpha-helical motif inhibited 
SAA-induced activation of both mitogen-activated protein kinases (MAPKs) and IL-8 
secretion in THP-1 cells. The results demonstrated that CLA-1 functioned as an 
endocytic SAA receptor and was involved in SAA-mediated cell signaling events 
associated with the inflammatory effects of SAA. In the same year, another group 
also found that SAA, both in lipid-free form and in reconstituted HDL particles, 
functioned as a high affinity ligand for SR-BI in Chinese hamster ovary (CHO) cells 
expressing SR-BI.
 38
 SAA also bound with high affinity to the hepatocyte cell line, 
HepG2. Moreover, SAA’s presence on HDL decreased (30-50%) selective 
cholesteryl ester uptake. Lipid-free SAA was an effective inhibitor of both SR-BI-
dependent binding and selective cholesteryl ester uptake of HDL. Hence, SR-BI 
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should play a key role in SAA metabolism through its ability to interact with and 
internalize SAA.  
    As SAA is also an inflammatory protein, the mechanism of its cytokine-like effects 
has been investigated. In 2003, He et al found that SAA induced IL-8 secretion in 
neutrophils was mediated through the activation of NFκB.
 40
 The proximal signaling 
events induced by SAA also included mobilization of intracellular Ca(2+) and 
activation of the MAP kinase ERK1/2 and p38. A Gi-coupled receptor, formyl 
peptide receptor-like 1/lipoxin A4 receptor (FPRL1/LXA4R), was a receptor for 
SAA-induced IL-8 secretion. Pertussis toxin effectively blocked SAA-induced IL-8 
secretion indicating involvement of a Gi-coupled receptor. Overexpression of 
FPRL1/LXA4R in HeLa cells led to a significant increase of the expression of NFκB 
and IL-8 luciferase reporters by SAA, and an antibody against the N-terminal domain 
of FPRL1/LXA4R inhibited IL-8 secretion. Lipoxin A4, a specific substrate of 
FPRL1/LXA4R, competitively suppressed SAA-induced IL-8 secretion. All these 
results indicated that the cytokine-like property of SAA was mediated through the 
activation of the Gi-coupled FPRL1/LXA4R followed by activation of MAPK and 
NFκB pathway. In 2004, Hatanaka et al found that SAA stimulated TNFα expression 
in human blood neutrophils. 41 The SAA-stimulated secretion of TNFα was strongly 
suppressed by the addition of wortmannin (a PI3K inhibitor), PD98059 (an ERK1/2 
inhibitor) and SB203580 (a p38 inhibitor). Hence the induction was mediated through 
MAPK pathway. In 2005, SAA was also found to activate MAPK and AKT pathway 
and subsequent NFκB activation and IL-8 secretion in human and murine intestinal 
epithelial cells.
 45




 in human monocytes and PGE2 production in neutrophiles.
 47
 However, the 
signaling mechanism is less studied in endothelial cells. To date only limited studies 
investigated the signal transduction pathway in ECs. In 2006, Mullan et al reported 
that the SAA-induced expression of ICAM-1, VCAM-1 and MMP-1 was suppressed 
by NFκB inhibition with PDTC (150mM) in HMVECs.
 43
 Furthermore, SAA induced 
IkBα degradation and NFκB translocation. Their results suggested that the 
proinflammatory effects of SAA were mediated in part by NFκB signaling. Other 
signaling molecules such as MAP kinases have not been studied at all. In the same 
year, Lee et al found that SAA stimulated the proliferation, migration, and tube 
formation of HUVECs in vitro, and enhanced the sprouting activity ex vivo and 
neovascularization in vivo. 48 The activity of SAA appeared to be mediated by FPRL1, 
as it was mimicked by a specific ligand for FPRL1, the WKYMVm peptide. Their 
observations indicated that the binding of SAA to FPRL1 may contribute to 
angiogenesis in RA. However, the mechanism of SAA effects still needs more 
investigation, especially in ECs.  This study attempted to examine the signaling 
pathways that are involved in the effects of SAA on ECs. 
 
1.3 Microarray studies in atherosclerosis research 
1.3.1 Background of microarray technology  
DNA microarray analysis was first described in 1995 by a Stanford group as a means 
to monitor the expression of thousands of genes simultaneously.
49
 This powerful 
technology was quickly adopted by many researchers for the study of a wide range of 
biological processes.
 50-52
 In microarrays, thousands of probes are fixed to a surface, 
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and RNA samples are labeled with fluorescent dyes for hybridization. After 
hybridization, the fluorescent intensity is measured by a laser scanner. The signal 
intensity represents the relative amounts of the different transcripts. 51 Currently the 
popular platforms for microarray are Affymetrix, Illumina and Nimblegen.
 53
 Among 
them, Affymetrix platform is the most widely-used one. Affymetrix GeneChips 
contain probe sets that are built in situ on quartz wafers by light-directed synthesis. 
Photolithographic masks are used to either block or transmit light onto specific 
locations on the slide surface, and coupling of the light-sensitive nucleotides could 
only occur on illuminated regions.  Such process is repeated with different 
nucleotides and the probe sequence is synthesized after 25 cycles. With this powerful 
technology, a great number of probes can be synthesized simultaneously. Currently 
one single largest GeneChip contains more than 1.3 million probes. Normally, 22 
different oligo probes are grouped as one “probe set”, with 11 designed to have 
perfect match (PM) to the target transcript and another 11 mismatch (MM). This 
design enables the measurement of both nonspecific and specific signals in order to 
estimate the confidence of detecting the intensity reading of each target transcript. 
Illumina is a relative newcomer to the microarray field and their BeadChip is used for 
whole-genome expression profiling. In this array, each target transcript is only 
represented by one oligo probe which is repeated on average, 30 times. Nimblegen is 
also a newcomer to the field. Its technology is similar to Affymetrix except in the use 
of photolithographic masks. Instead, arrays of miniature mirrors, known as a digital 
micromirror device (DMD), is used to pattern a great number of individual pixels of 




1.3.2 Applications of microarray technology 
Microarray technology has led the way from studies of the individual biological 
functions of a few related genes, proteins or pathways towards global investigations 
of cellular activity. The development of this technology immediately yielded a lot of 
information, and has produced more data than can be currently dealt with. Basically, 
microarray technology has two major applications.
 55
 Firstly, it is used to identify 
biological markers (biomarkers) associated with diseases and with these information 
new subclasses in diseases can be classified. The biomarkers are in the form of gene 
expression patterns. This is very useful in cancer research since it could be used to 
classify types of tumors and predict the outcome and response to chemotherapy. 
Secondly, microarrays are also used to compare two biological classes in order to 
identify the differential expression pattern of the genes of potential relevance to a 
wide range of biological processes, such as the progression of cancer, the causes of 
asthma and the progression of heart disease.  
1.3.3 Microarray studies in atherosclerosis research 
Research on heart disease, especially on atherosclerosis, has a long history. Each time 
when a new technique emerged, exciting progresses in atherosclerosis research were 
made. In recent decades, no methodology has transformed experimental medicine 
more than microarrays.  
    Some researchers have tried to find the mechanism of atherogenesis by comparing 
the gene expression profiles between atherosclerotic lesions and normal tissue.
 56-58
 
The expression of lipid-related genes was investigated by Forcheron et al in 2005.
 57
 
They measured the expression of perilipin, adipophilin, and regulatory factors of 
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cholesterol metabolism in human atheroma and nearby macroscopically intact tissue 
(MIT). They identified perilipin A in human arterial wall, whose expression was 
largely increased in atheroma compared with MIT. Adipophilin, acyl-coenzyme 
A:cholesterol acyltransferase 1 (ACAT1), and CD36 were also overexpressed in the 
atheroma. Transcriptional levels of low-density lipoprotein receptor (LDLR), 
HMGCR, and sterol regulatory element binding factor-2 (SREBP-2) remained 
unchanged. Other studies found more interesting results, which were not limited to 
the lipid-related genes.  In 2003, Tuomisto et al compared the macrophage-rich 
shoulder area of atherosclerotic lesions with normal intima and THP macrophages. 
Upregulation of 72 genes was detected and included HMGCR, colony stimulating 
factor (CSF) receptors, CD11A/CD18 integrins and interleukin receptors. 56 In 2005, 
Lutgens et al performed microarray analysis on transcripts of aortic arch of 
apolipoprotein E-deficient (apoE
-/-
) mice fed normal chow or western-type diet for 3, 
4.5 and 6 months. 
58 
Time-dependent expression clustering and functional grouping of 
changed genes suggested important functions for genes involved in inflammation 
(especially the small inducible cytokines MCP-1, MCP-5, macrophage inflammatory 
proteins) and matrix degradation (cathepsin-S, MMP-2 and12). In the same year, 





 They found that NFκB-related genes (ICAM-1, 
VCAM-1 and TNFα, IL-2 etc) were induced in apoE
-/-
 mice compared to C57/B mice 
and flavonoid treatment could restore the changes. In addition, average expression of 
the other gene clusters (basic transcription factors, growth factor cytokines, cell 




and reduced by flavonoid treatment. These microarray studies suggested that some 
inflammatory genes were induced in atheroma and confirmed the relationship 
between inflammation and atherosclerosis. Therefore further studies should be carried 
out to investigate the mechanism of atherosclerosis under different stimulating 
conditions, especially inflammation.  
    More common are researchers who use microarray to screen the changed genes 




 and shear 
stress.
63,64
 Most of these studies have yielded interesting results and have shed new 
light on the cardiovascular research. For example, a well-known CAD risk factor, 
homocysteine, was reported to induce HMGCR in endothelial cells41 and induce 
TNFα, and TNFβ in coronary arteries. 62 The results showed that homocysteine could 
induce in situ cholesterol production and cause proinflammation. In contrast, steady 
shear is considered by many to be the most important stimulus for NO production in 
endothelial cells. Shear stress for 6 and 24 h was reported to inhibit the gene 
expression of connective tissue growth factor, endothelin-1, MCP-1, and 
spermidineyspermine N1-acetyltransferase.
 63
 The changes observed suggest several 
potential mechanisms for increased NO production under shear stress in endothelial 
cells. Shear stress also upregulated antioxidant and anti-inflammatory genes in both 
porcine aortic endothelial cells and porcine aortic valve endothelial cells, including 
peroxiredoxins, superoxide dismutase (SOD2), and cytochromes.
 64
 The above studies 
confirmed that microarray is a very useful method to monitor the global gene 
expression profile under different conditions. They also suggested that CAD risk 
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factors or protective factors could influence the genes involved in inflammation, 
oxide stress, vasoreactivity and lipid metabolism.   
    Since inflammatory factors are also risk factors of CAD, it is attractive to apply 
microarray in this research field. In recent years, the effects of some inflammatory 









 and myeloid-related proteins.
 68 
In 2004, Mayer et al examined the gene expression 
program of IL-stimulated HUVECs at 0, 0.5, 1, 2.5 and 6 h and found that 36 
transcription factors (26% of all regulated genes) were identified in this narrow time 
course.
 65
 They included some well-characterized
 
transcription factors that mediate 
the immediate-early response, such as JUN, FOS and EGR1. They also included 
some transcription factors that had not been described in ECs, such as BHLHB2, 
EGR4, TIEG, MAFF, and NFIB. They still included 5 downregulated transcription 
factors
 
(CBFA2T1, ELK3, MAF, MEF2C, NFIB) that were known to be involved in
 
proliferation or differentiation, suggesting a concerted repression
 
of these processes 
by IL-1. In the same year, Franscini et al found that 6 h of IL-1β, TNFα and 
interferon-γ treatment regulated a wide range of genes, including transcription factors 
(NFκB) and inflammatory genes (CAMs, IL-6, IL-8 and MCP-1) in HCAECs. 66 In 
addition, activated protein C (APC) downregulated the expression and activity of 
genes related to inflammation which were induced under intermediate or mild 
inflammatory conditions. In 2006, Montero et al also measured the expression of 
MMPs and tissue inhibitor of metalloproteinase (TIMPs) under CRP treatment in 
HUVECs. Microarray results demonstrated that the expression of MMP-1 and -10 
were significantly induced (p < 0.05). Although no microarray study has been 
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performed in SAA-treated cells, one recent publication by Viemann et al emerged 
while our study was on going, which reported similar findings as ours. They 
performed microarray study in HMVECs with or without stimulation by myeloid-
related protein 8 (MRP8) and MRP14.
 68
 Their data showed that MRP8/MRP14 
induced a thrombogenic, inflammatory response in HMVECs by increasing the 
transcription of procoagulation factor (thrombospondin-1) proinflammatory 
chemokines (IL-8) and adhesion molecules (ICAM-1, VCAM-1) and by decreasing 
the expression of cell junction proteins and molecules involved in monolayer integrity 
(Catenin-1, Cadhesin, etc.). MRP8/MRP14 is similar as SAA to be found in 
inflammatory fluids in distinct inflammatory conditions, such as rheumatoid arthritis. 
However, MRP8/MRP14 is not a major acute phase protein and has not been 
regarded as a biomarker of CAD.  
 
1.4 Endothelial proinflammation 
1.4.1 Endothelial proinflammation in atherosclerosis 
Ross proposed in 1999 that atherosclerosis is an inflammatory disease and 
inflammatory factors play key roles in atherogenesis. 2 The lesions of atherosclerosis 
occur principally in large and medium-sized elastic and muscular arteries. They may 
be present throughout a person’s lifetime. The earliest type of lesion, which is 
common in infants and young children, 
69
 is a pure inflammatory lesion without lipid 
deposition, consisting only of macrophages and T lymphocytes. 
70 
The immune cells 
and inflammatory proteins also contribute to the advanced process of atherogenesis, 
such as complicated lesion formation, thrombosis, and plaque rupture.  
 25 
    The entry of leukocytes into the artery wall is mediated by adhesion molecules and 
chemotactic factors. 3 The first step in adhesion, the ‘rolling’ of leukocytes along the 
endothelial surface, is mediated by selectins which bind to carbohydrate ligands on 
leukocytes. Studies of mice deficient in platelet- and endothelial cell- derived 
selectins (P- and E-selectins) or ICAM-1, revealed the role of these adhesion 
molecules in atherosclerosis.
 71,72
 P-Selectin, E-selectin or ICAM-1 deficiency was 
found to substantially protect against atherosclerosis in apolipoprotein E-deficient 
mice. 
72 
ICAM-1(-/-) mice had significantly less lesion area than their ICAM-1(+/+) 
littermates, P < 0.0001. An even greater reduction in lesion area was observed in P-
selectin(-/-) mice, P < 0.001. The reduction in lesion area for the E-selectin null mice, 
was also significant, P < 0.01. In a P- and E-selectin-double-deficient mouse model, 
the LDLR-/- P/E-/- mice developed fatty streaks in the aortic sinus that were five 
times smaller than those in LDLR-/- P/E+/+ mice at 8 wk on atherogenic diet.
 71
 After 
22 wk on the diet, the lesions spread throughout the aorta but this process was 
delayed in LDLR-/- P/E-/- mice. The results suggested that P- and E-selectins 
together play an important role in both early and advanced stages of atherogenesis. 
ICAM-1 and VCAM-1 are involved in sequential firm adhesion facilitated by 
interaction with lymphocyte function antigen-1 (LFA-1) and very late antigen-4 
(VLA-4) respectively.
 73,74
  Purified ICAM-1 is a LFA-1. LFA-1+ but not LFA-1- 
cells bound to ICAM-1, and the binding could be specifically inhibited by anti-
ICAM-1 treatment or by anti-LFA-1 treatment of the cells. VCAM-1 is a ligand for 
VLA-4. The firm adhesion of monocytes and T cells to endothelium can be mediated 
by the interaction of VCAM-1 and VLA-4 on these cells.
 75 
Blocking VLA-4 was 
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found to decrease leukocyte entry and fatty streak formation in mice fed an 
atherogenic diet. 75Finally, mice deficient in MCP-1 or its receptor chemokine (C-C 
motif) receptor-2 (CCR2) had significantly reduced atherosclerotic lesions, 




1.4.2 Markers of endothelial proinflammation 
The endothelium, with its intercellular tight junctional complexes, normally functions 
as a selectively permeable barrier between circulation and tissues. It enters into a 
proinflammatory state once it is trigged by different stimuli such as oxidized LDL, 
smoking, homocysteine and cytokines. In such a state, endothelium produces CAMs 
(ICAM-1, VCAM-1 and E-selectin) and chemotactic factors (MCP-1) and is ready for 
the recruitment of leukocytes. E-selectin mediates initial leukocyte tethering and 
rolling, while ICAM-1 and VCAM-1 mediate firm adhesion and trans-endothelial 
migration of leukocytes.
 1, 78 
E-selectin initially creates a weak bond between 
activated endothelial cell and carbohydrate ligands on the surface of the leukocytes.
 1
 
ICAM-1 and VCAM-1 are involved in sequential firm adhesion facilitated by 
interaction with LFA-1 and VLA-4 respectively. 73,74   
    The elevated expression of CAMs is a biomarker of endothelial proinflammation. 
An increasing number of studies have also suggested that CAMs are significant 
biomarkers and predictors of CAD risk.
 7,79,80
 In 1997, Hwang et al examined the 
circulating levels of VCAM-1, E-selectin and ICAM-1 in  204 patients with CAD, 
272 patients with carotid artery atherosclerosis (CAA), and 316 control subjects from 




levels of E-selectin and ICAM-1 were observed for the patients with CAD and those 
with CAA compared with the control subjects. Results of logistic regression analyses 
indicated that ICAM-1 and E-selectin were independent risk factors of CAD and was 
most pronounced in the highest quartile. In 1998, Ridker et al measured ICAM-1 
concentrations for 474 participants who developed a first myocardial infarction, and 
474 controls.
 80
 They found a significant association between increasing concentration 
of ICAM-1 and risk of future AMI (p = 0.003), especially among participants with 
baseline ICAM-1 concentrations in the highest quartile (> 260 ng/ml; relative risk 1.6 
[95% Cl 1.1-2.4], p = 0.02). In addition, the risk of AMI associated with raised 
concentrations of sICAM-1 seemed to increase with length of follow-up. Hence, 
elevated levels of CAMs are risk factors of CAD. 
1.4.3 Regulation of CAMs 
As CAMs contribute directly to atherogenesis, it is important to find their possible 
regulators. The factors that can influence CAMs could subsequently influence 











 and another acute 
phase protein CRP.8  In HUVECs, incubation with recombinant human CRP (10 
µg/ml) for 24 hours induced significant expression of ICAM-1 and VCAM-1, 
whereas a 6-hour incubation induced significant E-selectin expression.
 8
 The 
induction of CAMs was similar to that observed in IL-1β-stimulated ECs. In 
HCAECs, induction of ICAM-1 and VCAM-1 was already present at 5 µg/ml and 
reached a maximum at 50 µg/ml, at which point a substantial increase in expression 
of E-selectin was also evident. Very recently, SAA was found to induce ICAM-1 and 
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VCAM-1 expression on HMVECs and promote peripheral blood mononuclear cells 
adhesion to HMVECs. 43 Measured by flow cytometry, SAA (10µg/ml) induced a 40-
fold increase in the percentage of VCAM-1–positive cells from 1.6 ± 0.15% to 64.3 ± 
1.5% cells (P < 0.05). The median fluorescence intensity of ICAM-1 increased 6-fold 
from 12.1 ± 0.5 to 77.8 ± 5.6 (P < 0.05). However, the study focused on rheumatoid 
arthritis (RA) and used HMVECs.  These are not commonly used in atherosclerosis 
research because they are not derived from large vessels.  They also did not examine 
the third CAM, E-selectin.   
1.4.4 Signaling pathway involved in CAM expression 
The mechanism of CAM induction has been well studied. The induction is commonly 
caused by the activation of their transcription promoter. NFκB is the key molecule to 
regulate the transcription of CAMs.
 84-86
 NFκB was first identified as a regulator of 
the expression of the kappa light-chain gene in murine B lymphocytes 
87
 but has 
subsequently been found in many different cells. Several different NFκ B proteins 
have been characterized. 
88,89 
The activated form of NFκB is a heterodimer, which 
usually consists of two proteins, a p65 (also called relA) subunit and a p50 subunit. 
Other subunits, such as rel, relB, v-rel, and p52, may also be part of activated NFκ 
B, and it is likely that the different forms of NFκB may activate different sets of 
target genes. Normally NFκB forms a complex with IκB in cytoplasm, which 
prevents it from entering the nuclei. 
90 
Once it receives a stimulus, IκB starts to 
phosphorylate and degrades by proteasome. 
91,92
 Activated NFκB subunits are 
released from the complex, translocate to the nucleus and bind to relevant DNA 
sequence in the promoter regions to initiate expression of target genes.  
 29 
    NFκB is a central signaling molecule in inflammation.
 93
 With increasing evidences 
that atherosclerosis is a chronic inflammatory disease, NFκB is now considered a 
major transcription factor regulating many functions of the vessels.  Moreover, NFκB 
activation is thought to lie downstream of many stimuli proposed to be involved in 
atherosclerosis, such as modified lipoproteins, cytokines and infectious agents.
 94
 
Recent study reported that SAA activated NFκB and proinflammatory gene 




In 2006, Mullan et al reported that the SAA-induced expression of 
ICAM-1and VCAM-1 was suppressed by NFκB inhibition with PDTC (150mM).
 43 
Furthermore, SAA induced IkBα degradation and NFκB translocation. Their results 
suggested that the proinflammatory effects of SAA were mediated in part by NFκB 
signaling. However, it is unclear whether SAA could influence NFκB in endothelial 
cells derived from large vessels and therefore lead to CAMs expression. 
 
1.5 Endothelial dysfunction 
1.5.1 Endothelial dysfunction in atherosclerosis 
Endothelial dysfunction is the initial step of atherogenesis. Over the last two decades 
the endothelium has been found to not only be an inert, single-cell lining covering the 
internal surface of blood vessels, but also play a crucial role in regulating vascular 
tone and structure.
 95
 Importantly, a healthy endothelium inhibits leukocyte adhesion, 
prevents platelet aggregation, and maintains a balance of profibrinolytic and 
prothrombotic activity.
 1
 Risk factors of atherosclerosis, such as hypercholesterolemia, 
hypertension, diabetes, and smoking, are associated with endothelial dysfunction, 
 30 
leading to a proinflammatory and prothrombotic phenotype of the endothelium. The 
advanced understanding of the mechanism of atherogenesis suggests that these 
alterations of endothelial function may play an important role in the development and 
progression of atherosclerosis and its clinical complications.  
    Endothelial function has largely been assessed as endothelium-dependent 
vasoreactivity, based on the assumption that impaired endothelium-dependent 
vasodilation also reflects the alteration of other important functions of the 
endothelium. The impairment of endothelium-dependent relaxations is commonly 
characterized by the reduced bioavailability of NO produced from endothelial NO 
synthase (eNOS). 2 NO has a variety of functions, such as inhibiting leukocyte 
adhesion, limiting platelet adhesion and aggregation, and the expression of PAI-1, a 
prothrombotic protein. However, its action as the endothelium-derived relaxing factor 
(EDRF) is the most important for the maintenance of vascular tone and activity.
 
In the 
vessels, NO is derived from endothelium by constitutive expression of eNOS, which 
is activated by mechanical stress such as blood shear-stress and stimulation with 
agonists such as bradykinin and acetylcholine.  
    Accumulating data suggest that the degree of impairment of endothelium-
dependent vasoreactivity, marked as the reduced endothelial NO availability, has 
profound and independent prognostic implications.
 96-98
 Suwaidi et al monitored 157 
patients with mild CAD for an average of 28 months and observed coronary events 
only in the patients showing the lowest tertile of coronary responses to acetylcholine.
 
96
 Similarly, in a study of 147 patients, 3 different stimuli were used for endothelial 




a follow-up period of about 8 years, responses to each of these stimuli were shown to 
be independent predictors of coronary events. In an even larger study from the 
National Institutes of Health, Halcox et al monitored 308 patients and showed that 
both epicardial and microvascular coronary endothelium-dependent vasodilator 
function were independent predictors of coronary events.
 98
 
1.5.2 Markers of endothelial dysfunction and their regulation 
Atherosclerosis is associated with an impairment of endothelium-dependent 
relaxations, which is characterized by the reduced bioavailability of NO produced 
from eNOS.
 2
 Nitric oxide derived from eNOS is a key endothelium-derived relaxing 
factor which promotes vasodilatation. 99 Decreased production of NO or endothelial 
dysfunction has been found to occur in the early stage of atherogenesis and contribute 
to the whole process.
 99
 Impaired NO release could promote vasoconstriction, 
leukocyte recruitment, platelet aggregation, oxidation, thrombosis, and even vascular 
inflammation. Indeed, decreased NO production has been proved to be associated 
with future risk of adverse cardiovascular events.
 95
All major known risk factors for 








103 are associated with impaired NO production and vasoreactivity.  
    In the vessels, NO is derived from endothelium by constitutive expression of eNOS, 
which is activated by mechanical stress such as blood shear-stress and stimulation 
with agonists such as bradykinin and acetylcholine. eNOS is a remarkably complex 
enzyme which acts on molecular oxygen, arginine, and nicotinamide adenine 






studies of eNOS demonstrated that the T allele of at the eNOS G894T site (encoding 
Glu298→Asp) leads to endothelial dysfunction and is a major risk for CAD. 105,106  
    eNOS is the key enzyme of the NO production. eNOS expression and bioactivity 












and IL-6 were reported to inhibit eNOS gene promoter activity and its transcription 
sequentially.
 111,113
 TNFα effected a time- and dose-dependent reduction in activity of 
a transiently transfected human -1197 eNOS-luciferase reporter.
 111
 This reduction 
was mediated through the NFκB cascade. Two Sp1-binding sites were found to be 
involved in the transcription inhibition. The decrease in eNOS expression caused by 
IL-6 treatment was found to be partly caused by inhibition of activation of signal 
transducer and transactivator-3 (Stat3).
 113
 Stat3 was phosphorylated in response to 
IL-6 stimulation of the IL-6 receptor and bound to the eNOS promoter region. CRP 
was also found to cause a marked downregulation of eNOS mRNA and protein 
expression. 
10,112
 Actinomycin D studies suggested that eNOS downregulation was 
related to decreased mRNA stability.
 
Incubation of ECs with CRP resulted in a 
significant inhibition of basal and stimulated NO release, with concomitant reductions 
in cGMP production. 10 However, it is completely unknown whether SAA could lead 
directly to endothelial dysfunction via eNOS inhibition.  
1.5.3 NO and angiogenesis 
In addition to being the key molecule to maintain the vascular reactivity, NO has also 
been regarded as an important modulator of angiogenesis, including cell proliferation, 
cell migration and capillary-like tube formation.
 114
 Angiogenesis is a key 
 33 
compensatory mechanism in response to chronic ischemia and has emerged as an 
important therapeutic target for ischemic heart disease. NO inhibits apoptosis and 
enhances endothelial cell proliferation, perhaps in part by increasing the expression of 
vascular endothelial growth factor (VEGF)
 115,116
 or fibroblast growth factor (FGF).
 
117
 NOS inhibitors block VEGF- or FGF-induced EC proliferation and capillary-like 
tube formation.
 
The genetic loss of eNOS in mice (eNOS-/-) significantly impaired 
angiogenesis in the ischemic hindlimb evaluated by either laser Doppler flow analysis 
or capillary density measurement.
 118
 Furthermore, the deficiency of blood flow 
recovery and ischemic remodeling in eNOS-/- mice could be rescued by adenovirus 
delivery of eNOS gene. 119 Another acute phase protein CRP (25µg/ml) has been 
previously reported to inhibit both basal and VEGF-stimulated angiogenesis as 





1.6.1 Procoagulation in atherosclerosis 
The initiation of coagulation plays an important role in thrombus formation, which is 
the major cause of acute coronary events. 120-122 The coagulation cascade is initiated 
as soon as tissue factor (TF) binds activated factor VII (FVIIa), which in turn 
activates factor X (FX), and ultimately leading to thrombin formation.  The 
procoagulant state is crucial in the pathogenesis of acute coronary syndromes. 
123 
Elevated TF expression has been shown in all stages of atherosclerosis; whereas a 
very low basal level in normal site is maintained.
 124,125 
 In normal vessels, TF is 




Peripheral blood cells and endothelium do not express TF under normal conditions. 
However, in the response to a variety of stimuli, TF expression is induced in different 
cell-types, including ECs. 121Furthermore, elevated levels of TF antigen and activity 
have been detected in atheroma specimens of patients with unstable angina or MI.
 N42
 
Elevated plasma TF level has also been found to predict short-term outcome in 
patients with acute coronary syndromes (ACS). 
129
 Badimon et al investigated the 
role of TF on thrombogenicity of disrupted human atherosclerotic plaques and the 
disrupted plaques were found to be more thrombogenic than less advanced 
atherosclerotic plaques.
 130
 Recent studies had demonstrated that TF could be 
markedly induced by some CAD risk factors, such as cytokines (TNFα131 and CRP11), 
histamine, 132 smoking,133,134  diabetes, 134 and hyperlipidemia. 134In contrast, CAD 




 could reduce plasma TF levels. 
Sambola et al found that high levels of circulating TF was observed in patients with 
type 2 diabetes mellitus, smokers and untreated hyperlipidemic subjects.
 134
 Diabetes 
patients with improvement in glycemic control showed a reduction in circulating TF 
together with reduced blood thrombogenicity. TF was also increased 2 h after 
smoking 2 cigarettes. Hyperlipidemic subjects also showed higher TF levels than 
healthy volunteers. Rao et al found that baseline TF- procoagulant activity (TF-PCA) 
levels in the patients with peripheral arterial disease were elevated compared to 
control subjects (p < 0.0001) and was declined following anti-platelet treatment with 
clopidogrel, aspirin and cilostazol.
 135
 Thus, TF contributes to the initiation and 
propagation of acute coronary syndromes.   
 35 
    TF pathway inhibitor (TFPI) is a plasma Kunitz-type serine protease inhibitor, 
which binds TF/FVIIA complex directly and inhibits the coagulation process. 93 
Inhibition of TF by recombinant TFPI was reported to reduce acute thrombus 
formation in human lipid-rich plaque
130 
and in animal injured plaques.
138,139
 In 1999, 
the therapeutic possibilities of TF specific inhibition by TFPI was examined in 
disrupted human atherosclerotic plaques.
 130
 Such Specific inhibition of TF activity 
reduced plaque thrombogenicity, inhibiting both platelet and fibrin deposition and 
thrombosis. Treatment with TFPI was also found to abolish thrombus formation after 
porcine coronary angioplasty.
 138
 Recombinant TFPI alone inhibited thrombosis 
without bleeding complications and reduced neointimal formation. Conversely, native 
TFPI degradation after thrombolysis may enhance procoagulation and lead to early 
reocclusion after thrombolysis in myocardial infarction.
 140
 Ott et al found a 
significant decrease in surface TFPI-1 on circulating monocytes 24 hours after 
thrombolysis (P=0.006) that was not observed after stenting.
 140
 Circulating TFPI-1 
concentrations increased immediately after stenting, whereas decreased after 
thrombolysis. They also found that plasmin decreased TFPI-1 surface expression 
dose-dependently. Furthermore, adenoviral overexpression of TFPI in injured arteries 
inhibited recurrent thrombosis induced by shear stress without affecting systemic 
coagulation parameters.
141,142
 Compared to its function, the biological regulation of 
TFPI remains completely obscure. 
 
1.6.2 Regulation of coagulation system and the signaling pathway 









 and oxidized LDL.
 144 
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Despite their diversity, most of these mediators share similar signal transduction 
pathways regulating TF induction. The MAP kinases p38, p44/42 MAP kinase 
(ERK1/2) and c-jun terminal NH2 kinase (JNK) are involved in endothelial TF 







 The MAP kinases are phosphorylated and activated under stimuli. They 
transfer the signal to transcription factors such as AP-1, NFκB, EGR-1, c-Fos, and c-
Jun.
 146,147 
Once the transcription factors are activated and translocated to the nuclei, 
they bind to the TF promoter and induce the transcription of TF mRNA. Unlike 
MAPK, the PI3-kinase pathway negatively regulates endothelial TF expression. 
Inhibition of PI3-kinase or its downstream mediators increases TF expression after 
treatment of TNFα, 148 thrombin145 and VEGF. 149 In contrast, HDL was found to 
inhibit thrombin-induced endothelial TF expression through stimulation of PI3-kinase.
 
150
 The PI3-kinase inhibitors wortmannin or LY294002 reversed the inhibitory effect 
of HDL on TF expression.  
    At the cellular level, TF expression and activity are counterbalanced by TFPI. TFPI 
is produced constitutively by vascular endothelium to maintain its anti-coagulation 
function. The last decade has brought remarkable progress in our understanding of the 
molecular basis and the role of TFPI in hemostasis. Although the function of TFPI 
has been well determined in the past decade, its regulation is poorly understood to 
date.  Inflammatory factors are believed to regulate the expression and activity of 
TFPI because they have widespread effects on thrombosis, including the balance of 
coagulation and fibrinolysis. However, these TF inducers did not show clear and 
consistent impacts on TFPI.  Shimokawa et al found that high dose of  TNFα 
 37 
(50ng/ml) and LPS (10-100 µg/ml), but not IL-1 (10 U/ml), could significantly 
decreased murine TFPI mRNA level in MSS-31 endothelial cells after 2-8 h treatment, 
with their effects wearing off after 24 h.151  Piro et al reported that TNFα (0.5nM), IL-
1β (10U/ml) and LPS (5 µg/ml) had no effects on transcription, secretion and surface 
concentration of TFPI in ECV304 cells for 6-24 h.
 152
 Szotowski et al found that TFPI 
was decreased in cell lysate of HUVECs but increased in supernatant after 5 and 18 h 
treatment by TNFα (10ng/ml) or IL-6 (10ng/l) , suggesting TFPI was secreted out 
from cells into the supernatant.
 153
 However they did not measure the TFPI 
transcription and total protein production. Hence to date, the TFPI regulation by 
inflammatory factors remains obscure.  
 
1.7 MMPs 
1.7.1 MMPs in atherosclerosis 
    Matrix metalloproteinases (MMPs) are a family of zinc-dependent endopeptidases 
capable of degrading extracellular matrix (ECM) components such as collagens, 
laminin, fibronectin and other glycoproteins.
 154 
A broader spectrum and/or higher 
level of MMP activation, especially when associated with inflammation, could lead to 
pathological matrix destruction and plaque rupture, which eventually promotes 
coronary thrombosis and AMI. 
155
 In 2006, Choudhary et al investigated the spatial 
distribution of MMPs and TIMPs in carotid atherosclerotic lesions using 
multicontrast MRI.
 156
 They found that fatty streak, fibroatheroma with hemorrhage 
and calcification, and fully occluded lesions were enriched in MMP-2, MMP-9, and 
TIMP-1 and TIMP-2, respectively. Many studies have examined the association 
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between MMPs and atherosclerosis. MMP-2 was found to be associated with stable 
and MMP-8 and -9 with vulnerable carotid atherosclerotic lesions.157 Overexpression 
of MM-9 was demonstrated to promote intraplaque hemorrhage in advanced lesions 
but not at earlier stages of atherogenesis.
 158
 Macrophage expression of active MMP-9 
could induce acute plaque disruption in apoE-deficient mice.
 159
 Enhanced expression 
of MMP-9 was also found in apoE-null mice with hyperhomocysteinemia and was 
associated with increased atherosclerotic lesion area and complexity.
 160 
Polymorphism studies provide further evidences for the contribution of MMPs in 
atherosclerosis. A common functional polymorphism within the MMP-12 promoter 
was demonstrated to influence coronary artery luminal dimensions in diabetic patients 
with manifest coronary artery disease. 161 5A/5A genotype of MMP-3 was also found 




1.7.2 Regulation of MMPs 
MMPs are regulated by soluble cytokines and cell-cell interaction. Proinflammatory 
cytokines, such as tumor necrosis factor-α (TNFα) and interleukin-1β (IL-1β), could 
induce MMPs in both smooth muscle cells (SMCs) 
163
 and endothelial cells (ECs).
164
 
Oxidize LDL was also found to induce MMP expression.165 Recently, C-reactive 
protein (CRP) was also reported to induce MMP-1 and -10 in ECs. Increased CRP 




    As induced MMPs are usually associated with inflammation, it would be 
interesting to examine the effect of anti-inflammation therapy on MMPs.  One 
common anti-inflammation therapy is to selectively inhibit cycooxygenase-2 (COX-2) 
 39 
activity and its major product prostaglandin E2 (PGE2). Some studies also found that 
production of several MMPs (MMP-2 and -9) within atheroma were associated with 
the inducible COX-2 and were mediated through a PGE2-dependent pathway.
166,167  
Hence a widely-used COX-2 inhibitor, celecoxib, may be effective to prevent the 
MMP induction beyond its anti-inflammatory function. Although reports from 
clinical trials on the efficacy and effects of COX-2 inhibitors or coxibs are currently 
controversial, some clinical trials had demonstrated that administration of coxibs, 
such as celecoxib, may lead to an increased cardiovascular risk.
168,169
 On the other 
hand, a recent systematic review of observational studies of coxibs suggested that 
rofecoxib may increase the risk of cardiovascular events, whereas celecoxib does not. 
170 Interestingly, celecoxib treatment was found to significantly decrease MCP-1 
expression, neointimal hyperplasia and macrophage infiltration in rabbit 
atherosclerotic balloon injury model. 
171
 Some recent in vitro studies also examined 
the pleiotropic effects of celecoxib based on the inflammatory status induced by 
TNFα or IL-1β stimulation. Steffel et al demonstrated that 10µM of celecoxib could 
decreased TNFα-induced tissue factor (TF) expression and activity in human aortic 
endothelial cells, whereas rofecoxib and NS-398 had no effects. 131 Since MMPs play 
a role in atherosclerosis, the effects of celecoxib on MMPs have also been 
investigated. Celecoxib was reported to suppress the secretion of MMP-1, -2 and -9, 
which were induced by cytokines (TNFα and IL-1β) in rheumatoid fibroblast-like 
synoviocytes.
 172
 However, its effect on other MMPs remains unknown.  
    The inhibitory effect of celecoxib suggested that COX-2/PGE2 pathway may 
regulate the MMP-10 expression.  Higher expression of COX-2, PGEs, and MMPs 
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were found in symptomatic atherosclerotic lesions, especially at the plaque shoulder. 
166 The -765 G→C polymorphism of COX-2 gene was reported to have led to lower 
expression of COX-2 and MMPs. 173  The same study also found association of the 
polymorphism with a decreased risk of myocardial infarction and stroke.  Moreover, 
Cipollone et al demonstrated that direct treatment of PGE2 (0.1µM) could induce 




 from human 
atherosclerotic plaque. However, the direct effect of PGE2 on ECs remains unknown. 
1.7.3 MMP-10 
MMP-10 has not been as well-studied as MMP-2, -3 and -9.
 176
  However, recent 
studies have demonstrated that MMP-10 is similarly associated with vascular disease 
and has important functions as other MMPs. MMP-10 (or stromelysin-2) has a wide 
substrate repertoire, which includes most of the ECM proteins and proteoglycans 
except intact fibrillar collagens.
 155
 Elevated MMP-10 levels were reported in subjects 
with higher carotid intima-media thickness (IMT), 
12 
and were associated with 
inflammatory markers (fibrinogen and CRP). Recently MMP-10 was reported to 
activate MMP-1 and accelerate capillary tubular network collapse and regression of 
ECs in vitro. 177 Another study examined the cardiovascular abnormalities in histone 
deacetylase 7 (HDAC7) mutant mice and suggested that their impaired vascular 
integrity was caused by overexpression of MMP-10. 
178
 These findings suggested that 
MMP-10 may contribute to vascular diseases such as atherosclerosis.
 
Although the 
regulation of MMP-10 is not clear to date, some studies revealed that MMP-10 could 
also be induced by TNFα and ILs.
 179
 Recently, Montero et al found that CRP, 
 41 
another acute phase protein, could induce MMP-10 expression and activity in human 
ECs. 12 However, the effect of SAA on MMP-10 has not been investigated.  
 
 42 
1.8 Research objectives and significances 
Many results from both laboratory experiments and clinical trials have demonstrated 
that SAA may play a direct role in atherosclerosis. However, to date the primary role 
of SAA remains unclear. Based on the multiple effects of inflammation and lipid on 
atherosclerosis, it is reasonable to speculate that SAA could have diverse effects on 
endothelial cells, such as endothelial proinflammation, dysfunction, procoagulation, 
plaque instability or even lipid synthesis and transport. Since some studies have 
shown that SAA could induce the expression of some vascular proinflammatory 
molecules, it will be insightful to screen the global expression profile by means of 
DNA microarray. With the application of microarray, we can obtain an overview of 
the impact of SAA on human ECs to shed new light on the mechanism of 
atherogenesis. The present project attempts to investigate the global effects of SAA 
on ECs and their clinical significances. The signal transduction pathways involved in 
its function are also examined. 
    The aims of this thesis are: 
1) to monitor the effects of SAA on gene expression profile in HUVECs; 
2) to examine the effects of SAA on endothelial proinflammation in human ECs and 
its mechanism;  
3) to determine the effects of SAA on eNOS expression and NO production in human 
endothelial cells; 
4) to determine the effects of SAA on expression and activity of a pair of coagulation-
related genes, TF and TFPI, as well as the signal transduction pathway; 
5) to find the impact of SAA on MMPs and the additional impact of celecoxib.  
 43 
    The findings from this study should confirm the impact of inflammation on 
atherosclerosis and shed light on new mechanisms of atherosclerosis which SAA may 
be involved in. It might even lead to  the identification of SAA as  a potential novel 
treatment target for CAD or the prevention of CAD through SAA-lowering treatment.  
    This study examines the direct in vitro impact of SAA on atherogenesis from the 
different facets of endothelial functions. As the growth environment of cultured cells 
is very different from in vivo conditions, it is acknowledged that the effects of SAA 
on blood vessels in vivo will require more investigations. Clinical studies as well as in 
vivo studies in a suitable animal model should be completed to ascertain the 
relationship between SAA-lowering treatment and its impact on CAD. In order to 
attain the objectives of this project, a series of studies were carried out. These are 
described in Chapter 2-6.   
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Chapter 2 
Study I – The effects of SAA on gene expression profile in human 
endothelial cells 
DNA microarray analysis was first described in 1995 by a Stanford group as a means 
to monitor the expression of thousands of genes simultaneously.
49
 This powerful 
technology was quickly adopted by many researchers for the study of a wide range of 
biological processes.
 50-52
 In microarrays, thousands of probes are fixed to a surface, 
and RNA samples are labeled with fluorescent dyes for hybridization. After 
hybridization, the fluorescent intensity is measured by a laser scanner. The signal 
intensity represents the relative amounts of the different transcripts. 51 Microarray 
technology has led the way from studies of the individual biological functions of a 
few related genes, proteins or pathways towards global investigations of cellular 
activity. The development of this technology immediately yielded a lot of information, 
and has produced more data than can be currently dealt with. Basically, microarray 
technology has two major applications.
 55
 Firstly, it is used to identify biological 
markers (biomarkers) associated with diseases and with these information, new 
subclasses in diseases can be classified. This is very useful in cancer research since it 
could be used to classify types of tumors and predict the outcome and response to 
chemotherapy. Secondly, microarrays are also used to compare two biological classes 
in order to identify the differential expression pattern of the genes of potential 
relevance to a wide range of biological processes, such as the progression of cancer, 
the causes of asthma and the progression of heart disease. Research on heart disease, 
especially on atherosclerosis, has a long history. Each time when a new technique 
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emerged, exciting progresses in atherosclerosis research were made. In recent decades, 
no methodology has transformed experimental medicine more than what microarrays 
could achieve. Some researchers have attempted to find the mechanism of 
atherogenesis by comparing the gene expression profiles between atherosclerotic 
lesions and normal tissue.
 56-58
 More common are researchers who use microarray to 


















 Most of these studies have yielded interesting results and have 
shed new light on the pathology of atherosclerosis. It is therefore not unexpected that 
an increasing number of researchers are adopting this powerful technology as their 
major research tool or as a basic screening tool to spawn leads for further studies.  
    CAD is a complex disease and its pathological basis, atherosclerosis, involves an 
intricate network of many molecules with different functions. Briefly, atherogenesis 
begins with endothelial dysfunction and proinflammation, and progresses with early 
fatty-streak formation, advanced lesion formation, unstable fibrous plaque formation 
and may end with a plaque rupture.
 2
  Endothelial dysfunction is marked with reduced 
production of nitric oxide, along with the reduced eNOS level. Vascular 
proinflammation is characterized by a high induction of CAMs, including ICAM-1, 
VCAM-1 and E-selectin. Atherogenesis and its severe complications like AMI also 
result from a hypercoagulable state which is marked by a disturbed expression and 
activity of TF and tissue pathway inhibitor (TFPI). Another leading cause of AMI is 
plaque instability caused by activation of MMPs.
 3
 Because of the wide range of 
 46 
molecules involved in the process of atherogenesis, it is necessary to monitor as many 
molecules as possible in both physiological and pathological states. 
    SAA is a major acute phase protein and it has been proven to be a useful biomarker 
of CAD.
 6,17
 SAA is unique in that it is both an inflammatory protein and also an 
apolipoprotein. Since inflammatory agents and lipids play important roles in 
atherogenesis and are known to interact with each other, it is logical to speculate that 
SAA may have wide effects on atherosclerosis. However to date, the effects of SAA 
is poorly understood and is less studied compared to another acute phase protein CRP, 
whose effects on endothelial cells have been examined by means of DNA microarray 
in 2005. 12 In the current study, the effects of SAA on gene expression profile were 
examined by DNA microarray method in human endothelial cells. With the leads 
from microarray results, some important effects of SAA were further studied in the 
following chapters.  
 
2.1 Methods 
2.1.1 Cell Culture  
Primary HUVECs (Clonetics) were cultured on tissue culture flasks at 37°C in a CO2 
incubator (Thermo Forma). The culture medium was EGM-2MV medium (Clonetics) 
with full supplements (hydrocortisone, growth factors and gentamicin/amphotericin-B) 
and 5% fetal bovine serum (FBS). In setting up a culture, an appropriate amount of 
medium (1ml/5cm
2
) was added to the flasks and equilibrated in a 37°C under the 5% 
CO2 humidified incubator for at least 30 minutes. The cryovial containing cells was 
quickly thawed in a 37°C water bath but without full submersion. After resuspending 
 47 
with full-supplemented medium in a sterile cabinet (Gelman), cells were seeded into 
the culture flasks (Nunc) at a concentration of 2,500-5,000 cells/cm2. After overnight 
incubation, cells were attached to the wall and started to grow.  The culture medium 
was changed for the first time to remove the DMSO residue in the culture. 
Subsequently, the cells were cultured with a change of medium every other day.  
Upon obtaining 90% confluence, the cells were detached from the surface by trypsin-
EDTA (0.025%) and split at a 1-to-4 ratio into tissue culture flasks. Briefly, a culture 
flask was washed twice with 1x PBS and added with appropriate amount of 0.025% 
trypsin (2ml/25cm
2
).  The trypsinization was continued for 6-8 min at room 
temperature. After gentle rapping, cells were released and collected into a 15ml sterile 
tube. FBS was added to neutralize the trypsin at a concentration of 10%(V/V). The 
harvested cells were centrifuged at 220 g for 5 min to obtain a pellet. After removing 
the supernatant, cells were resuspended with the appropriate volume of medium to 
obtain a concentration of between 0.5-2.0 x 10
6
cells/ml. For storage, 10% of total 
volume of ice-cold DMSO was added and cells were stored at -80°C overnight and 
then transferred to liquid nitrogen for permanent storage. For subculture, cells were 
seeded again in culture flasks as described before. HUVECs from passage 4 were 
used in all of the following experiments. 
    In SAA treatment studies, cells were cultured to confluence in 6-well plates and 
stimulated with 20 µg/ml of SAA (PeproTech) for 0, 4, 24 and 48 h. The endotoxin 
levels of ≤ 1 EU/ µg protein in SAA preparation were confirmed by E-TOXATE test 
kit (Sigma-Aldrich) (See Appendix 1). 
2.1.2 Analysis of gene expression profile 
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To determine the cellular transcript profile in Control and 3 different SAA groups 
(S4h, S24h and S48h), the relative abundance of mRNAs in SAA groups were 
compared with Control by use of high-density oligonucleotide microarrays, Human 
Genome U133 Plus 2.0 Array (HG-U133 Plus 2.0, Affymetrix)) containing probes for 
about 39,000 known human genes. Each group had 2 individual samples and each 
sample was applied onto one GeneChip. 
2.1.3 RNA isolation 
Total RNA was isolated from fresh endothelial samples by using RNeasy Mini Kit 
(Qiagen). HUVECs were culture to confluence and treated with 20 µg/ml of SAA for 
different time durations as described before. At the endpoint, cells were washed twice 
with 1 x PBS and disrupted by addition of Buffer RLT containing 1% (V/V) β-
mercaptoethanol. The lysate was homogenized by passing 30 times through a 1ml tip. 
One volume of 70% ethanol was added to the homogenized lysate and mixed well by 
pipetting. The sample was applied to an RNeasy mini column and centrifuged for 15 s 
at 13,000 rpm. The flow-through was discarded and the column was washed with 
Buffer RW1. After washing two more times with Buffer RPE, the column was 
centrifuged for 2 min at 13,000 rpm to dry the RNeasy silica-gel membrane. Finally, 
30-50 µl RNase-free water was added directly onto the membrane and centrifuged at 
13,000 rpm for 1 min. The concentration of the eluted total RNA was quantified by 
NanoDrop ND-1000 UV-Vis Spectrophotometer (NanoDrop).         
2.1.4 Sample preparation, array hybridization, and scanning 
In accordance to the Affymetrix protocol, 2 µg of purified total RNA was reverse 
transcribed to the first-strand cDNA with the use of T-7 Oligo(dT) primer (First Base) 
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and  Superscript II (Invitrogen Life Technologies). The second-strand cDNA was 
synthesized with the use of E. coli. DNA ligase, E. coli. DNA polymerase and RNase 
H (Invitrogen). Subsequently, the double-strand cDNA was transcribed in vitro to 
biotinylated cRNA by using the RNA transcript Labeling Kit (Affymetrix). After 
cleaned up with GeneChip Sample Cleanup Module (Affymetrix), 15 µg of labeled 
cRNA was fragmented and mixed with control oligonucleotide B2, control cRNA 
(BioB, BioC, BioD) (Affymetrix), herring sperm DNA (Promega), BSA (Invitrogen) 
and the hybridization buffer.  The hybridization cocktail was then injected into the 
GeneChip HG-U 133 Plus 2.0 cartridge and incubated at 45°C for 16 h on a rotisserie 
at 60 rpm. After hybridization, the arrays were washed in GeneChip Fluidics Station 
400 and stained with streptavidinphycoerythrin (Molecular Probes, S-866). After 
washing, probe arrays were scanned using the Affymetrix GeneChip® Scanner 3000. 
The quality of the fragmented biotin-labeled cRNA in each experiment was checked 
before being hybridized onto array by using a Test-3 array and analysis as a measure 
of quality control, as recommended by the Affymetrix manual. 
2.1.5 GeneChip Data analysis 
Affymetrix Microarray Suite version 5.0 (Affymetrix) was used to analyze the 
scanned image. The software could automatically calculate intensity values for each 
probe cell and make a “present” or “absent” call for each probe cell. Algorithms in 
the software used probe cell intensities to calculate an average intensity for each set 
of 11 probe pairs representing a gene that directly correlated with the amount of 
mRNA. This software could also be used for group comparison data analysis. In order 
to obtain the 3 group comparison datasets (S4h/C, S24h/C and S48h/C), expression 
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patterns for each duplicated SAA sample (4h, 24h and 48h) were compared to each 
duplicated control sample. Hence, each group comparison had 4 individual sample 
comparisons. For example, group comparison S4h/C was the combination of the 
following 4 individual sample comparisons: S4h1/C1, S4h2/C1, S4h1/C2 and 
S4h2/C2. Sample comparisons were first analyzed. In order to get the robust 
“increase” expression profile, I, the experimental “Absent” cells were eliminated, 
only the genes flagged as “I” with Signal Log Ratio (log2 ratio to control) not less 
than 1.0 were selected. Likewise for robust “decrease” profile, D, the “Absent” cells 
were also eliminated and  only the genes flagged as change “D” with Signal Log 
Ratio” not more than -1.0 were selected. Finally, group comparisons were analyzed 
based on the results of sample comparisons. If the gene is robust “increased” or 
“decreased” in all 4 individual sample comparisons of the total 4 comparisons, it was 
labeled as “I” or “D” in the gene list table of final group comparison and the data 
represented mean values of signal log ratio of the 4 sample comparisons. Others were 
labeled as “NC” which meant no change. The selected genes were classified 
according to their biological processes using Affymetrix Gene Ontology (GO) 
browser.  The complete signal intensity data were uploaded to Gene Expression 
Omnibus (GEO) with the access number GSE6241. 
2.1.6 Quantitative Real-time PCR (QRT-PCR) 
QRT-PCR was used to validate the results from microarray. To obtain enough 
statistical power, each group had at least 3 individual samples. The LightCycler RNA 
Master SYBR Green I kits (Roche) were used to quantify the starting mRNA of the 
selected genes.  This kit uses a hot start reverse transcription-PCR protocol to provide  
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Table 2. Primer sequences for quantitative real-time PCR (QRT-PCR).  





























































LDLR NM_000527          75bp 
very sensitive detection and quantification of defined RNA sequences. The house-
keeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as 
internal control. Primer sequences for the selected functional genes and GAPDH were 
listed in Table 2. Following the manufacturer’s manual, 90 ng RNA template, primers, 
Mn(OAc)2 and LightCycler RNA Master SYBR Green I  were mixed well and 
transferred to LightCycler capillaries. The program of LightCycler® 2.0 system was 
set up to carry out reverse transcription, denaturation, amplification, melting curve 
analysis, and final cooling. The temperature and duration of each procedure was set 
up as recommended by the manufacturers’ manual. The crossing point of each sample 
was calculated after analysis of the fluorescent signals of each amplification cycle. 
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The relative treatment vs control ratio of each target gene was analyzed with 
LightCycler Software Version 3.5. In order to compare with the results from 
microarray, the data of ratio to control were transformed to log2 ratio to control.   
2.1.7 Statistics 
The measurements of microarray and QRT-PCR were expressed as mean values in 
the tables. The differences of real-time PCR log2 ratio data were compared by Mann-
Whitney test using SPSS 12.0.  Significant difference was defined as P value < 0.05.  
The detailed data were further indicated in the following chapters. The correlation 
coefficient between microarray data and QRT-PCR data was analyzed using 
Microsoft Excel and SPSS 12.0.  
 
2.2 Results 
2.2.1 Gene expression profiling 
We used DNA microarrays to reveal changes in the gene expression profile in 
HUVECs when they were treated with SAA. Gene expression levels in HUVECs 
treated with 20 µg/ml SAA for 4h, 24h or 48h were compared with basal gene 
expression levels using the Affymetrix HG-U133 Plus 2.0 GeneChip. SAA treatment 
for 4h, 24h and 48h caused robust increase in the expression of 452, 264 and 145 
genes; whereas 174, 214 and 50 gene were robustly suppressed, respectively (Table 
3). Most of the genes were involved in cellular processes, such as development, 
proliferation, death, cell adhesion, cell communication, metabolism and response to 
stimuli. Stimulation by SAA for 4 h influenced more genes than that for 24h and 48 h. 
In particular, the genes involved in signal transduction and nucleotide metabolism  
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were induced. Among them, transcription factors were the most important molecules. 
As shown in Table 4, 69 transcription factors were induced by 4 h SAA treatment, 
including nuclear factor kappa B gene (NFκB), jun B proto-oncogene(JunB), 
CCAAT/enhancer binding protein (C/EBP), beta (CEBPB), cAMP responsive 
element binding protein 3 (Creb3), mitogen-activated protein kinase kinase 3 
(MAP2K3), interferon regulatory factor 1 (IRF1), activating transcription factor 3 
(ATF3), transcription factor AP-2 alpha, RelB, SMAD3, histone deacetylase 9 
(HDAC9), msh homeo box homolog 1, Kruppel-like factor 5, and so on. The wide 
Table 3. Overview of the genes with robust changes. Data represent the number of the 
genes with robust changes after SAA (20µg/ml) treatment for different durations. 
Genes in the bold categories were further studied. The number of genes do not add up 
to the total due to some genes being classified under multiple categories.   
   Increase             Decrease 
Gene Category 
4h 24h 48h 4h 24h 48h 
Cellular process 313 172 105 111 136 31 
  Development 74 34 18 32 38 15 
  Proliferation 42 24 12 8 8 1 
  Cell adhesion 32 32 20 3 19 4 
  Locolization 68 49 22 19 26 6 
  Death 43 21 13 6 9 3 
  Cell communication 150 78 49 33 46 10 
    Signal transduction 140 72 48 28 40 8 
      Intracellular signaling 38 28 20 18 15 4 
  Coagulation 6 4 4 2 7 3 
  Metabolism 156 86 49 82 77 15 
    Protein 62 41 25 31 34 4 
    Nucleotide 81 27 17 51 24 4 
      Transcription 69 14 11 46 26 3 
    Lipid 11 11 5 6 6 3 
    Carbohydrate 6 1 2 2 6 0 
    Nitric oxide 2 2 0 1 2 0 
  Response to stimulus 107 106 57 23 33 12 
    Immune response 83 89 45 0 11 8 
      Inflammatory response 34 30 21 0 1 0 
Unknown  139 92 40 63 78 19 
Total 452 264 145 174 214 50 
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Table 4. Gene list 1 of the genes involved in Transcription. Data represent the mean 
signal log ratio control. Blank: no robust changes. Same in Table 5-11. 
SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
+1.3   
212614_at 
AT rich interactive domain 
5B (MRF1-like) ARID5B 
+3.0   
1554980_a_at 
activating transcription factor 
3 ATF3 
+2.2   227198_at  AFF3 
+4.7   202672_s_at  ATF3 
+2.2   
1558706_a_at 
Atonal homolog 8 
(Drosophila) ATOH8 
+1.3   204908_s_at B-cell CLL/lymphoma 3 BCL3 
+1.5   
203140_at 
B-cell CLL/lymphoma 6 
(zinc finger protein 51) BCL6 
+2.0 +1.0  
201170_s_at 
basic helix-loop-helix domain 
containing, class B, 2 BHLHB2 
+3.8   
221530_s_at 
basic helix-loop-helix domain 
containing, class B, 3 BHLHB3 
+2.5   
1554283_at 
CCR4 carbon catabolite 
repression 4-like (S. 
cerevisiae) CCRN4L 
+2.0   
212501_at 
CCAAT/enhancer binding 
protein (C/EBP), beta CEBPB 
+2.7  +2.0 
203973_s_at 
CCAAT/enhancer binding 
protein (C/EBP), delta CEBPD 
+1.0   
209432_s_at 
cAMP responsive element 
binding protein 3 CREB3 
+1.3   
1553646_at 
chromosome X open reading 
frame 43 CXorf43 
+2.0   228033_at E2F transcription factor 7 E2F7 
+2.3   
214446_at 
elongation factor, RNA 
polymerase II, 2 ELL2 
+2.2   226099_at  ELL2 
+1.5   226982_at  ELL2 
+2.2   
1555355_a_at 
v-ets erythroblastosis virus 
E26 oncogene homolog 1 
(avian) ETS1 
+2.2   
224833_at 
v-ets erythroblastosis virus 
E26 oncogene homolog 1 
(avian) ETS1 
+1.7   205935_at forkhead box F1 FOXF1 
+1.2   223287_s_at forkhead box P1 FOXP1 
+3.8 +2.1 +2.9 205659_at histone deacetylase 9 HDAC9 




4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
+2.8   
212641_at 
human immunodeficiency 




+2.7   212642_s_at  HIVEP2 
+2.8   202531_at interferon regulatory factor 1 IRF1 
+1.4   226267_at jun dimerization protein 2 JDP2 
+2.2 +1.3  201473_at jun B proto-oncogene JUNB 
+2.6   221841_s_at Kruppel-like factor 4 (gut) KLF4 
+1.9   
209211_at 
Kruppel-like factor 5 
(intestinal) KLF5 
+2.6   230636_s_at Kruppel-like factor 9 KLF9 
+1.7   
200704_at 
lipopolysaccharide-induced 
TNF factor LITAF 
+1.4   200706_s_at  LITAF 
+1.2   
226038_at 
LON peptidase N-terminal 
domain and ring finger 1 LONRF1 




homolog (avian) MAF 




homolog F (avian) MAFF 
+1.9   205193_at  MAFF 
+2.2   
215498_s_at 
mitogen-activated protein 
kinase kinase 3 MAP2K3 
+2.1 +1.2 +1.1 
205932_s_at 
msh homeobox homolog 1 
(Drosophila) MSX1 
+1.1   
210162_s_at 
nuclear factor of activated T-
cells, cytoplasmic, 
calcineurin-dependent 1 NFATC1 
+2.1 +1.0  
209239_at 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 (p105) NFKB1 
+2.0   
209636_at 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 2 (p49/p100) NFKB2 
+1.9   207535_s_at  NFKB2 
+3.1   
209706_at 
NK3 transcription factor 
related, locus 1 (Drosophila) NKX3-1 
+1.0   
212377_s_at 






nuclear receptor subfamily 3, 
group C, member 1 
(glucocorticoid receptor) NR3C1 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
      
+3.9   
207978_s_at 
nuclear receptor subfamily 4, 
group A, member 3 NR4A3 
+1.9   206237_s_at neuregulin 1 NRG1 
+1.9   
228964_at 
PR domain containing 1, with 
ZNF domain PRDM1 
+1.2   
204681_s_at 
Rap guanine nucleotide 
exchange factor (GEF) 5 
RAPGEF
5 
+2.9 +1.7  
205205_at 
v-rel reticuloendotheliosis 
viral oncogene homolog B, 
nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 3 (avian) RELB 
+3.6  +2.6 
205397_x_at 
SMAD, mothers against DPP 
homolog 3 (Drosophila) SMAD3 
+1.5   205398_s_at  SMAD3 
+1.3 +1.1  218284_at  SMAD3 
+2.4 +2.7 +1.7 
1566342_at 
Superoxide dismutase 2, 
mitochondrial SOD2 
   215078_at  SOD2 
+3.3 +3.6 +2.7 215223_s_at  SOD2 
+3.4 +3.4 +2.8 216841_s_at  SOD2 
+1.5 +1.4 +1.2 213112_s_at sequestosome 1 SQSTM1 
+3.2   
204653_at 
transcription factor AP-2 
alpha (activating enhancer 
binding protein 2 alpha) TFAP2A 
+1.7   
201207_at 
tumor necrosis factor, alpha-
induced protein 1 
(endothelial) TNFAIP1 
+1.6   
218145_at 
tribbles homolog 3 
(Drosophila) TRIB3 
+1.3   200670_at X-box binding protein 1 XBP1 
+1.1   227399_at vestigial like 3 (Drosophila) VGLL3 
+1.3   
219778_at 
zinc finger protein, multitype 
2 ZFPM2 
+1.4   226514_at zinc finger protein 71 ZNF71 
+1.3   219540_at zinc finger protein 267 ZNF267 
+1.2   239406_at Zinc finger protein 193 ZNF193 
+1.1   
225076_s_at 
zinc finger, NFX1-type 
containing 1 ZNFX1 
 +1.5  208078_s_at SNF1-like kinase SNF1LK 
 +1.7  208012_x_at SP110 nuclear body protein SP110 
 +1.4  209762_x_at  SP110 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
  +1.6 
202600_s_at 
nuclear receptor interacting 
protein 1 NRIP1 
  +1.3 204341_at tripartite motif-containing 16 TRIM16 
  +2.2 
205966_at 
TAF13 RNA polymerase II, 
TATA box binding protein 
(TBP)-associated factor, 
18kDa TAF13 
      
   
236401_at 
Amiloride binding protein 1 
(amine oxidase (copper-
containing)) ABP1 
-1.6 -2.7  215306_at TFIIA-alpha/beta-like factor ALF 
-1.3   218031_s_at checkpoint suppressor 1 CHES1 
-1.4   222494_at  CHES1 
-1.4   219990_at E2F transcription factor 8 E2F8 
   227242_s_at early B-cell factor 3 EBF3 
-1.4 -1.4  
206127_at 
ELK3, ETS-domain protein 
(SRF accessory protein 2) ELK3 
-1.2   
207347_at 
excision repair cross-
complementing rodent repair 
deficiency, complementation 
group 6 ERCC6 
-1.1   
241926_s_at 
v-ets erythroblastosis virus 
E26 oncogene like (avian) ERG 
-2.2   1553613_s_at forkhead box C1 FOXC1 
-1.6   209710_at GATA binding protein 2 GATA2 
-2.6 -1.2  209602_s_at GATA binding protein 3 GATA3 
-2.4   209604_s_at  GATA3 
-2.8   
229896_at 
General transcription factor 
II, i GTF2I 
-1.3 -1.3  
203395_s_at 
hairy and enhancer of split 1, 
(Drosophila) HES1 
-1.4   
202815_s_at 
hexamethylene bis-acetamide 
inducible 1 HEXIM1 
-1.6   
213359_at 
Heterogeneous nuclear 
ribonucleoprotein D (AU-rich 
element RNA binding protein 
1, 37kDa) HNRPD 
-2.0   213844_at homeobox A5 HOXA5 
-1.8   209905_at homeobox A9 HOXA9 
-1.2   214651_s_at  HOXA9 
-1.6   213147_at homeobox A10 HOXA10 
-1.4   213150_at  HOXA10 
-1.6   213823_at homeobox A11 HOXA11 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
-2.3 -2.2  206201_s_at mesenchyme homeobox 2 MEOX2 




homolog B (avian) MAFB 
-1.2 -1.2  
200049_at 
MYST histone 
acetyltransferase 2 MYST2 
-1.8   224970_at nuclear factor I/A NFIA 
-1.3 -1.1  209289_at nuclear factor I/B NFIB 
-1.6 -1.4  213029_at  NFIB 
-2.1 -1.8  213032_at  NFIB 
-2.5   213033_s_at  NFIB 
-2.6   230791_at  NFIB 
-1.5   
209119_x_at 
nuclear receptor subfamily 2, 
group F, member 2 NR2F2 
-1.7   
209048_s_at 








-1.4   
202876_s_at 
pre-B-cell leukemia 
transcription factor 2 PBX2 
-1.2   
213677_s_at 
PMS1 postmeiotic 
segregation increased 1 (S. 
cerevisiae) PMS1 
-2.7 -2.0 -1.6 
205529_s_at 
runt-related transcription 








(polypyrimidine tract binding 
protein associated) SFPQ 
-1.9   
204790_at 
SMAD, mothers against DPP 
homolog 7 (Drosophila) SMAD7 
-2.5 -2.1  
219568_x_at 
SRY (sex determining region 
Y)-box 18 SOX18 




signal transducer and 
activator of transcription 1, 
91kDa STAT1 
-1.7   
203221_at 
transducin-like enhancer of 
split 1 (E(sp1) homolog, 
Drosophila) TLE1 
-1.5   223283_s_at teashirt family zinc finger 1 TSHZ1 
-1.0   207781_s_at zinc finger protein 6 ZNF6 
-2.6 -1.8  218149_s_at zinc finger protein 395 ZNF395 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 




testicular feminization; spinal 
and bulbar muscular atrophy; 
Kennedy disease) AR 
 -1.3 -1.9 213905_x_at biglycan BGN 
    (teashirt family zinc finger 1) (TSHZ1) 
 -1.1  
200878_at 
endothelial PAS domain 
protein 1 EPAS1 
 -5.2  
237269_at 
Ecotropic viral integration 
site 1 EVI1 
 -1.3  211467_s_at nuclear factor I/B NFIB 
 -1.0  230291_s_at  NFIB 
 -1.2  
212148_at 
Pre-B-cell leukemia 
transcription factor 1 PBX1 
 -1.1  
207469_s_at 
pirin (iron-binding nuclear 
protein) PIR 




 -1.2  
1557938_s_at 
polymerase I and transcript 
release factor PTRF 
 -2.1  
205528_s_at 
runt-related transcription 




 -1.6  
203408_s_at 
special AT-rich sequence 
binding protein 1 (binds to 
nuclear matrix/scaffold-
associating DNA's) SATB1 
 -1.1  212774_at zinc finger protein 238 ZNF238 
 effects of SAA on transcription factors sequentially influenced the transcription of 
the functional genes. For example, transcription factor NFκB was induced at 4 h; its 
related genes were also highly induced, such as ICAM-1, VCAM-1, E-selectin and 
TF. 
 
2.2.2 Genes involved in inflammatory response and cell adhesion 
According to the gloss classification of the genes, we further examined the genes with 
potential implications in atherogenesis. Endothelial proinflammation promotes  
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Table 5. Gene list 2 of the genes involved in Inflammatory response 
SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
 +2.2 +1.1 221087_s_at apolipoprotein L, 3 APOL3 
+1.5   203140_at B-cell CLL/lymphoma 6 
(zinc finger protein 51) 
BCL6 




+4.4 +5.2  204655_at chemokine (C-C motif) 
ligand 5 
CCL5 
 +2.3  1405_i_at  CCL5 
 +3.7  1555759_a_at  CCL5 
+9.7 +6.2  205476_at chemokine (C-C motif) 
ligand 20 
CCL20 
+2.0   212501_at CCAAT/enhancer binding 
protein (C/EBP), beta 
CEBPB 
+5.4 +3.4 +1.8 823_at chemokine (C-X3-C motif) 
ligand 1 
CX3CL1 
+6.2 +4.4  203687_at  CX3CL1 
+5.1 +3.8 +4.2 204470_at chemokine (C-X-C motif) 
ligand 1 (melanoma growth 
stimulating activity, alpha) 
CXCL1 
+4.8 +3.6 +3.9 209774_x_at chemokine (C-X-C motif) 
ligand 2 
CXCL2 
+7.6 +4.6 +4.4 207850_at chemokine (C-X-C motif) 
ligand 3 
CXCL3 
+3.8 +4.6 +4.0 214974_x_at chemokine (C-X-C motif) 
ligand 5 
CXCL5 
+4.6 +6.5 +5.1 215101_s_at  CXCL5 
+7.5 +7.1 +7.3 206336_at chemokine (C-X-C motif) 
ligand 6 (granulocyte 
chemotactic protein 2) 
CXCL6 
+2.5 +3.9  204533_at chemokine (C-X-C motif) 
ligand 10 
CXCL10 
+1.6 +4.3 +2.4 210163_at chemokine (C-X-C motif) 
ligand 11 
CXCL11 
+1.6 +4.4 +2.3 211122_s_at  CXCL11 
+3.8 +2.1 +2.9 205659_at histone deacetylase 9 HDAC9 
+1.4   205579_at histamine receptor H1 HRH1 
+4.3 +3.2 +3.3 210118_s_at interleukin 1, alpha IL1A 
+5.8 +5.2 +5.1 211506_s_at interleukin 8 IL8 
+4.9 +4.1 +4.4 202859_x_at  IL8 
+2.0   1553740_a_at interleukin-1 receptor-
associated kinase 2 
IRAK2 
+3.1 +1.7 +1.6 231779_at  IRAK2 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
+2.1 +1.0  209239_at nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells 1 (p105) 
NFKB1 
+1.0   201865_x_at nuclear receptor subfamily 3, 
group C, member 1 
(glucocorticoid receptor) 
NR3C1 




+5.0 +3.4 +2.6 1554997_a_at prostaglandin-endoperoxide 
synthase 2 (prostaglandin 




+4.8 +3.5 +2.3 204748_at  PTGS2 
+2.9  +1.2 209544_at receptor-interacting serine-
threonine kinase 2 
RIPK2 
+2.7 +1.2  209545_s_at  RIPK2 
 
+7.2 +5.3 +3.2 206211_at selectin E (endothelial 
adhesion molecule 1) 
SELE 
+1.6   228121_at Transforming growth factor, 
beta 2 
TGFB2 
+2.6 +3.1  204924_at toll-like receptor 2 TLR2 
 +1.9  206271_at toll-like receptor 3 TLR3 
+5.2   206025_s_at tumor necrosis factor, alpha-
induced protein 6 
TNFAIP6 
+3.4   206026_s_at  TNFAIP6 
 
leukocytes recruitment and induces vascular permeability. In Affymetrix GO Browser, 
endothelial proinflammation is further subdivided into inflammatory response and 
cell adhesion. As shown in Table 3, SAA induced 34, 30 and 21 genes for 
inflammatory response after 4h, 24h and 48h incubation, while almost no gene was 
inhibited. All the genes with robust increase are listed in Table 5. The chemokine 
superfamily was highly influenced, such as chemokine (C-C motif) ligands (CCLs), 
chemokine (C-X3-C motif) ligand 1 (CX3CL1) and chemokine (C-X-C motif) 
ligands (CXCLs). The cytokine superfamily was also induced, including interleukins 
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Table 6. Gene list 3 of the genes involved in Cell adhesion. 
SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 




+4.4 +5.2  204655_at chemokine (C-C motif) 
ligand 5 
CCL5 
 +2.3  1405_i_at  CCL5 
 +3.7  1555759_a_at  CCL5 
+1.0   212063_at CD44 molecule (Indian 
blood group) 
CD44 
 +1.3  1557905_s_at  CD44 
 +1.5  204490_s_at  CD44 
 +1.6  213857_s_at CD47 molecule CD47 
 +1.7  211075_s_at  CD47 
 +1.4  226016_at  CD47 
+1.0   203440_at cadherin 2, type 1, N-
cadherin (neuronal) 
CDH2 
+1.6   222549_at claudin 1 CLDN1 
+6.2 +4.4  203687_at chemokine (C-X3-C motif) 
ligand 1 
CX3CL1 
+5.4 +3.4 +1.8 823_at  CX3CL1 
 +1.3 +1.2 224911_s_at discoidin, CUB and LCCL 
domain containing 2 
DCBLD2 
  +1.5 213865_at  DCBLD2 
+2.0 +1.3  201983_s_at epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian) 
EGFR 
+5.4 +4.4 +3.1 202637_s_at intercellular adhesion 
molecule 1 (CD54), human 
rhinovirus receptor 
ICAM1 
+5.8 +4.5 +3.2 202638_s_at  ICAM1 
+5.3 +4.2 +2.9 215485_s_at  ICAM1 
+5.8 +5.2 +5.1 211506_s_at interleukin 8 IL8 
+4.9 +4.1 +4.4 202859_x_at  IL8 
+1.7 +2.6 +2.4 203828_s_at interleukin 32 IL32 
+1.9   205884_at integrin, alpha 4 (antigen 
CD49D, alpha 4 subunit of 
VLA-4 receptor) 
ITGA4 
+1.5   205885_s_at  ITGA4 
+1.4 +1.3  236251_at Integrin, alpha V 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
+2.7   226189_at integrin, beta 8 ITGB8 
+3.8   205816_at  ITGB8 
+2.6   207029_at KIT ligand KITLG 
+2.6   211124_s_at  KITLG 
+2.4   226534_at  KITLG 
+2.5 +4.6 +4.0 202267_at laminin, gamma 2 LAMC2 
 +3.1 +3.4 207517_at  LAMC2 
  +1.6 204114_at nidogen 2 (osteonidogen) NID2 
+1.7   203045_at ninjurin 1 NINJ1 
 +1.3  205893_at neuroligin 1 NLGN1 
 +1.9  204105_s_at neuronal cell adhesion 
molecule 
NRCAM 
 +2.8 +2.4 226435_at papilin, proteoglycan-like 
sulfated glycoprotein 
PAPLN 
+1.6   205656_at protocadherin 17 PCDH17 
  +1.5 219656_at protocadherin 12 PCDH12 
+1.8 +1.4  209493_at PDZ domain containing 2 PDZD2 
 +2.0  205923_at reelin RELN 
+3.6  +1.8 210056_at Rho family GTPase 1 RND1 
 +1.4  213194_at roundabout, axon guidance 
receptor, homolog 1 
(Drosophila) 
ROBO1 
+7.2 +5.3 +3.2 206211_at selectin E (endothelial 
adhesion molecule 1) 
SELE 




+5.2   206025_s_at tumor necrosis factor, 
alpha-induced protein 6 
TNFAIP6 
+3.4   206026_s_at  TNFAIP6 
 +1.7 +1.4 223303_at UNC-112 related protein 2 URP2 




(ILs). In addition, SAA induced the expression of another marker of inflammation, 
prostaglandin-endoperoxide synthase 2 which also known as cyclooxygenase (COX-
2). 
    Similarly, SAA upregulated 32, 32 and 20 genes for cell adhesion after 4h, 24h and 
48h incubation respectively, while much less genes were downregulated. The genes 
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in the list of cell adhesion (Table 6) shows the partial overlap to those involved in 
inflammatory response.  Genes that are overlapping included CCLs, CX3CL1, and 
ILs. SAA also highly induced 3 important cellular adhesion molecules (CAMs): 
ICAM-1, VCAM-1 and E-selectin. 
2.2.3 Genes involved in NO metabolism 
Endothelial dysfunction is the initial step of atherogenesis. Impaired endothelial 
production of nitric oxide caused by reduced endothelial nitric oxide synthase (eNOS) 
expression is the marker of endothelial dysfunction.  Table 7 shows that eNOS was 
inhibited by SAA incubation at 24h.  
Table 7. Gene list 4 of the genes involved in Nitric oxide metabolism 
SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
+2.0 +1.3  201983_s_at epidermal growth factor 
receptor (erythroblastic 
leukemia viral (v-erb-b) 
oncogene homolog, avian) 
EGFR 
+3.1 +1.3  204224_s_at GTP cyclohydrolase 1 (dopa-
responsive dystonia) 
GCH1 
      
-1.3   
236401_at 




 -1.2  224567_x_at metastasis associated lung 
adenocarcinoma transcript 1 
(non-coding RNA) 
MALAT1 





2.2.4 Genes involved in lipid metabolism 
Basically, atherosclerosis is initiated and subsequently progresses through the 
interaction of lipids with inflammatory agents. The deposition of lipids in the vessels 
is the typical pathological characteristic of atherosclerotic lesions. The robustly  
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Table 8. Gene list 5 of the genes involved in Lipid metabolism 
SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
+2.2 +2.1 +2.0 204567_s_at ATP-binding cassette, sub-
family G (WHITE), member 
1 
ABCG1 
 +1.7 +1.6 211113_s_at  ABCG1 
 +2.0  209546_s_at apolipoprotein L, 1 APOL1 
 +1.4  219181_at lipase, endothelial LIPG 




 +2.0  210145_at  PLA2G4A 




 +3.3  215724_at phospholipase D1, 
phosphatidylcholine-specific 
PLD1 
+1.3   209147_s_at phosphatidic acid 
phosphatase type 2A 
PPAP2A 
+1.9   209355_s_at phosphatidic acid 
phosphatase type 2B 
PPAP2B 
+2.0   212226_s_at phosphatidic acid 
phosphatase type 2B 
PPAP2B 
+1.8   212230_at  PPAP2B 
+5.0 +3.4 +2.6 1554997_a_at prostaglandin-endoperoxide 
synthase 2 (prostaglandin 




+4.8 +3.5 +2.3 204748_at  PTGS2 
+1.2   219257_s_at sphingosine kinase 1 SPHK1 
+1.7 +1.3  204881_s_at UDP-glucose ceramide 
glucosyltransferase 
UGCG 
+1.7 +1.4  224967_at  UGCG 
 -2.2  203504_s_at ATP-binding cassette, sub-
family A (ABC1), member 1 
ABCA1 
 -2.2  203505_at  ABCA1 
-1.3   
236401_at 




-1.7   202912_at adrenomedullin ADM 
-1.2   202054_s_at aldehyde dehydrogenase 3 
family, member A2 
ALDH3A
2 
 -1.2 -2.6 222043_at clusterin CLU 
  -2.2 208791_at  CLU 
  -2.0 208792_s_at  CLU 
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SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 
-1.5   204573_at carnitine O-
octanoyltransferase 
CROT 
-1.6   223921_s_at glucosidase, beta (bile acid) 2 GBA2 
-1.5   209119_x_at nuclear receptor subfamily 2, 
group F, member 2 
NR2F2 
 -1.3  208771_s_at leukotriene A4 hydrolase LTA4H 
 -1.2  212148_at Pre-B-cell leukemia 
transcription factor 1 
PBX1 




changed genes for lipid metabolism are listed in Table 8. Although some lipases and 
apolipoprotein were induced by SAA treatment, the key enzymes for cholesterol and 
triglycerides, such as sterol regulatory element binding factors (SREBP1 and 2), 3-
hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR), LDL receptor (LDLR), 
ATP citrate lyase, fatty acid synthase and Stearoyl-Coenzyme A desaturases (SCD1 
and 2), were not robustly changed. Hence, SAA did not affect the synthesis of 
cholesterol and triglycerides. Interestingly, ATP-binding cassette, sub-family A, 
member 1 (ABCA1) which is the major cholesterol transport protein was suppressed 
by SAA. It suggests that SAA may inhibit the cholesterol efflux from cells.  
 
2.2.5 Genes involved in coagulation 
Endothelial procoagulation is important in thrombosis and CAD. Procoagulation 
represents the activation of coagulation system and the inhibition of the fibronolysis 
system. The robustly changed genes for coagulation are listed in Table 9. SAA 
markedly stimulated tissue factor (TF, also known as factor III) expression at 4h. 
Plasminogen activator inhibitor type 1 (PAI-1) which is a fibrinolysis inhibitor was 
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also induced after SAA treatment for 4h. On the other hand, tissue factor pathway 
inhibitor (TFPI) and thrombomodulin were inhibited after SAA treatment for 24h.  
 
Table 9. Gene list 6 of the genes involved in Coagulation 
SAA treatment 
4h 24h 48h 
Affy. ID Gene  
Gene 
Symbol 





 +1.8 +2.0 206429_at coagulation factor II 
(thrombin) receptor-like 1 
F2RL1 
 +1.7 +1.6 213506_at  F2RL1 




+2.3  +1.6 211668_s_at  PLAU 
 +1.6  205576_at serpin peptidase inhibitor, 
clade D (heparin cofactor), 
member 1 
SERPIND1 
+1.7   1568765_at serpin peptidase inhibitor, 
clade E (nexin, plasminogen 




+1.5 +1.3  209277_at Tissue factor pathway 
inhibitor 2 
TFPI2 
+1.2   209278_s_at  TFPI2 
      
-1.3 -2.3 -1.3 207691_x_at ectonucleoside triphosphate 
diphosphohydrolase 1 
ENTPD1 
-1.4 -2.0 -1.2 209474_s_at  ENTPD1 
 -3.8  228585_at  ENTPD1 
 -1.4  205612_at multimerin 1 MMRN1 





 -1.2  210665_at  TFPI 
 -1.7 -1.4 203887_s_at thrombomodulin THBD 
 
2.2.6 Genes involved in plaque instability  
Plaque rupture, the major cause of acute coronary events, is the outcome of 
extracellualr matrix (ECM) degradation. Matrix degradation is caused by the 
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Table 10. Microarray results for MMPs and TIMPs 
10a). Transcriptional comparison in SAA-stimulated HUVECs. Data represent the 
mean signal log ratio to control. NC: no change; I: increase. 
SAA (20 µg/ml) treatment 
Gene 
4h 24h 48h 
MMP-1  NC  NC  NC 
MMP-2  NC  NC  NC 
MMP-3  NC  NC  NC 
MMP-7  NC  NC  NC 
MMP-8  NC  NC  NC 
MMP-9  NC  NC  NC 
MMP-10 +3.3 I +3.7 I +3.2 I 
MMP-11  NC  NC  NC 
MMP-12  NC  NC  NC 
MMP-13  NC  NC  NC 
MMP-14  NC  NC  NC 
MMP-15  NC  NC  NC 
MMP-16  NC  NC  NC 
MMP-17  NC  NC  NC 
MMP-18  NC  NC  NC 
MMP-19  NC  NC +2.3 I 
MMP-20  NC  NC  NC 
MMP-21  NC  NC  NC 
MMP-23  NC  NC  NC 
MMP-24  NC  NC  NC 
MMP-25  NC  NC  NC 
MMP-26  NC  NC  NC 
MMP-27  NC  NC  NC 
MMP-28  NC  NC  NC 
TIMP-1  NC  NC  NC 
TIMP-2  NC  NC  NC 
TIMP-3  NC  NC  NC 
TIMP-4  NC  NC  NC 
10b). Raw signal intensity of MMP-10 and MMP-19. P:present; A: absent; M: margin. 
SAA (20 µg/ml) treatment 
Gene Affy. ID 














































































induction and activation of metalloproteinases (MMPs) or inhibition of tissue 
inhibitors of metalloproteinases (TIMPs). The MMPs and TIMPs were screened by 
microarray (Table 10a) and only MMP-10 and -19 were found to be robustly 
increased. As shown in Table 10b, the raw signal data of probe sets for MMP-19 were 
quite low even after induction and only one probe set had robust change at 48 h. 
Hence, only MMP-10 was selected for further study in Chapter 6. 
 
2.2.7 Correlation coefficient between microarray and QRT-PCR data 
To validate the microarray result, QRT-PCR was carried out using individual 
HUVEC samples with the same SAA stimulation conditions. Only the functional 
genes with robust changes were selected for QRT-PCR. However, HMGCR and 
LDLR were also included to exclude the possible false negative result from 
microarray. After the 24 h SAA treatment, the log2 ratio to control of HMGCR and 
LDLR were -0.19 ± 0.19 and 0.24 ± 0.20, respectively. There was no significant 
difference between SAA group and control group in HMGCR and LDLR expression 
levels. For all the other selected genes with robust changes, QRT-PCR showed 
significant differences between SAA group and control group. Detailed data were 
shown in the Chapter 3-6. Table 11 shows the relative mRNA levels of selected genes 
at different time points. The QRT-PCR results for each gene were compared to the 
microarray results. The correlation coefficient between the 2 data sets was 0.898 and 
p value was less than 0.001 (Figure 2.1), confirming the reliability of the microarray 
study.  Using log2 ratio value “± 1.0” as the cutoff for upregulation and 
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downregulation, no false positive or false negative results were observed in Figure 2.1.  
QRT-PCR results showed 100% concordance with microarray results.  
Table 11. List of selected genes with robust changes for further study. M: microarray; 
P: QRT-PCR. The data represent log2 ratio to control. 
SAA (20 µg/ml) treatment 
4h 24h 48h Function Gene 




+5.8 +9.5 +4.5 +6.3 +3.2 +6.6 
 VCAM-1 +7.2 +10.1 +5.3 +5.9 +3.2 +5.4 
 E-selectin +6.4 +5.3 +5.2 +3.6 +3.9 +2.5 
 COX-2 +5.0 +4.5 +3.4 +4.1 +2.6 +1.9 
Vasoreactivity eNOS   -1.8 -1.7   
Coagulation TF +5.9 +7.8     
 TFPI   -1.2 -1.7   
Plaque stability MMP-10 +3.3 +2.8 +3.7 +3.2 +3.2 +2.3 
Lipid metabolism ABCA1   -2.2 -1.8   
 HMGCR   +0.2 -0.2   
 LDLR   +0.4 +0.2   
y = 1.1578x - 0.0575
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Figure 2.1. The correlation coefficient between microarray data and QRT-PCR data. r 
= 0.898, p < 0.001. The areas labeled gray are true positive areas using log2 ratio 





In the past decades, inflammatory factors (such as TNFα, ILs and CRP) have been 
found to have wide effects on atherogenesis. 
1 
Our time-course microarray study has 
shown that SAA could also exert wide effects on the gene expression profile in 
human endothelial cells, including the genes involved in endothelial dysfunction, 
proinflammation, coagulation, and plaque rupture.   
    Understanding complex physiological or pathological mechanisms requires the 
global analysis of different cellular process. DNA microarray is certainly the most 
powerful tool for such studies and it has already made important contributions, most  
notably to gene-expression studies. 50 At present, gene transcriptional profiling is the 
most commonly used application in different disease studies, including CAD. In 2003, 
Tuomisto et al compared the macrophage-rich shoulder area of the atherosclerotic 
lesions with normal intima and THP macrophages. 
56
Upregulation of 72 genes was 
detected and included HMGCR, colony stimulating factor (CSF) receptors, 
CD11A/CD18 integrins and interleukin receptors.
 
In 2005, Lutgens et al performed 
microarray analysis on transcripts of aortic arch of apolipoprotein E-deficient (apoE-/-) 
mice fed normal chow or western-type diet for 3, 4.5 and 6 months. 58Time-dependent 
expression clustering and functional grouping of changed genes suggested important 
functions for genes involved in inflammation (especially the small inducible 
cytokines MCP-1, MCP-5, macrophage inflammatory proteins) and matrix 
degradation (cathepsin-S, MMP-2 and12).
 
Hishikawa et al examined the effects of 




 They found 
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that NFκB-related genes (ICAM-1, VCAM-1 and TNFα, IL-2 etc) were induced in 
apoE-/- mice compared to C57/B mice and flavonoid treatment could restore the 
changes. Furthermore, average expression of the other gene clusters (basic 
transcription factors, growth factor cytokines, cell adhesion proteins and extracellular 
matrix) was significantly higher in apoE
-/-
 mice and reduced by flavonoid treatment. 
All the above microarray studies suggested that some inflammatory genes were 
induced in atheroma and confirmed the relationship between inflammation and 
atherosclerosis. Therefore further studies should be carried out to investigate the 
mechanism of atherosclerosis under different stimulating conditions, especially 
inflammation.  
    In recent years, an increasing number of microarray studies have been carried out 
to assess the impact of various disease risk factors and the therapeutic effects of 
potential drug targets. For example, a well-known CAD risk factor, homocysteine, 
was reported to induce HMGCR in endothelial cells
61
 and induce TNFα, and TNF β 
in coronary arteries.
 62
 The results showed that homocysteine could induce cholesterol 
production and cause proinflammation. In contrast, steady shear is considered by 
many to be the most important stimulus for NO production in endothelial cells. Shear 
stress for 6 and 24 h was reported to inhibit the gene expression of connective tissue 
growth factor, endothelin-1, MCP-1, and spermidineyspermine N1-acetyltransferase.
 
63
 The changes observed suggest several potential mechanisms for increased NO 
production under shear stress in endothelial cells. Shear stress also upregulated 
antioxidant and antiinflammatory genes in both porcine aortic endothelial cells and 




 The above studies confirmed that microarray is a very 
useful method to monitor the global gene expression profile under different 
conditions. They also suggested that CAD risk factors or protective factors could 
influence the genes involved in inflammation, oxide stress, vasoreactivity and lipid 
metabolism.  Interestingly, our study confirmed SAA could influence the genes with 
those functions. SAA induced endothelial inflammatory response with elevated 
expression of many cytokines, chemokines and cellular adhesion molecules.  SAA 
inhibited eNOS expression which is the key enzyme of NO production. Unlike 
homocysteine, SAA did not influence the in-site synthesis of lipids because it did not 
change the expression of SREBP-regulated genes such as HMGCR and LDLR. 
However, SAA did inhibit ABCA1 expression, which is the key efflux transporter of 
cholesterol. Decreased ABCA1 expression level was found in atherosclerotic plaque 
compared to microscopically intact tissue.
 180
 Such inhibition contributed to the 
cholesterol accumulation in atheroma. The cellular physiology of cholesterol efflux in 
vascular endothelial cells is not completely understood.
 
Connell et al reported that 
endothelial ABCA1 expression was low or absent and was not affected by treatment 
with 20 µg/mL cholesterol or 2.5 µg/mL 22(R)-hydroxycholesterol for 24 h. 181 
However, more recently Zhu et al reported that oxidized LDL inhibited cholesterol 
efflux from ECs through liver X receptor (LXR) inhibition and sequential ABCA1 
suppression.
182
 Our study showed that basal ABCA1 expression in endothelial cells 
was not low and it was robustly inhibited by SAA treatment for 24 h. The mean 
signal intensity of ABCA1 in control group was 1208 and that in S24h group was 218 
(detailed in Appendix 2a). Moreover, ABCA1 protein was also present in control and 
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significantly suppressed by SAA treatment (Appendix 2b). The effect of SAA on 
ABCA1 expression was similar to that of the oxidized LDL. Therefore endothelial 
cholesterol efflux may also be regulated by this inflammatory protein.    
    Since inflammatory factors are also risk factors of CAD, it is attractive to apply 
microarray in this research field. Mayer et al examined the gene expression program 
of IL-stimulated HUVECs at 0, 0.5, 1, 2.5 and 6 h and found that 36 transcription 
factors (26% of all regulated genes) were influenced in this narrow time course.
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Our study showed the similar trends that short-term stimulation influenced more 
genes than prolonged (24 and 48 h) stimulation. Moreover, stimulation for 4h induced 
more much more transcription factors, including NFκB, JunB, IRF1, ATF3, RelB, 
SMAD3, HDAC9, and Kruppel-like factor 5.  Franscini et al found that 6 h of IL-1β, 
TNFα and interferon-γ treatment regulated a wide range of genes, including 
transcription factors (NFκB) and inflammatory genes (CAMs, IL-6, IL-8 and MCP-1).
 
66
 Not surprisingly, our study demonstrated that SAA had similar effects as those 
common cytokines. Moreover, our time-course study revealed genes other than 
transcription factor and inflammatory genes, such as ABCA1, eNOS, TFPI and 
MMP-10, that can be influenced by SAA. Although no microarray study has been 
performed in SAA-treated cells, one recent publication by Viemann et al emerged 
while our study was ongoing, reported similar findings as ours. They performed 
microarray study in HMVECs with or without stimulation by myeloid-related protein 
8 (MRP8) and MRP14.
 68
 MRP8/MRP14 is similar as SAA to be found in 
inflammatory fluids in distinct inflammatory conditions, such as rheumatoid arthritis. 
However, MRP8/MRP14 is not a major acute phase protein and has not been reported 
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to be involved in atherosclerosis. Their data showed that MRP8/MRP14 induced a 
thrombogenic, inflammatory response in HMVECs by increasing the transcription of 
procoagulation factor (thrombospondin-1), proinflammatory chemokines (IL-8) and 
adhesion molecules (ICAM-1, VCAM-1) and by decreasing the expression of cell 
junction proteins and molecules involved in monolayer integrity (Catenin-1, Cadhesin, 
etc.).  Our results showed SAA also induced proinflammtory genes (ICAM-1, 
VCAM-1, E-selectin and IL-8) and procoagulation genes. However, it influenced 
coagulation in a different pattern. It induced TF and PAI-1 but inhibited TFPI and 
thrombomodulin.  Moreover, SAA also regulated NO production and MMPs 
expression which was not reported in their study. 
    In a summary, our time-course microarray study showed SAA had wide effects on 
gene expression profile in human endothelial cells. Among the regulated genes, those 
with important clinical implications were studied in depth in the following chapters. 
They include the genes involved in proinflammation, vasoreactivity, procoagulation 
and plaque instability.     
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Chapter 3 
Study II- The effects of SAA on endothelial proinflammation 
Atherosclerosis can be regarded as a chronic inflammatory disease of the vascular 
wall.
2 
Besides hypercholesterolemia, inflammation plays important roles in the 
development of atherosclerosis.
 1
 Many inflammatory proteins are elevated in CAD 
and related to future coronary events.
 5
 Currently some of these have been monitored 
in populations as sensitive biomarkers of CAD.  Furthermore, effectors of the 
immune system, such as leukocytes, lymphocytes, adhesion molecules, cytokines and 
chemokines, are involved directly in all stages of atherogenesis,
 183
 which begins with 
proinflammation of the vascular walls.  
     Serum amyloid A (SAA) has attracted increasing level of interests in CAD 
research.  As a major acute phase protein in inflammation, circulating SAA levels are 
known to be elevated by 100-1000 folds through acute inflammation stimuli.
13,15 
Accumulating evidences in the past decades have shown that SAA is also associated 
with CAD. Elevated circulating SAA level was found in patients with unstable angina 
and acute myocardial infarction,
 16
 and is a significant predictor of CAD risk and 
coronary events. 6, 17  Furthermore, it has been reported that the traditional risk factor 
of high-cholesterol diet could increase circulating SAA levels in female LDL-receptor 
null mice,
 26
  as well as in lean insulin-sensitive human subjects.
 27
 Although SAA is 
normally produced in the liver, its expression has also been found in human 
atherosclerotic lesion
 23
 and was increased at the site of ruptured plaque in acute 
myocardial infarction.
 24
 These evidences implicate that SAA may play a direct role 
in atherogenesis. Recent studies have demonstrated that SAA may act as a cytokine 
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and leads to vascular proinflammation on the facet of leukocytes. SAA was reported 
to induce TNF and IL-8 expression in neutrophils, as well as T lymphocyte migration 
and adhesion.39-41 The increased serum levels of SAA also contributed to the 




    Cellular adhesion molecules (CAMs) are significant biomarkers and predictors of 
CAD risk.
 7,79,80
 Furthermore, CAMs recruit leukocytes to vessels and directly lead to 
vascular proinflammation, which is also known as the proatherogenic state. E-selectin 
mediates initial leukocyte tethering and rolling, while ICAM-1 and VCAM-1 mediate 
firm adhesion and trans-endothelial migration of leukocytes. 1, 78 CAMs are 
upregulated by various stimuli, including ILs, 81 TNF, 81 thrombin, 82 LPS, 83 virus 
protein
84
 and another acute phase CRP.
8 
Very recently, SAA was found to induce 
ICAM-1 and VCAM-1 expression on human microvascular endothelial cells 
(HMVECs) and promote peripheral blood mononuclear cells adhesion to HMVECs.
 43
 
However, the study focused on rheumatoid arthritis (RA) and used HMVECs.  These 
are not commonly used in atherosclerosis research because they are not derived from 
large vessels. As such, the direct proinflammation effects of SAA on large vessels 
remain obscure to date. 
   NFκB is a central signaling molecule in inflammation.
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 With increasing evidences 
that atherosclerosis is a chronic inflammatory disease, NFκB is now considered a 
major transcription factor regulating many functions of the vessels.
 
 Moreover, NFκB 
activation is thought to lie downstream of many stimuli proposed to be involved in 




recent study reported that SAA activated NFκB and proinflammatory gene 
expressions (IL-8, COX2) in intestinal epithelial cells (EPCs). 35 In 2006, Mullan et al 
reported that the SAA-induced expression of ICAM-1and VCAM-1 was suppressed 
by NFκB inhibition with PDTC (150mM) in HMVECs.
 43
 However, it is unclear 
whether SAA could influence NFκB in ECs derived from large vessels and therefore 
lead to CAMs expression. 
    Hypothesis We hypothesized that SAA could induce endothelial proinflammation 
through the induction of CAMs. 
 In this study, we investigated the effects of SAA on CAMs expression on 
endothelial cells to shed light on the obscure role of SAA on atherogenesis. In 




3.1.1 Cell Culture  
HUVECs and HCAECs (Clonetics) were cultured in EGM-2MV medium (Clonetics) 
with full supplements and 5% FBS. The medium was changed every other day until 
the cells reached 90% confluence. Cells were then trypsinized and reseeded. 
HUVECs from passage 4-5 and HCAECs from passage 3-4 were used in the 
following experiments. 
    In SAA treatment studies, cells were cultured to confluence and SAA (PeproTech) 
was added to the medium at concentrations of 0-40 µg/ml at the following time points: 
0, 0.5, 1, 2, 4, 6, 8 and 24 h. The endotoxin levels of ≤ 1 EU/ µg SAA were confirmed 
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by E-TOXATE test kit (Sigma). To exclude the influence of endotoxin, cells were 
treated with 4ng/ml (40EU/ml) of LPS (Sigma) as a control. 
    In our pathway study, cells were pretreated with 100 µmol/l of the NFκB inhibitor 
PDTC (Sigma-Aldrich) for 0.5 h and then treated with SAA 20 µg/ml for 4 or 24 h.   
3.1.2 Gene Expression Level Determination by QRT-PCR  
Cells were cultured to confluence in 6-well plate. After treatments of different time 
points (0-24 h) and concentrations (0-40 µg/ml), total RNA was isolated from fresh 
cells using RNAeasy Mini Kits (Qiagen). The LightCycler RNA Master SYBR Green 
I kits (Roche) were used to quantify the starting mRNA of ICAM-1, VCAM-1 and E-
selectin.  The house-keeping gene GAPDH was used as internal control. Primer 
sequences for CAMs and GAPDH were listed in Table 2. The following procedure 
was described in Chapter 2.  
3.1.3 Cell surface ELISA for CAMs 
Cell surface ELISA was performed to determine the cell surface expression of CAMs 
as previously reported but with modifications.
 51
 HUVECs of the same density (5000 
cells/well) were seeded onto the 96-well plates. After 48 hours, confluent cells were 
treated with 0-40 µg/ml SAA for 4h. Cells were washed twice with 1x PBS and fixed 
at room temperature with 0.1% glutaraldehyde solution in 1x PBS for 5 min.  After 
aspiration and briefly drying the cell culture plates, the wells were preincubated with 
ELISA buffer (1% skim milk in PBS) for 15 min. For ICAM-1 and E-selectin assay, 
the wells were incubated with 1x HRP-conjugated primary antibody (Biosource) in 
50µl ELISA buffer for 1.5 h at 37°C. After thorough washing, TMB substrate 
solution (with 0.01% buffered hydrogen peroxide) was added and incubated for 15 
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min for color development. The surface protein expression was determined by the 
absorbance at 450nm with a reference reading at 620nm after addition of stop 
solution (1M phosphoric). The background OD values were subtracted and 
normalized to the protein level in each well. The data were expressed as ratio to 
control. 
    For VCAM-1 assay, the procedures were the same except that the wells were 
incubated with 50µl biotin-labeled primary antibody (Biosource) for 2 h at 37°C. 
After washing, 100 µl 1x streptavidin-HRP (Biosource) was added and incubated for 
30 min at room temperature.  
3.1.4 ELISA for secreted CAMs 
Cells of same density (5000 cells/well) were cultured to confluence in 96-well plate 
and treated with SAA of concentration 0-40 µg/ml for 24 h. The culture mediums 
were collected and the secreted CAM levels were determined by the respective 
ELISA kits (Biosource). Sample volumes for ICAM-1, VCAM-1 and E-selectin 
assays were 100 µl, 50 µl and 80 µl respectively. All the procedures were carried out 
according to the kit manufacturers’ manuals. For ICAM-1 and Selectin E assay, 
culture medium was added to anti-ICAM-1 or anti-Selectin E primary antibody 
coated plate and then incubation with HRP-conjugated secondary antibody 50 µ l for 
2 h. After washing for 3 times, TMB substrate solution was added and incubated for 
15 and 30 min for color development. The protein concentration was determined by 
the absorbance at 450/620nm after stop solution adding. For VCAM-1 assay, culture 
medium 50 µl was incubated together with biotinylated anti-VCAM-1 solution in 
primary antibody coated plate for 2 h. After thoroughly washing, streptavidin-HRP 
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100 µl was added and incubated for 30 min. After washing, TMB substrate solution 
was added and incubated for 30 min. After stop solution adding, the protein level was 
calculated by OD 450 reading. Standard curves were carried out in each run 
according to the manufacturers’ manual. 
3.1.5 Nuclear Protein Extraction 
HUVECs were grown to confluence, treated with 20 µg/ml SAA for 0, 0.5, 1, and 2 h, 
and collected by trypsination and washed with 1x PBS. Nuclear protein was isolated 
using the Nuclear Extraction Kit (Chemicon). Briefly, cells were incubated with 
cytoplasmic lysis buffer and disrupted by pushing them through a syringe with a 27-
gauge needle. After centrifugation at 8,000 g for 20 minutes at 4°C, the supernatant 
containing the cytosolic portion of the cell lysate was transferred to a fresh tube and 
store at -80°C.  The nuclear pellet was resuspended with nuclear extraction buffer and 
disrupted by pushing it through a syringe with a 27-gauge needle again.  The nuclear 
suspension was gently agitated in an orbital shaker at 4°C for 60 minutes. After 
centrifugation at 16,000 g for 5 minutes at 4°C, the nuclear extraction was transferred 
to tubes and stored at -80°C in aliquots.  
3.1.6 NFκB Transcription Factor Assay  
The nuclear NFκB level was measured by TransFactor Profiling Kit- Inflammation 1 
(BD Biosciences). This assay combines the principle of the electrophoretic mobility 
shift assay (EMSA) and ELISA. Briefly, 40 µg nuclear extract was incubated for 1 h 
in the wells pre-coated with designed capture probes containing the flanked DNA 
binding consensus sequence for NFκB. After washing, the bound NFκB subunits, p50 
or p65, were incubated with specific primary antibodies for 1 h, washed again and 
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HRP-conjugated secondary antibody was added and incubated for 30 min. After 
another thorough washing, TMB was added and incubated for 30 min. Stop solution 
was added, the NFκB p50/p65 levels were read at OD 450nm with a reference wave 
length of 630nm in a spectrophotometric plate reader (Sunrise).  
3.1.7 Statistical Analysis 
Measurements were expressed as mean ± SD from at least 3 independent samples. 
The differences of real-time PCR log2 ratio data, CAMs ELISA data and NFκB 
p50/p65 OD value data were compared by Mann-Whitney test using SPSS 12.0.  
Significant difference was defined as P value < 0.05.    
 
3.2 Results 
3.2.1 SAA induces gene transcription of CAMs in endothelial cells 
Real-time quantitative PCR was carried out to examine whether SAA could lead to 
endothelial proinflammation by measuring gene transcription levels of 3 typical 
adhesion molecules (ICAM, VCAM and E-selectin) with or without SAA incubation. 
Figure 1 shows the effects of SAA on gene transcription of CAMs in HUVECs. 
Recombinant human SAA (20 µg/ml) markedly induced gene transcription of CAMs 
after 2 h, peaking between 4-6 h, and declining after 8 h (Figure 3.1a). Incubation 
with SAA for 4 h significantly induced ICAM, VCAM and E-selectin up to 716 ± 72 
folds (log2 ratio 9.48 ± 0.15 vs 0 ± 0.34, p < 0.05), 1089 ± 284 folds (log2 ratio 
10.05± 0.40 vs 0 ± 0.35, p < 0.05 ), and 40.3 ± 8.0 folds  (log2 ratio 5.31 ± 0.30 vs 0 ± 
0.4, p < 0.05) respectively.  Figure 3.1b shows the dose-dependent effects of SAA.  
Elevation of CAMs transcription levels was effected with only 1 µg/ml of SAA 
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incubation and continued to be dose-dependent with maximal effect at 20 µg/ml.  
Both the data from time course and dose-response experiments suggest that SAA 







































































































































Figure 3.1. The effects of SAA on gene transcription of CAMs in HUVECs (a,b) and 
HCAECs (c). a). Time course of SAA (20 µg/ml) effects. b). Dose-dependent effects 
of SAA (4h). c). HCAECs were incubated with SAA (20 µg/ml) for 4 h. c *: P < 0.05 



















































Figure 3.2. The effects of SAA on cell surface expression of CAMs in HUVECs. 
Cells were incubated with SAA or LPS (4ng/ml) for 4 h. *: P < 0.05 vs Control. n = 
3-4. 
 
3.2.2 SAA stimulates cell surface expression of CAMs in endothelial cells   
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To further investigate the effects of SAA on CAM protein levels, cell surface 
expression of the CAMs was measured. As shown in Figure 3.2, SAA treatment for 4 
h significantly induced surface expression of CAMs in a dose-dependent manner. The 
effects were observable even at low concentration of 1 µg/ml and reached its peak 
with concentration of 40 µg/ml. The high induction was not caused by endotoxin. 
Thus SAA could highly induce cell surface expression of CAMs and potentially 
recruit leukocytes to vessels.  
3.2.3 SAA stimulates protein secretion of CAMs in HUVECs and HCAECs   
Elevated circulation levels of CAMs are useful biomarkers of CAD in clinical studies. 
To determine whether CAMs secretion is related to the level of SAA stimulation, the 
concentration of CAMs in culture medium was assayed by ELISA. Figure 3.3 shows 
the elevated secretion of CAMs from both HUVECs and HCAECs after SAA 
incubation for 24 hours.  SAA induced protein secretion of CAMs in a dose-
dependent manner. After incubation with 20 µg/ml of SAA, the levels of ICAM, 
VCAM and E-selectin in HUVECs medium were significantly elevated from 0.75 ± 
0.03 ng/ml, 1.74 ± 0.51 ng/ml and 1.31 ± 0.26 ng/ml to 5.62 ± 1.09 ng/ml, 25.54 ± 
4.56 ng/ml and 4.96 ± 0.96 ng/ml, respectively (p<0.05). The levels in HCAECs 
medium showed the same trends. The ELISA data suggest that SAA is able to 
stimulate endothelial cells to secrete CAMs.  
3.2.4 NFκB inhibitor PDTC inhibits the stimulating effects of SAA 
NFκB is widely known to be involved in various inflammatory responses, including 
CAM expression. To examine whether the proinflammatory effects of SAA are via 








































































































































Figure 3.3. The effects of SAA on secretion of CAMs from HUVECs (a-c) and 
HCAECs (d). Cells were incubated with SAA or LPS (4ng/ml) for 24 h. Medium 
were collected to assay for CAMs level. *: P < 0.05 vs Control. n = 3-6. 
 
SAA incubation. Figure 3.4 shows the inhibition of PDTC on gene transcription and 
protein production of CAMs induced by SAA. Comparing to SAA 20 µg/ml 
incubation alone, mRNA levels of CAMs were markedly attenuated by PDTC 100 
µmol/l pretreatment (Figure 3.4a). Furthermore, the secretion of CAMs was also 
significantly inhibited by PDTC (Figure 3.4b). These data confirm that PDTC could 
inhibit the proinflammatory effects of SAA. PDTC is a common NFκB inhibitor 
which blocks the NFκB pathway via inhibition of degradation of IkBa. Therefore, the 
effects of SAA are likely to be mediated through the NFκB pathway.     
3.2.5 SAA causes NFκB translocation and activation 
To further examine the direct effects of SAA on NFκB pathway, nuclear proteins 
were extracted and the active subunits of NFκB, p65/p50, were assayed by ELISA. 
Figure 3.5 shows the effects of SAA on NFκB translocation and activation in 
HUVECs. The results demonstrated that SAA significantly induced the nuclear 
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translocation of NFκB subunits p65 and p50 after 0.5-1 h incubation. Thus, SAA may 







































































Figure 3.4. The inhibition effects of PDTC on expressions of CAMs induced by SAA 
in HUVECs. a) Relative gene transcription levels. c) Secretion of CAMs. Cells were 
pretreated with PDTC 100 µM for 0.5h and then treated with SAA 20 µg/ml for 4 h (a) 






























Figure 3.5. The effects of SAA on NFκB tranlocation and activation in HUVECs. 
Cells were incubated with SAA (20 µg/ml) for 0-2 hour. Active subunit NFκB 
p65/p50 levels in nuclear extraction were determined by ELISA . *: P < 0.05 vs 




Ross proposed in 1999 that atherosclerosis is an inflammatory disease and 
inflammatory factors play key roles in atherogenesis.
 2
 Many classical cytokines have 
been shown to lead directly to endothelial proinflammation and their readiness for 
leukocytes recruitment, which constitute the initial step of atherogenesis. This study 
has shown that SAA could induce the expression of adhesion molecules in both 
HUVECs and HCAECs. The results are consistent with a previous study which 
assayed ICAM and VCAM by flow cytometer in HMVECs and RA fibroblast-like 
synoviocytes.
43
 Our study has specifically shown SAA had similar effects on human 
endothelial cells that are derived from large vessels as those on HMVECs. Our study 
has further shown that in addition to the two commonly studied ICAM-1 and VCAM-
1 a third CAM, E-selectin, was also highly induced. This phenomenon has not been 
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reported before. The transcriptional peak of E-selectin (4 h) appeared earlier than 
ICAM-1 and VCAM-1 (6 h) due to their different functions during the adhesion 
cascade. E-selectin initially creates a weak bond between activated endothelial cell 
and carbohydrate ligands on the surface of the leukocytes.
 184
 ICAM-1 and VCAM-1 
are involved in sequential firm adhesion facilitated by interaction with lymphocyte 
function antigen-1 and very late antigen-4 respectively.
 73,74
  In this study, the three 
typical adhesion molecules of endothelial cells have been examined in terms of their 
mRNA (Figure 3.1) and cell surface protein levels (Figure 3.2). Our data confirm our 
hypothesis that SAA may directly lead to vascular proinflammation at the endothelial 
cells besides being mediated through leukocytes. In order to compare our data to 
clinical studies in which secreted CAM levels were measured in the plasma or serum, 
we measured the secretion of CAMs from our cell lines. Elevated CAM levels in 
circulation are useful biomarkers and potential predictors of CAD. In our study, the 
elevated concentration of CAMs in cell culture medium after SAA incubation (Figure 
3.3) is analogous to the observation that plasma or serum levels of CAMs are 
increased in CAD patients with elevated SAA levels.  
    SAA shares many similar characters with another acute phase protein CRP. The 
circulating levels of these two major acute phase proteins can be elevated induced by 
100-1000 folds in their circulation levels when subjected to acute inflammation 
stimuli. Increasing number of clinical studies has shown that both proteins are 
elevated in CAD patients and are related to future coronary events.
 
The Women’s 
Health Study showed that elevated plasma levels of CRP and SAA were significantly 
associated with CAD risk and had strong predicting value.
 6
 CRP is believed to 
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contribute to atherogenesis directly and its primary functions have been investigated 
widely in the past decade.  Many in vitro studies have demonstrated that CRP 
activates the entire recruitment cascade of white blood cells by inducing the release of 
ICAM-1, VCAM-1, E-selectin, and monocyte chemotactic protein-1 (MCP-1).
 8,9
 In 
this study, highly-purified recombinant SAA without azide was used and the LPS 
effects were tested and proven to have little influence on SAA impacts. Therefore, the 
proinflammatatory effects observed in this study could undoubtedly be attributed to 
SAA. Furthermore, SAA has its own special characters. Firstly, SAA was reported as 
a potential substrate of Scavenger Receptor Class B type I (SR-BI). SAA was found 
to bind to SR-BI and mediate IL-8 secretion in Hela cells. 44 Secondly, SAA is an 
apolipoprotein. At normal levels, SAA associates with high-density lipoprotein (HDL) 
to form a heterogeneous HDL fraction containing SAA and predominant apoA-I. At 
elevated concentrations however, SAA displaces apoA-I to bind HDL predominantly 
or exists in circulation as lipid-free form. The biological characteristics of SAA as 
both an inflammatory protein and an apolipoprotein are of great interest in CVD 
research because both are involved in atherogenesis.  An animal study
26 
has proven 
the link between a high-fat diet, SAA and atherosclerosis.  In the study, female LDL-
receptor–null (LDLR-/-) mice were fed with high-fat diets (21%, wt/wt) for 10 weeks 
and plasma SAA levels were observed to be elevated.  The addition of cholesterol in 
the diet further increased SAA levels by 2-fold. They also observed that plasma SAA 
levels correlated significantly with the extent of atherosclerosis at the aortic arch. 
Moreover, SAA levels obtained after 5 weeks on diet correlated significantly with 10-
week lesion areas at the aortic sinus. Their results demonstrated that SAA levels 
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could predict the extent of atherosclerosis in LDLR-/- mice and that SAA might be 
involved in lesion development. In a lean insulin-sensitive human group, SAA level 
was also reported to be significantly elevated after cholesterol feeding for 4 weeks. 27 
Therefore, SAA might be the bridge that links lipids with atherosclerosis. We 
speculate that besides being responsible for fatty deposits on vascular walls, lipids 
may lead to atherosclerosis through triggering the expression of SAA.  If stimuli are 
sustained and SAA level remains elevated, leukocytes may accumulate in vessels and 
finally lead to atheroma formation. 
    The signal transduction pathway related to SAA and its effects were also examined 
in this study. NFκB is a central signaling molecule in inflammation. 93 With 
increasing evidences that atherosclerosis is also a chronic inflammatory disease, 
NFκB is now considered to be a major transcription factor regulating many functions 
of the vessels.
 
 Moreover, NFκB activation is thought to lie downstream of many of 
the stimuli proposed to be involved in atherosclerosis, such as modified lipoproteins, 
cytokines and infectious agents.
 94
 Interestingly, this study has shown that SAA could 
induce nuclear translocation and activation of NFκB (Figure 3.5). Furthermore, a 
NFκB inhibitor PDTC inhibits the effects of SAA on CAMs (Figure 3.4). Normally 
NFκB forms a complex with IκB. Once it receives a stimulus, IκB starts to 
phosphorylate and degrades. Activated NFκB subunits are released from the complex, 
translocate to the nucleus and bind to relevant DNA sequence to initiate expression of 
target genes. Inhibition of IκB degradation by PDTC can prevent NFκB escape and 
block the cascade pathway. In this study, the inhibition of SAA effects by PDTC may 
be through the inhibition of IκB degradation. We have clearly demonstrated that SAA 
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could induce the expression of adhesion molecules in endothelial cells and this was 
mediated through the NFκB pathway. A recent study reported that SAA could 
activate NFκB and proinflammatory gene expressions (IL-8, COX2) in intestinal 
epithelial cells (EPCs).
 45
 The results of our study are consistent with those carried out 
with EPCs. This suggests that SAA may have wide-spread effects in different cells 
via the NFκB pathway and therefore, may also influence other vaso-related cells, such 
as smooth muscle cells.  
    In summary, this study is the first to investigate the direct roles of SAA on 
atherosclerosis. SAA was found to induce proinflammatory effects in cultured 
HUVECs and HCAECs. The effects were expressed through activation of NFκB, a 
key signaling molecule in the inflammatory responses.  These findings suggest that 
SAA may be involved in the initial step of atherogenesis and could be a potential 







Study III - The effects of SAA on endothelial dysfunction 
Inflammation is known to play a critical role in all stages of atherosclerosis, from 
nascent lesion to plaque rupture.
2
 Serum amyloid A (SAA), in many ways similar to 
C-reactive protein (CRP)
5
, is a significant marker of inflammation and has been 
shown in numerous prospective studies to predict future cardiovascular events.
 6,16,17 
However, unlike CRP, SAA is relatively less well studied. Some experiment data 
have suggested that SAA may contribute to atherogenesis.
 23
 Recently SAA has been 
reported to induce adhesion molecule expression 
43
 and cytokine secretion 
25
 in 
cultured human endothelial cells (ECs). However, little is known about SAA beyond 
its proinflammatory effects.  
A crucial enzyme present in endothelial cells (ECs) is endothelial nitric oxide 
synthase (eNOS), which catalyze the reaction of converting L-arginine to nitric oxide 
(NO). NO is a key endothelium-derived relaxing factor (EDRF) which promotes 
vasodilatation.
 99
 NO also exerts its wide inhibitory effects on LDL oxidation, platelet 
adhesion and aggregation, and monocyte recruit to endothelium.
 104
 Decreased 
production of NO or endothelial dysfunction has been found to occur in the early 
stage of atherogenesis and contribute to the whole process. 99 Impaired NO release 
could promote vasoconstriction, leukocyte recruitment, platelet aggregation, 
oxidation, thrombosis, and even vascular inflammation. Indeed, decreased NO 
production has been shown to be associated with future risk of adverse cardiovascular 
events.
 185
All major known risk factors for atherosclerosis such as hyperlipidemia, 




In the current years, NO is also noted as a key modulator of 
angiogenesis, including cell proliferation, cell migration and capillary-like tube 
formation. 114  
Hypothesis We hypothesized that SAA could impair the vasoreactivty through the 
inhibition of eNOS expression.  
In this study, we tested the effect of SAA on eNOS expression and bioactivity in 
human umbilical endothelial cells (HUVECs) and human coronary artery endothelial 
cells (HCAECs) to determine if SAA could impair eNOS expression, NO production 
and cell proliferation. 
 
4.1 Methods 
4.1.1 Cell Culture  
Human umbilical vein endothelial cells (HUVECs) and human coronary artery 
endothelial cells (HCAECs) (Clonetics) were cultured as described in Chapter 2 
HUVECs from passage 4-5 and HCAECs from passage 3-4 were used in all of the 
following experiments. 
    In SAA treatment studies, cells were cultured to confluence and SAA (PeproTech) 
was added to the medium at concentrations of 0-40 µg/ml for 24 h. In protein study, 
TNFα (10 ng/ml) were used as a positive control.     
4.1.2 . Gene Expression Level Determination by QRT-PC. 
QRT-PCR was carried out as described in Chapter 2. The primers for eNOS were 
listed in Table 2.  
4.1.3 SDS-PAGE and Western Blot 
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The stimulated and unstimulated HUVECs in 6-well plate were washed with ice-cold 
1 x PBS. The cells were lysed with 1 x SDS-sample buffer with proteinase inhibitors, 
containing 62.5mM Tris-HCl (PH 6.8), 2% w/v SDS, 10% glycerol, and 50mM DTT. 
After homogenizing by repeated drawing and injecting through a 27-gauge needle, 
the cell lysates were centrifuged for 10 minutes at 12,000 rpm at 4°C. Total protein 
concentration was determined by the Bradford method and aliquots were stored at – 
80 °C. Thirty-microgram samples were loaded and separated by 8 % SDS-PAGE gel. 
After an electrotransfer for 2 h at 90 V, the nitrocellulose membranes were blocked 
for 1 h with 5% skimmed milk (w/v) and 0.1% Tween 20 in Tris-buffered saline 
(TBS). After washing, the membranes were incubated with diluted primary antibodies 
for 1 h at room temperature or overnight at 4 °C. Mouse monoclonal anti–eNOS 
antibody (Cell signaling) was used at a concentration of 1:1000. After washing, the 
membranes were incubated with diluted secondary antibody for 1 h at room 
temperature. Anti-mouse secondary antibody coupled to horseradish peroxidase (Cell 
signaling) was used at a concentration of 1:2000. After thorough washing, the blots 
were developed with the LumiGLO substrate (Cell signaling) for 1 minute and 
exposed with Clear Blue X-ray film (Pierce). Bands were quantified by densitometry 
using a scanner and the Quantity One 4.6.1 software (Bio-Rad). The signals were 
normalized with β-actin (Sigma-Aldrich). Evenness of sample loading was confirmed 
by Ponceau S staining.      
4.1.4 Nitric oxide product colorimetric assay 
HUVECs of the same density (10,000 cells/well) were seeded onto the 96-well plates. 
After overnight incubation, cells were stimulated with 0-40 µg/ml SAA for 24h. The 
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culture supernatants were collected and the total nitric oxide production was 
determined by Nitrate/Nitrite Colorimetric Assay Kit (Caymen). The final products of 
NO are nitrite (NO2-) and nitrate (NO3-). The Caymen Chemical Nitrate/Nitrite 
Assay Kit provides an accurate and convenient method for measurement of total 
nitrate/nitrite concentration in a simple two-step process. The first step is the 
conversion of nitrate to nitrite using nitrate reductase. The second step is the addition 
of the Griess reagents (R1 and R2) which convert nitrite into a deep purple azo 
compound. Photometric measurement of the absorbance due to this azo chromophore 
accurately determines NO2- concentration. All the procedures were carried out 
according to the kit manufacturers’ manuals.  Briefly, 80 µl of culture supernatant, 10 
µl of enzyme cofactor mixture and 10 µl of nitrate reductase mixture were added to 
96-well plate and incubated at room temperature for 2 h. After incubation, 50 µl of 
Griess Reagent R1 and 50 µl of Griess Reagent R2 were added to each of the wells. 
After the color development for 10 min, the absorbance was measured at 540 nm 
wavelength by a microplate reader (Sunrise). A standard curve (0, 3, 6, 9, 12, and 15 
µM nitrate standard) was carried out in each run. The nitrate/nitrite concentration was 
calculated according to the OD reading.  
4.1.5 Cell proliferation assay 
We selected the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] 
method to assay for EC proliferation, which served as an index of angiogenesis.
 187 
MTT is a tetrazolium salt which is cleaved by active mitochondria to form a dark blue 
formazan product. This has been used as a measure of proliferation as living cells 
produce the formazan product and correlation has been shown with cell number. In 
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this study, HUVECs of the same density (5,000 cells/well) were seeded onto the 96-
well plates. After 4h incubation, cells were stimulated with 0-40 µg/ml SAA in 
medium with or without 5% FBS for 24h. MTT assay was carried out to assay the cell 
proliferation. Twenty microliter of MTT (Molecular Probes) stock solution in 1 x 
PBS (5mg/ml) was added into each well 5 h before the endpoint and incubated at 
37ºC with 5% CO2. At the endpoint, medium was removed and 200 µl of DMSO was 
added into each well and incubated at room temperature for 5 min. The absorbance 
was measured at 550 nm by a microplate reader (Sunrise). The relative cell 
proliferation was calculated from the different OD readings.  
4.1.6 Statistical Analysis 
Measurements were expressed as mean ± SD from at least 3 independent experiments. 
The differences were compared by Mann-Whitney test using SPSS 12.0. Significant 
difference was defined as P value < 0.05.    
 
4.2 Results 
4.2.1 SAA inhibits eNOS gene transcription 
To study the effect of SAA on eNOS gene expression, we first tested the mRNA level 
in stimulated or unstimulated samples with the use of QRT-PCR. As shown in Figure 
4.1, incubation with SAA (20 µg/ml) for 24 h markedly inhibited eNOS mRNA level 
by 68.4 ± 1.0 % in HUVECs. In HCAECs, eNOS transcription was similarly 
suppressed by 78.0 ± 7.0 % by SAA treatment for 24 h. 
4.2.2 SAA inhibits eNOS protein level 
 99 
We further examined the eNOS protein level in cell lysate by western blot. Incubation 
with SAA (20 µg/ml) for 24 h markedly inhibited eNOS protein level in HUVECs 
































Figure 4.1. SAA inhibits eNOS transcription in HUVECs and HCAECs. Cells were 


























eNOS:              -140KDa 
β-actin:             -42KDa 
Figure 4.2. SAA inhibits eNOS gene expression. HUVECs were incubated with or 
without SAA 20 µg/ml for 24 h. Blots are representative of 4 individual experiments. 
The data of SAA treatment are comparable to those of TNFα (10ng/ml) treatment. *: 
P < 0.05 vs Control. n=4. 
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mRNA and protein results suggest that SAA could inhibit eNOS expression in 
cultured endothelial cells. 
4.2.3 SAA inhibits NO production  
NO production was determined by the measurement of its final products nitrate 
 (NO3-) and nitrite (NO2-) in different culture supernatants. As shown in Figure 4.3, 
SAA inhibited NO production in a concentration-dependent manner. SAA with the 























Figure 4.3. SAA inhibits nitric oxide production in a concentration-dependent manner. 
HUVECs were incubated with SAA 0-40 µg/ml for 24 h. *: P < 0.05 vs Control. n=4-
5. 
 
                    
4.2.4 SAA inhibits endothelial cell proliferation 
NO is a signal molecule regulating many cellular processes, including cell 
proliferation. Hence we tested the effects of SAA on endothelial cell proliferation. As 
shown in Figure 4.4, cell proliferation was significantly suppressed by 10-40 µg/ml 































Figure 4.4. SAA inhibits endothelial cell proliferation in a concentration-dependent 




Atherosclerosis is associated with impairment of endothelium-dependent relaxations, 
which is characterized by the reduced bioavailability of NO produced from eNOS. 2 
NO has a variety of functions, but its action as the endothelium-derived relaxing 
factor (EDRF) is the most important for the maintenance of vascular tone and activity.
 
In the vessels, NO is derived from endothelium by constitutive expression of eNOS, 
which is activated by mechanical stress such as blood shear-stress and stimulation 
with agonists such as bradykinin and acetylcholine. Some studies of eNOS 
demonstrated that the T allele of at the eNOS G894T site (encoding Glu298→Asp) 
leads to endothelial dysfunction and is a major risk for CAD. 
105,106
 Furthermore, 
eNOS expression and bioactivity has been found to be suppressed by many CAD risk 






). TNFα and IL-6 were reported to inhibit eNOS gene 
 102 
promoter activity and its transcription sequentially.
 111,113
 CRP was also shown to 
attenuate eNOS expression and NO production. 10,112 Given the character of SAA as 
an acute phase protein similar to CRP, we sought to determine whether SAA could 
lead directly to endothelial dysfunction via eNOS inhibition. Using a variety of 
techniques, we convincingly show that SAA could significantly inhibit the expression 
and bioactivity of eNOS in human endothelial cells. Our results showed a markedly 
decrease of eNOS expression in both mRNA and protein levels after 24 h SAA 
incubation. Moreover, its bioactivity was also significantly attenuated which was 
marked by the reduced release of NO.  
    In addition to being the key molecule to maintain the vascular reactivity, NO has 
also been regarded as an important modulator of angiogenesis. 114 Angiogenesis is a 
key compensatory mechanism in response to chronic ischemia and has emerged as an 
important therapeutic target for ischemic heart disease. NO inhibits apoptosis and 
enhances endothelial cell proliferation, perhaps in part by increasing the expression of 
vascular endothelial growth factor (VEGF)
 115,116
 or fibroblast growth factor (FGF).
 
117
 NOS inhibitors block VEGF- or FGF-induced EC proliferation and capillary-like 
tube formation. The genetic loss of eNOS in mice (eNOS-/-) significantly impaired 
angiogenesis in the ischemic hindlimb evaluated by either laser Doppler flow analysis 
or capillary density measurement.
 118
 Furthermore, the deficiency of blood flow 
recovery and ischemic remodeling in eNOS-/- mice could be rescued by adenovirus 
delivery of eNOS gene.
 119
 Another acute phase protein CRP (25µg/ml) has been 
previously reported to inhibit both basal and VEGF-stimulated angiogenesis as 
assessed by EC migration and capillary-like tube formation.
 10
 We selected the MTT 
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method to assay for EC proliferation as an index of in vitro angiogenesis.
 
Our data 
showed that SAA (≥ 10µg/ml) attenuated EC proliferation corresponding to a reduced 
NO production. Moreover, endothelial cell proliferation was inhibited by SAA with 
or without 5% FBS which contained various growth factors. Thus, SAA could also 
impair in vitro angiogenesis regulated by eNOS-derived NO.  
In conclusion, our study presents further evidence of the critical role of SAA in 
atherogenesis. Along with the capacity to induce vascular proinflammation, it also 
results in endothelial dysfunction by inhibiting eNOS expression and bioactivity, as 









Study IV- The effects of SAA on procoagulation 
Coronary artery disease (CAD) is one of the top causes of death in affluent societies. 
Atherosclerosis, which is the pathological basis of CAD, is now considered a chronic 
inflammatory disease of the vascular wall.
2 
Many inflammatory proteins are elevated 
in CAD and correlated with the future coronary events.
 5 
Furthermore, effectors of the 
immune system interact with metabolic and other risk factors to initiate, propagate, 
and activate lesions in the arterial tree.
 4
 SAA is a major acute phase protein and a 
useful biomarker of CAD. Recent studies have demonstrated that SAA may act as a 
cytokine to cause proinflammation in cultured endothelial cells, which is the initial 
step of atherosclerosis.
 43
 However, the possible impact of SAA on the other stages of 
atherogenesis remains obscure.    
The initiation of coagulation plays an important role in thrombus formation, which 
is the major cause of acute coronary events.
 120-122
 The coagulation cascade is initiated 
as soon as tissue factor (TF) binds activated factor VII (FVIIa), which in turn 
activates factor X (FX), and ultimately leading to thrombin formation.  The 
procoagulant state is crucial in the pathogenesis of acute coronary syndromes. 123 TF 
can be highly induced in the process of atherosclerotic plaque formation by 
endothelial cells and monocytes, which do not normally express TF under 
physiological conditions. Furthermore, elevated levels of TF antigen and activity have 
been detected in plasma and atheroma specimens of patients with unstable angina. 
Elevated TF expression has been shown in all stages of atherosclerosis; whereas a 
very low basal level in normal site is maintained. In vitro studies had demonstrated 
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that TF could be markedly induced by some CAD risk factors, such as cytokines 
(TNFα131 and CRP11), histamine 132 and oxidized LDL. 144 Thus, TF is involved in the 
initiation and propagation of acute coronary syndromes.  TF pathway inhibitor (TFPI) 
is a plasma Kunitz-type serine protease inhibitor, which binds TF/FVIIA complex 
directly and inhibits the coagulation process. 
137 
Inhibition of TF by recombinant 
TFPI was reported to reduce acute thrombus formation in human lipid-rich plaque
130 
and in animal injured plaques.
138,139
 Conversely, native TFPI degradation after 
thrombolysis may enhance procoagulation and lead to early reocclusion after 
thrombolysis in myocardial infarction.
 140
 Although the function of TFPI has been 
well determined in the past decade, its regulation is poorly understood to date.     
Hypothesis We hypothesized that SAA could induce precoagulation through the 
induction of TF and inhibition of TFPI.   
    In this study, we investigated the effects of SAA on endothelial expression and 
activity of TF and TFPI in order to shed some light on the obscure role of SAA on 
hemostasis. In addition, we also examined the signal transduction pathway involved 
in the SAA function.  
 
5.1 Methods 
5.1.1 Cell Culture  
HUVECs and HCAECs (Clonetics) were cultured as described in Chapter 2. 
HUVECs from passage 4-5 and HCAECs from passage3-4 were used in all of the 
following experiments. 
    In SAA treatment studies, cells were cultured to confluence and SAA (PeproTech) 
was added to the medium at concentrations of 0-20 µg/ml for 2-48 h. The endotoxin 
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levels in the SAA preparation were confirmed by E-TOXATE test kit (Sigma-Aldrich) 
to be ≤ 1 EU/ µg protein. 
    In our pathway study, three groups of cells were pretreated with 5 or 50 µmol/l of 
PD98059 (Sigma-Aldrich), 1 or 10 µmol/l of SB203580 and 1or 10 µmol/l of SP 
600125 (ALEXIS Biochemicals) each for 1 h and then treated with SAA 20 µg/ml for 
4 h.  These are specific inhibitors of the mitogen-activated protein kinases (MAPK) 
p38, ERK1/2 and JNK respectively.   
5.1.2 Protein Expression Estimation by Western Blot 
Total protein was isolated as described in Chapter 4. Thirty-microgram samples were 
loaded and separated by 12 % SDS-PAGE gel. After an electrotransfer for 1.5 h at 90 
V, the nitrocellulose membranes were blocked for 1 h with 5% skimmed milk (w/v) 
and 0.1% Tween 20 in Tris-buffered saline (TBS). After washing, the membranes 
were incubated with diluted primary antibodies for 1 h at room temperature or 
overnight at 4 °C. Rabbit polyclonal anti–TF antibody (American Diagnostica Inc.), 
mouse monoclonal anti-phospho-p38 MAPK (Thr180/Tyr182) antibody and mouse 
monoclonal anti-phospho-JNK (Thr183/Tyr185) were used at a concentration of 
1:500 while that of anti-phospho-ERK1/2 (Thy202/Tyr204) antibody (Cell Signaling) 
was used at 1:1000. After washing, the membranes were incubated with diluted 
secondary antibody for 1 h at room temperature. Anti-rabbit or anti-mouse secondary 
antibody coupled to horseradish peroxidase (Cell signaling) was used at a 
concentration of 1:2000. After thorough washing, the blots were developed with the 
LumiGLO substrate (Cell signaling) for 1 minute and exposed with Clear Blue X-ray 
film (Pierce). Bands were quantified by densitometry using a scanner and the 
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Quantity One 4.6.1 software (Bio-Rad). The signals were normalized with β-actin 
(Sigma-Aldrich). 
5.1.3 Measurement of Cellular and Secreted TFPI by ELISA 
HUVECs of the same density (10,000 cells/well) were seeded onto the 96-well plates. 
After an overnight incubation, cells were stimulated with 0-20 µg/ml SAA or 10 
ng/ml TNFα for 4, 24 or 48h. The culture supernatants were collected and the TFPI 
levels were determined by ELISA (American Diagnostica). All the procedures were 
carried out according to the manufacturer’s manual.  Culture medium 50 µl diluted 
with 50 µl of assay buffer was added to primary antibody coated plate and incubated 
overnight at 4°C. After washing, 80 µl of biotinylated anti-human TFPI F(ab')2 was 
added to each well and incubated for 1 h at room temperature. After 4 times washing, 
100 µl of diluted strepavidin-HRP conjugate to each well and incubated for 1 hour at 
room temperature. After thorough washing, 100 µl of TMB substrate solution was 
added and incubated for 20 min for color development. A standard curve (5, 2.5, 1.25, 
0.625, 0.312 and 0 ng/ml TFPI standard) was conducted. The protein concentration 
was determined by the absorbance at 450/620 nm after stop solution adding.  
    Cellular TFPI protein levels were also determined by the same ELISA kit. 
HUVECs were cultured to confluence in 6-well plates and stimulated with 20 µg/ml 
SAA, 10 ng/ml TNFα or vehicle for 24h. The cells were lysed in a cell lysis buffer 
with proteinase inhibitors containing 50mM Tris-HCl (pH 7.6), 100mM NaCl and 
0.1% Triton X-100. Sixty microgram of each individual samples were added to the 
microwell plate to measure the TFPI levels following the protocol.  
5.1.4 Gene Expression Level Determination by QRT-PCR 
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Cells were cultured to confluence in 6-well plate. After treatments with SAA for 
various durations (2-48 h) and concentrations (0-20 µg/ml), total RNA was isolated 
using RNAeasy Mini Kits (QIAGEN). QRT-PCR was carried out as described in 
Chapter 2. The primers for TF, TFPI and GAPDH were listed in Table 2.  
5.1.5 TF and TFPI activity assay 
Actichrome TF activity assay kit (American Diagnostica Inc.) was used to determine 
the TF activity of the cell lysates of HUVECs with or without 20 µg/ml SAA 
treatment for 4 h. Cells were lysed by repeated drawing and injecting through 27-
gauge needle in a buffer of 50mM Tris-HCl, 100mM NaCl and 0.1% Triton X-100, 
pH 7.4. Thirty-microgram samples were mixed with assay buffer and incubated with 
20 µl of Human Factor VIIa and 20 µl of Human Factor X at 37°C for 15 min. 
Another 20 µl of Spectrozyme FXa substrate was added to develop color at 37°C for 
20 min. After addition of 50 µl of glacial acetic acid, the absorbance was measured at 
a 405/490 nm wavelength by a microplate reader (Sunrise). A standard curve (60, 30, 
15, 7.5, 3.75, 1.88, and 0 pM TF standard) was carried out in each run. 
    Actichrome TFPI activity assay kit (American Diagnostica Inc.) was used to 
determine the TFPI activity of the culture medium of stimulated and unstimulated 
HUVECs. Thirty-microgram samples were mixed with assay buffer and incubated 
with 25 µl of TF/VIIa complex at 37°C for 30 min. According to the manufacturer’s 
manual, human Factor X, Spectrozyme FXa substrate and EDTA were added 
sequentially at 37°C. After addition of glacial acetic acid, the absorbance was 
measured at a 405/490 nm wavelength by a microplate reader. A standard curve (0.2, 
0.1, 0.08, 0.06, 0.04, 0.02, and 0 U/ml TFPI standard) was conducted in each run. 
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    For cell surface TF or TFPI activity, HUVECs of the same density (10,000 
cells/well) were seeded onto the 96-well plates and incubated overnight. Cells were 
treated with SAA 20 µg/ml for 4 h or 24 h. The performing protocols were same as 
above except that cell monolayers were washed twice with 1 x PBS and reagents were 
added directly to the cell culture wells. 
 5.1.6 Statistical Analysis 
Measurements were expressed as mean ± SD from at least 3 samples. The differences 
were compared by Mann-Whitney test using SPSS 12.0.  Significant difference was 
defined as P value < 0.05.    
 
5.2 Results 
5.2.1 SAA induces TF expression in HUVECs and HCAECs 
To examine whether SAA could lead to endothelial procoagulation, TF expression 
levels were investigated at both the protein and mRNA level in relation to varying 
concentration and time exposure to SAA stimulation. Western blot analysis (Figure 
5.1a) shows the induction of endothelial TF protein level by SAA over time. 
Recombinant human SAA (20 µg/ml) markedly induced TF expression between 4-8 h. 
QRT-PCR data (Figure 5.1b-c) confirmed the TF transcription were highly induced 
between 2-16 h and the induction was concentration-dependent. The TF transcription 
in HCAECs after SAA (20 µg/ml for 4h) incubation showed a similar trend (Figure 
5.1d), thus confirming the observation that SAA could highly induce TF expression 
within 24 h.  
5.2.2 SAA inhibits TFPI expression in HUVECs and HCAECs 
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TFPI is the endogenous inhibitor of the TF/FVIIa complex and is therefore potentially 
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Figure 5.1. SAA induces TF expression in HUVECs (a-c) and HCAECs (d). 1a). 
SAA (20 µg/ml) induces TF protein levels. b-c). Time- and concentration-dependent 
effects of SAA on TF mRNA. d) SAA (20 µg/ml, 4h) induces TF mRNA in HCAECs. 
*, P < 0.05 vs Control. n=3-4. 
 
obscure to date. To investigate the effects of SAA on TFPI, its expression pattern in 
relation to duration of SAA treatment was determined by ELISA and QRT-PCR. The 
effect of SAA on TFPI secretion over time is shown in Figure 2a. SAA did not 
significantly inhibit TFPI at 4h, but only thereafter. TFPI level in supernatants of 
SAA (20 µg/ml) samples was significantly declined by 38.2 ± 2.2% at 24 h compared 
to the non-stimulated controls and 26.0 ± 3.1 % at 48 h. The inhibitory effects of 
SAA on TFPI secretion was concentration-dependent (Figure 5.2b).  The inhibitory 
effects of SAA on TFPI secretion was concentration-dependent (Figure 5.2b). 
Cellular TFPI levels were simultaneously decreased with SAA treatment for 24 h 
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(Figure 5.2c). Interestingly, a common cytokine TNFα (10ng/ml) showed a similar 
inhibitory effect on TFPI expression. QRT-PCR confirmed that the gene transcription 
was also inhibited in longer-term SAA incubation (Figure 5.2d). Incubation of SAA 
(20 µg/ml ) for 24 and 48 h suppressed TFPI transcription by 67.7 ± 9.4%  and 51.7 ± 
1.4 %, respectively.  Similar gene expression pattern was obtained again in TNFα 
samples.  As a further confirmation in a different cell line, incubation HCAECs with 
SAA (20 µg/ml) was also shown to inhibit TFPI mRNA level (Figure 5.2e) with a 
similar time-course trend. This demonstrated that SAA has the dual effect of 


































































































































































Figure 5.2. SAA inhibits TFPI expression in HUVECs (a-d) and HCAECs (e). a-b). 
TFPI secretion in cell supernatants. c). TFPI protein levels in cell lysates. d-e) TFPI 
mRNA. . Cells were incubated with SAA 20µg/ml or TNFα (10ng/ml) for 24 h. *, P < 
0.05 vs Control or “0”. n=3-5 
 
5.2.3 The Effect of SAA on TF and TFPI activity  
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Beyond investigation of the effects of SAA on TF and TFPI expression, we went on 
to investigate its effects on TF and TFPI activity levels as these are crucial in the 
blood coagulation cascade. Stimulation with SAA (20 µg/ml) for 4 h dramatically 
induced surface TF activity levels up by 26.3 ± 2.5 fold (Figure 5.3a). Cellular TF 
activity in lysate was also induced. Guided by the results of the time course study of 
SAA treatment on TFPI transcription and protein expression levels, we studied the 
effects of 24 h SAA treatment on cell surface TFPI activity, which declined by 15.1 ± 
1.8% (Figure 5.3b). Correspondingly, supernatant TFPI activity declined by 33.7 ± 
































































Figure 5.3. SAA induces TF activity (a) and inhibits TFPI activity (b). Cells were 
incubated with SAA 20µg/ml for 4h (TF activity) or for 24 h (TFPI activity). TNFα 
was used at 10ng/ml for  24h.  *: P < 0.05 vs Control. n = 3-5. 
 
5.2.4 The induction of SAA on TF is mediated through MAPK pathway 
MAP kinase activation regulates TF expression in response to several cytokines. To 
assess whether the induction of TF by SAA is mediated through MAPK pathway, we 
examined the effect of specific pathway inhibitors on TF induction. SB203580, PD 
98059 and SP600125 are specific inhibitors for p38, ERK1/2 and JNK respectively.  
Preincubation with these inhibitors was shown to significantly inhibit SAA-induced 
TF expression (Figure 5.4a) and activity (Figure 5.4b).  
    To determine whether SAA can activate MAPK pathway directly, HUVECs were 
examined at different time points after stimulation (Figure 5.4c). p38, ERK, and JNK 
were transiently activated after stimulation with SAA (20 µg/ml). Maximal 
phosphorylation of p38, ERK and JNK occurred between 15-45 minutes and declined 
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phospho-p38                  40KDa 
β-actin                     
phospho-ERK1/2           44, 42KDa 
β-actin                    
phospho-JNK                 54,46KDa  
β-actin                          
SAA 20µg/ml:          0       5       15      30     45     60 min 
 
Figure 5.4. The induction of SAA on TF expression is mediated by MAP kinases p38, 
ERK and JNK.  SB203580 (10µM), PD98059 (50µM) and SP600125 (10µM) inhibit 
the SAA-induced TF expression (a). They also inhibit cell surface TF activity in a 
concentration-dependent manner (b). Concentration unit: µM. 4c). SAA induces p38 
MAPK, ERK1/2 and JNK phosphorylation. *: P < 0.05 vs Control. #: P < 0.05 vs 
SAA group. n = 3-4. 
 
5.3 Discussion 
Ross proposed in 1999 that atherosclerosis is an inflammatory disease and that 
inflammatory factors play key roles in atherogenesis. 
2
Many classical cytokines have 
been shown to lead directly to endothelial procoagulation through TF induction. Our 
time-course study has shown that SAA could exert very significant effect on the 
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expression and activity of TF and TFPI in human endothelial cells - inducing TF 
between 4-8 h and inhibiting TFPI between 24-48 h. With 20 µg/ml of SAA, TF gene 
transcription and protein production could be markedly induced, whereas TFPI gene 
expression and protein secretion could be inhibited. The increase in TF expression 
was translated into a marked increase of both cellular and surface TF activities; while 
a decreased expression led to a correspondent reduction of TFPI activity in both cell 
supernatants and cell surface. The presence of at least 10ug/ml of SAA could bring 
about the hypercoagulable state through either an elevation of TF or an inhibition of 
TFPI. These phenomena have not been reported before in earlier studies involving 
SAA or other common cytokines.  
    The ability of SAA to induce TF expression is not surprising. Although SAA is not 
a classical cytokine in the likes of TNFα and the interleukins (ILs), recent studies 
have demonstrated that SAA may act as a cytokine and could lead to vascular 
proinflammation. SAA was reported to induce TNFα and IL-8 expression in 
neutrophils, 
40
as well as T lymphocyte migration and adhesion.
39  
The increased 
serum levels of SAA also contributed to the sustained accumulation and activation of 
phagocytes in chronic granulomatous disease patients. 42 Furthermore, SAA was 
found to induce ICAM-1, VCAM-1 and E-selectin expression on human endothelial 
cells.
 43
 As for TF, it is highly sensitive to cytokines such as TNFα, IL-1β
 120
 and 
another acute-phase protein, CRP.
 11
 SAA and CRP are two major acute phase 
proteins which can be elevated by 100-1000 folds in circulation when subjected to 
acute inflammation stimuli.  These two proteins share many similar biological 




The Women’s Health Study has shown that elevated plasma levels of 
CRP and SAA were significantly associated with CAD risk and had strong predictive 
value. 17 CRP is believed to contribute to atherogenesis directly and its primary 
functions include the induction of TF expression in endothelial cells and monocytes. 
Therefore, it is reasonable to speculate that SAA may also stimulate TF expression 
and activity. Our results have shown that that SAA could markedly induce TF at three 
different levels: mRNA, protein and activity. The SAA-dependent TF induction 
appeared after a period of short stimulation (4-8 h), with its effect wearing off after 
16h. This time-dependent effect is comparable to other stimuli, such as TNFα, IL-1β, 
CRP, thrombin, histamine and oxidized LDL. 120   
    At the cellular level, TF expression and activity are counterbalanced by TFPI. TFPI 
is characterised by multiple protease inhibitory domains.  Its first Kunitz domain is 
involved in the inhibition of VIIa/TF catalytic complex, whereas the second domain 
mediates the binding and inhibition of FX(a). 
137 
TFPI is produced constitutively by 
vascular endothelium to maintain its anti-coagulation function. The last decade has 
brought remarkable progress in our understanding of the molecular basis and the role 
of TFPI in hemostasis. Native TFPI degradation after thrombolysis may enhance 
procoagulation and lead to early reocclusion after thrombolysis in myocardial 
infarction.
 140
 Conversely, inhibition of TF by recombinant TFPI was reported to 
reduce acute thrombus formation in human lipid-rich plaque and in animal injured 
plaques.
 130,138,139
 Furthermore, adenoviral overexpression of TFPI in injured arteries 




 Compared to its function, the biological regulation of 
TFPI remains completely obscure.  
    Inflammatory factors are believed to regulate the expression and activity of TFPI 
because they have widespread effects on thrombosis, including the balance of 
coagulation and fibrinolysis. However, these TF inducers did not show clear and 
consistent impacts on TFPI.  Shimokawa et al found that high dose of  TNFα 
(50ng/ml) and LPS (10-100 µg/ml), but not IL-1 (10 U/ml), could significantly 
decreased murine TFPI mRNA level in MSS-31 endothelial cells after 2-8 h treatment, 
with their effects wearing off after 24 h.
151
  Piro et al reported that TNFα (0.5nM), IL-
1β (10U/ml) and LPS (5 µg/ml) had no effects on transcription, secretion and surface 
concentration of TFPI in ECV304 cells for 6-24 h. 152 Szotowski et al found that TFPI 
was decreased in cell lysate of HUVECs but increased in supernatant after 5 and 18 h 
treatment by TNFα (10ng/ml) or IL-6 (10ng/l) , suggesting TFPI was secreted out 
from cells into the supernatant.
 153
 However they did not measure the TFPI 
transcription and total protein production. In order to obtain more comprehensive 
results, we measured the transcription, protein production and activity levels of TFPI 
through a time course of SAA treatment for 0-48 h. Our data demonstrated that SAA 
could significantly inhibit TFPI expression and secretion with longer treatment (24-48 
h), but not in the short treatment (4h).  Both cellular and secreted TFPI protein levels 
were simultaneously inhibited by SAA in a concentration-dependent manner, 
suggesting that such effect was not due to protein redistribution from the cells to the 
supernatant but caused by lower protein synthesis. Our mRNA results confirmed that 
TFPI transcription was also inhibited after cells were incubated with SAA for 24-48h. 
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The effects of SAA on both TF and TFPI suggest that the hypercoagulable state could 
be sustained for at least 48 h. Such time course effects have not been reported before 
in earlier studies of SAA and other cytokines.  
    We tested another cytokine, TNFα, and obtained similar sustained effects for 48 h. 
The hypercoagulable state induced by SAA may have an important clinical 
implication as SAA is known to be expressed at the site of atherosclerotic plaque
23
 
and elevated after plaque rupture.
 24
  SAA-dependent TF induction may contribute to 
the thrombosis and acute coronary events. On the other hand, inhibited TFPI 
expression and activity may explain the reocclusion of the coronary arteries after 
thrombolysis treatment since native TFPI degradation was believed to play a role in 
reocclusion. 
    The MAP kinases p38, ERK and JNK are involved in endothelial TF induction 
through stimulation by many agents, such as TNFα, histamine and thrombin.
 120
 Our 
study showed specific MAPK inhibitors could block the SAA-induced TF expression. 
Furthermore, results from western blot demonstrated that SAA directly activated p38, 
ERK and JNK by rapid phosphorylation. Hence SAA-induced TF expression is 
mediated through the MAPK pathway. Activation of p38 and ERK were reported in 
SAA-stimulated neutrophils and impacted on IL-8 secretion. 40 Recently SAA was 
found to activate p38, ERK and JNK in human intestinal epithelial cells (HT-29 
cells).
45
 Our findings have proven that the MAPK pathway also plays a regulatory 
role in human endothelial cells. Therefore, SAA may have wide-spread effects in 
different cells via the MAPK pathway.  
 121 
    In summary, this study has investigated the direct roles of SAA on procoagulation. 
SAA was found to rapidly induce TF expression and activity; whereas the inhibitory 
effect on TFPI was more slow acting. The TF induction was mediated through the 
MAPK pathway.  These findings suggest that SAA may have implications in CAD 




Study V- The effects of SAA on MMP expression 
Extracellular matrix (ECM) degradation plays a key role in the severe complications 
of atherosclerosis, such as AMI. Matrix metalloproteinases (MMPs) are the central 
enzymes for ECM damage. MMPs are a family of zinc-dependent endopeptidases 
capable of degrading extracellular matrix (ECM) components such as collagens, 
laminin, fibronectin and other glycoproteins.
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A broader spectrum and/or higher 
level of MMP activation, especially when associated with inflammation, could lead to 
pathological matrix destruction and plaque rupture, which eventually promotes 
coronary thrombosis and AMI. 155 MMPs are regulated by soluble cytokines and cell-
cell interaction. Proinflammatory cytokines, such as tumor necrosis factor-α (TNFα) 
and interleukin-1β (IL-1β), could induce MMPs in both smooth muscle cells (SMCs) 
105
 and endothelial cells (ECs). 
164
 Recently, C-reactive protein (CRP) was also 
reported to induce MMP-1 and -10 in ECs. Increased CRP and MMP-10 colocalized 
in endothelial layer and macrophage-rich areas in advanced atherosclerotic plaque.
 12
 
As induced MMPs are usually associated with inflammation, it would be interesting 
to examine the effect of anti-inflammation therapy on MMPs.  One common anti-
inflammation therapy is to selectively inhibit cycooxygenase-2 (COX-2) activity and 
its major product prostaglandin E2 (PGE2). Some studies also found that production 
of several MMPs (MMP-2 and -9) within atheroma were associated with the 
inducible COX-2 and were mediated through a PGE2-dependent pathway.
 166,167
  
Hence a widely-used COX-2 inhibitor, celecoxib, may be effective to prevent the 
MMP induction beyond its anti-inflammatory function. Although the primary impact 
 123 
of celecoxib in CAD remains in debate, some researchers recently reported that 
celecoxib treatment could have protective effects. Celecoxib has been shown to 
significantly decrease monocyte chemoattractant protein-1 (MCP-1) expression, 
macrophage infiltration 
171
, and TNFα-induced TF expression and activity.
 131
  
Recently, celecoxib was reported to suppress MMP-1, -2 and -9 secretion induced by 
cytokines (TNFα and IL-1β).
 172
  However, its effect on other MMPs remains 
unknown.  
Hypothesis We hypothesized that SAA could impair the stability of atherosclerotic 
plaque through the induction of MMPs. 
 In this study, we examined the effect of SAA on endothelial MMP-10 expression 
and also investigated the corresponding inhibitory effect of celecoxib. .  
 
6.1 Materials and Methods 
6.1.1. Cell Culture  
HUVECs and HCAECs (Clonetics) were cultured as described in Chapter 2. 
HUVECs from passage 4-5 and HCAECs from passage3-4 were used in all of the 
following experiments. 
    In SAA treatment studies, cells were cultured to confluence and SAA (PeproTech) 
was added to the medium at concentrations of 0-20 µg/ml for 4-48 h. The endotoxin 
levels of ≤ 1 EU/ µg protein in SAA preparation were confirmed by E-TOXATE test 





for 1 h and then treated with SAA 20 µg/ml for 
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24 h. In PGE2 study, cells were incubated with PGE2 (Sigma-Aldrich) at a 
concentration of 0.1-1 µM for 24 h. 175        
6.1.2 Gene Expression Level Determination by QRT-PCR 
After SAA (20 µg/ml) treatments of different time points (4, 24 and 48 h), total RNA 
was isolated using RNAeasy Mini Kits (QIAGEN). The LightCycler RNA Master 
SYBR Green I kits (Roche) were used to quantify the starting mRNA of MMP-10 and 
COX-2.  The house-keeping gene GAPDH was used as internal control. Primer 
sequences were listed in Table 2. QRT-PCR was carried out as described in Chapter 2.  
6.1.3 SDS-PAGE and Western Blot 
Thirty-microgram of total protein samples were loaded and separated by 12 % SDS-
PAGE gel. After electrotransfer for 1.5 h at 90 V, the nitrocellulose membranes were 
blocked for 1 h with 5% nonfat dry milk and 0.1% Tween 20 in tris-buffered saline 
(TBS). The membrane was incubated with mouse monoclonal anti-COX-2 antibody 
(1:1000) (Caymen) overnight at 4 °C. Following washing, the membranes were 
incubated with diluted anti-mouse secondary antibody (1:2000) (Cell signaling) for 1 
h at room temperature. After thorough washing, the blots were developed with the 
LumiGLO substrate (Cell signaling) for 1 minute and exposed to Clear Blue X-ray 
film (Pierce). For MMP-10 assay, 10 µl of conditioned culture medium samples were 
separated by 12% SDS-PAGE gene and blotted at 90V for 1h. Primary rabbit 
polyclonal anti-MMP-10 antibody (Affinity Bioreagents) was used at a concentration 
of 1:2000 and that of anti-rabbit secondary antibody (Cell signaling) was 1:2000. 
Bands were quantified densitometrically using a scanner and with the Multianalyst 
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software (Bio-Rad). The signals were normalized with β-actin. Evenness of sample 
loading was confirmed by Ponceau S staining.      
6.1.4 MMP-10 level determination by ELISA 
Cells of the same density (10,000 cells/well) were seeded onto the 96-well plates. 
After an overnight incubation, cells were stimulated with 0-20 µg/ml SAA or 0-1 µM 
prostaglandin E2 for 24h. The culture supernatants were collected and the MMP-10 
levels were determined by Quantikine ELISA kit (R&D systems). Culture medium 20 
µl diluted with 30 µl of calibrator diluents and 100 µl of assay diluents were added to 
primary antibody coated plate and incubated for 2 h at room temperature with shaking. 
After washing, 200 µl of MMP-10 conjugate was added to each well and incubated 
for 2 h at room temperature. Following thorough washing, 200 µl of substrate 
solution was added and incubated in the dark for 30 min for color development. The 
protein concentration was determined by the absorbance at 450/540 nm after stop 
solution adding. A standard curve (5000, 2500, 1250, 625, 312, 156.3, 78.1 and 0 
pg/ml MMP-10 standard) was conducted in each run. 
6.1.5 Prostagladin E2 level measurement by EIA 
The level of PGE2, the primary product of COX-2, was measured by a commercial 
EIA kit (Caymen). The procedure was carried out according to the manufacturers’ 
manual. Briefly, 50µl of conditioned medium was incubated with 50µl of PGE2 
AChE Tracer and 50 µl of monoclonal antibody at 4 °C for 18 h. After thorough 
washing, 200 µl of Ellman’s Reagents was added to each well and incubated in the 
dark for 75min. The absorbance was measured at 410 nm by a microplate reader 
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(Sunrise). A standard curve (1000, 500, 250, 125, 62.5, 31.3, 15.6, 7.8 and 0 pg/ml 
PGE2 standard) was carried out according to the manufacturers’ manual. 
6.1.6 Statistical Analysis 
Measurements were expressed as mean ± SD from at least 3 independent experiments. 
The differences were compared by Mann-Whitney test using SPSS 12.0.  Significant 
difference was defined as P value < 0.05.  
   
6.2 Results 
6.2.1 SAA induces MMP-10 expression in HUVECs and HCAECs 
To examine the effects of SAA on endothelial MMP-10 expression, QRT-PCR, 
ELISA and western blots were carried out to measure MMP-10 at both the mRNA 
and protein levels. Figure 6.1a shows that SAA induced MMP-10 gene transcription 
from 4h to 48h in both HUVECs and HCAECs. The data from QRT-PCR were 
consistent with those obtained from microarrays. Total secreted MMP-10 protein in 
conditioned medium was also induced by SAA incubation in a concentration-
dependent manner using the 24h time point (Figure 6.1b). SAA was shown to be 
effective at a concentration of 10µg/ml.  Moreover, SAA induced both zymogen 
(56KDa) and active form (46KDa) of MMP-10 (Figure 6.1c). In HCAECs, MMP-10 
production was similarly induced by SAA treatment after 24h (Figure 6.1d).  
6.2.2 Celecoxib inhibits the SAA-dependent MMP-10 induction 
To determine other benefits of celecoxib beyond anti-inflammation, we measured the 

























































































































































Figure 6.1. SAA induces MMP-10 transcription, secretion and activation in HUVECs 
(a-c) and HCAECs (a, e). The blot is a represent of 3 independent blots. Cells were 
incubated with SAA 20µg/ml for 24 h in the case without special indication. *: 
significant difference to control, p < 0.05. n = 3-4. 
 
pretreatment.  SAA-induced MMP-10 secretion in conditioned medium was 
significantly suppressed by celecoxib preincubation in both ECs (Figure 6.2a). 
Furthermore, both the pro- and active- form of MMP-10 was inhibited by celecoxib 
(Figure 6.2b). However, celecoxib did not influence the transcription level of MMP-














































































































Figure 6.2. Celecoxib inhibits the SAA-dependent MMP-10 secretion (a) and 
activation (b) but not transcription (c).  . HUVECs were used in the case without 
special indication. Cells were pretreated with celecoxib 10µM for 1h before SAA 
(20µg/ml) treatment for 24 h. The blot is a represent of 3 independent blots. #: 
significant difference to SAA samples, p < 0.05. n = 3-4. 
 
6.2.3 Celecoxib inhibits the SAA-dependent PGE2 production 
To find the possible mediator of MMP-10 induction, we further examined the COX-2 
pathway. The COX-2 mRNA levels were markedly induced by SAA treatment over 











































































COX-2:                72KDa 




























Figure 6.3. Celecoxib inhibits the SAA-dependent PGE2 production. a,b) SAA 
induces COX-2 expression. c). Celecoxib inhibits SAA-dependent PGE2 induction. 
HUVECs were incubated with SAA 20µg/ml for 24 h in the case without special 
indication. For celecoxib study, HUVECs were pretreated with celecoxib 10µM for 
1h before SAA treatment. *: significant difference to control, p < 0.05. n = 3-4. 
 
induced (Figure 6.3b). PGE2 is the primary COX-2 product of arachidonic acid and 
its activity influences inflammation, immune modulation and vascular integrity. 
Figure 6.3c shows that SAA significantly elevated the PGE2 production and 
pretreatment with celecoxib (10 µM) could effectively suppress the SAA-induced 
PGE2 production.  
6.2.4 PGE2 has no effects on MMP-10 expression 
Based on the result that celecoxib could repress the SAA-dependent MMP-10 
induction, we determined whether the SAA-induced MMP-10 expression could be 
directly mediated through PGE2 production. Our results showed that the addition of 
0.1-1µM PGE2 in culture medium could upregulate neither transcription nor 
secretionof MMP-10 (Figure 6.4). Since PGE2 did not have any direct effect on 







































































Figure 6.4. PGE2 has no effects on MMP-10 gene transcription (a) and protein 
secretion (b). Cells were incubated with PGE2 (0-1µM) for 24 h. n = 3-4. 
 
inhibitory effect of celecoxib on MMP-10 are probably dependent on another 
pathway. 
6.4. Discussion 
Ross proposed in 1999 that atherosclerosis is an inflammatory disease and that 





Many soluble cytokines have been shown to initiate matrix 
degradation through MMP induction and activation.
 188 
Our time-course study has 
shown that SAA could exert very significant effect on the expression of MMP-10 in 
human endothelial cells and that the induction could last for at least 48 h. With the 
addition of 20 µg/ml of SAA in the endothelial cell culture medium, MMP-10 gene 
transcription and protein production could be markedly induced. Both the precursor 
and active form of MMP-10 were shown to be elevated. These phenomena have not 
been reported before in earlier studies involving SAA.  
    Our results suggested that among the MMPs, SAA only had specific effect on 




However, recent studies have demonstrated that MMP-10 is similarly associated with 
vascular disease and has important functions as other MMPs. MMP-10 (or 
stromelysin-2) has a wide substrate repertoire, which includes most of the ECM 
proteins and proteoglycans except intact fibrillar collagens.
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  Recently, elevated 
MMP-10 levels were reported in subjects with higher carotid intima-media thickness 
(IMT), and were associated with inflammatory markers (fibrinogen and CRP). 
12,189
 
Recently MMP-10 was reported to activate MMP-1 and accelerate capillary tubular 
network collapse and regression of ECs in vitro.
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  Another study examined the 
cardiovascular abnormalities in histone deacetylase 7 (HDAC7) mutant mice and 
suggested that their impaired vascular integrity was caused by overexpression of 
MMP-10. 178 These findings suggested that MMP-10 may contribute to vascular 
diseases such as atherosclerosis.
 
Although the regulation of MMP-10 is not clear to 
date, some studies revealed that MMP-10 could also be induced by TNFα and ILs.
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Recently, Montero et al found that CRP, another acute phase protein, could induce 
MMP-10 expression and activity in human ECs.
 12
 Our study showed that SAA could 
exert significant effect on the expression of MMP-10 in both HUVECs and HCAECs, 
confirming that SAA could have similar effects as other cytokines. Since MMP-10 
contributes to ECM degradation, SAA may have another direct role in atherosclerosis 
beyond merely being proinflammatory.   
    With the accumulated evidences on the association between inflammation and 
atherosclerosis, anti-inflammation therapy such as COX-2 inhibition has been 
proposed as a preventive strategy for CAD.
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 However, reports from clinical trials 
on the efficacy and effects of COX-2 inhibitors or coxibs are currently controversial.  
 134 
Some clinical trials had demonstrated that administration of coxibs, such as celecoxib, 
may lead to an increased cardiovascular risk. 168,169 On the other hand, a recent 
systematic review of observational studies of coxibs suggested that rofecoxib may 
increase the risk of cardiovascular events, whereas celecoxib does not. 
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Interestingly, celecoxib treatment was found to significantly decrease monocyte 
chemoattractant protein-1 (MCP-1) expression, neointimal hyperplasia and 
macrophage infiltration in rabbit atherosclerotic balloon injury model. 
171
 Some 
recent in vitro studies also examined the pleiotropic effects of celecoxib based on the 
inflammatory status induced by TNFα or IL-1β stimulation. Steffel et al demonstrated 
that 10µM of celecoxib could decreased TNFα-induced tissue factor (TF) expression 
and activity in human aortic endothelial cells, whereas rofecoxib and NS-398 had no 
effects. 
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 Since MMPs play a role in atherosclerosis, the effects of celecoxib on 
MMPs have also been investigated. Celecoxib was reported to suppress the secretion 
of MMP-1, -2 and -9, which were induced by cytokines (TNFα and IL-1β) in 
rheumatoid fibroblast-like synoviocytes.
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  Our study has demonstrated the 
proinflammatory effects of SAA in highly inducing COX-2 expression and PGE2 
production. Based on the selective COX-2 induction by SAA treatment, we further 
pretreated ECs with celecoxib (10µM) and its effect was confirmed by the suppressed 
PGE2 secretion. Our study also demonstrated the inhibitory effects of celecoxib on 
SAA-induced MMP-10 expression and activation. Similar suppression was also 
observed in TNFα-induced MMP-10 expression (data shown in supplementary file). 
This first study on celecoxib and MMP-10 shows consistent results with previous 
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studies of MCP-1, TF and other MMPs. Therefore, celecoxib may play beneficial 
roles to prevent matrix degradation and CAD.   
    We subsequently attempted to find the possible mediator of MMP-10 induction. 
The inhibitory effect of celecoxib suggested that COX-2/PGE2 pathway may regulate 
the MMP-10 expression.  Higher expression of COX-2, PGEs, and MMPs were found 
in symptomatic atherosclerotic lesions, especially at the plaque shoulder. 166 The -
765 G→C polymorphism of COX-2 gene was reported to have led to lower 
expression of COX-2 and MMPs.
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  The same study also found association of the 
polymorphism with a decreased risk of myocardial infarction and stroke.  In addition, 
other studies have shown that PGE2 (0.1 µM) could directly induce MMP-2 and -9 
expression in monocytes107 and macrophages. 167 However, we failed to induce MMP-
10 expression directly by PGE2 (0.1-1 µM) treatment. Our results suggested that the 
MMP-10 induction by SAA and TNFα may be mediated by another unknown 
mechanism other than the COX-2/PGE2 pathway and might possibly explain the 
different effects of similar coxibs (rofecoxib, celecoxib and NS-398) on CAD.  
    In summary, this study has investigated the effects of SAA and celecoxib on MMP 
expression. SAA was found to markedly induce MMP-10 expression; whereas 




Atherosclerosis is currently regarded as a chronic vascular inflammation by an 
increasing number of researchers and clinicians. Inflammatory factors are believed to 
contribute to various stages of atherosclerosis, from the initial proinflammation and 
endothelial dysfunction to thrombosis and the eventual rupture of the plaque. SAA, 
which is an acute phase inflammatory protein, has been found to be involved in 
atherogenesis by both clinical investigations and laboratory experiments. As the first 
study to investigate the direct roles of SAA in atherosclerosis, this project attempts to 
prove that SAA could widely influence the endothelial function in human endothelial 
cells. This chapter reviews and discusses the main findings and contributions of the 
research work described in the previous chapters. The suggestions for future work are 
also discussed and concluding remarks are given. 
 
7.1 Main findings 
7.1.1 SAA influences gene expression profile in human endothelial cells 
In the past decade, inflammatory factors (such as TNFα, ILs and CRP) have been 
found to play a role in atherogenesis. Using microarray technology, our time-course 
study has shown that SAA alters the gene expression profile in human endothelial 
cells. The genes affected include those involved in endothelial dysfunction, 
proinflammation, coagulation and plaque rupture.  Our study has shown that early 
stimulation (4h) affects expression profiles more profoundly than prolonged (24 and 
48 h) stimulation. Moreover, more transcription factors were induced when cells were 
 137 
stimulated for 4h, such as NFκB and MAPK. In addition, there were changes in gene 
expression for genes that are not involved in inflammatory process; these genes 
include ABCA1, eNOS, TF, TFPI and MMP-10. 
7.1.2 SAA induces endothelial proinflammation through NFκB activation 
Many classical cytokines have been shown to lead directly to endothelial 
proinflammation and their readiness for leukocytes recruitment, which constitute the 
initial step of atherogenesis. One of the major findings of this project is that SAA 
highly induced CAMs expression at both the transcriptional and translational level in 
cultured endothelial cells, suggesting an endothelial proinflammation or 
proatherogenic state. Although ICAM and VCAM have been found to be induced by 
SAA in HMVECs, 43 our study has specifically shown the similar effects on HUVECs 
and HCAECs. In addition, our study also shows that a third CAM, E-selectin, was 
also highly induced. Moreover, this study has shown that the SAA-dependent CAM 
induction was prevented by a specific NFκB inhibitor, PDTC. SAA has also been 
shown to cause nuclear translocation and activation of NFκB. Hence, the SAA-
induced CAM expression is mediated through NFκB pathway. 
7.1.3 SAA leads to endothelial dysfunction  
Atherosclerosis is associated with an impairment of endothelium-dependent 
relaxations, which is characterized by the reduced bioavailability of NO produced 
from eNOS. Using a variety of techniques, we had convincingly shown that SAA 
could significantly inhibit the expression and bioactivity of eNOS in human 
endothelial cells. Our results show a marked decrease of eNOS expression in both 
mRNA and protein levels after 24 h SAA incubation. Moreover, its bioactivity was 
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also significantly attenuated which was marked by the reduced release of NO. 
Because NO is a regulator of angiogenesis, we also examined the effects of SAA on 
endothelial proliferation, which is an index of angiogenesis. SAA has been shown to 
attenuate EC proliferation through reduced NO production. Thus, SAA could also 
impair in vitro angiogenesis regulated by eNOS-derived NO   
7.1.4 SAA leads to procoagulation  
The initiation of coagulation plays an important role in thrombus formation, which is 
a major cause of acute coronary events. Either TF induction or TFPI inhibition leads 
to a hypercoagulable state. Interestingly, our results show that SAA could highly 
induce TF and inhibit TFPI, although at different time frames. The inducing effect of 
SAA on TF was faster acting (4-8 h), while its inhibitory effect on TFPI required 
longer exposure time (24-48 h). Our findings suggest that the impact of SAA on 
hemostasis could be sustained for a relative long time by TFPI inhibition beyond the 
transient TF induction. SAA also directly induced activation of p38 MAP kinase 
(p38), p44/42 MAP kinase (ERK1/2), and c-jun terminal NH2 kinase (JNK) in a 
time-dependent manner. The pretreatment of cells with the respective specific 
mitogen-activated protein kinase (MAPK) inhibitors (SB203580, PD98059, and 
SP600125) could block the effects of SAA on TF induction. Hence, the SAA-
dependent TF induction is mediated through MAP kinase pathway which is shared 
with other cytokines, such as TNFα and CRP.   
7.1.5 SAA induces MMP-10 
Inflammatory factors play key a role in ECM destruction and plaque rupture. Many 
soluble cytokines have been shown to lead directly to matrix degradation through 
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MMP induction and activation.
 
Our time-course study has shown that SAA induces 
and activates MMP-10in human endothelial cells and the induction lasted for at least 
48 h. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, suppressed the 
MMP-10 secretion induced by SAA. We further examined COX-2 and its major 
product, prostaglandin E2 (PGE2), as the possible mediator of MMP-10 induction. 
However, direct PGE2 treatment could not induce MMP-10 induction.  
 
7.2 Suggestions for future work 
7.2.1 In vivo study of effects of SAA 
This project provided clear evidence that SAA could lead to endothelial 
proinflammation, dysfunction, procoagulation and MMP induction in cultured human 
endothelial cells. However, because of the limitation of in vitro study, more 
investigations are still needed. Culture cells and medium are different from intact 
endothelium and blood and the human body might response differently. It is 
completely unclear whether elevated SAA in circulation might lead to 
proinflammation of vessels or its effects might be nullified by the body’s anti-
inflammatory response. As such, in vivo study of the effects of SAA on 
atherosclerosis will be useful. SAA transgenic mice which overexpress SAA may be 
a useful candidate to investigate the in vivo atherogenesis of sustained SAA 
stimulation. Additionally, recombinant SAA should be injected into animals to 
observe whether vaso-reactivity is impaired. Only after a successful in vivo study 
with results consistent with the in vitro study can SAA be clearly proven to be 
directly involved in atherosclerosis.      
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7.2.2 SAA-lowering treatment 
Another interesting direction for study is in the effect of SAA-lowering. Recent 
studies have demonstrated that some traditional CAD treatments could also lower the 
levels of inflammatory biomarkers. For example, in CAD patients treated with statins, 
the anti-inflammatory benefits occur much earlier than the lipid-lowering effects.
191
 
Thus, an anti-inflammatory approach might improve clinical outcome in CAD 
patients. It might thus be rewarding to observe the effects of SAA-lowering treatment 
in atherosclerosis mouse model. The in vivo study can be extended to CAD patients if 
the study proves safe and efficacious.  
 
7.3 Summary of major contributions 
This project is the first to examine the direct effects of SAA on atherosclerosis. The 
major contributions of this thesis are summarized below. 
1) Investigating the effects of SAA on endothelial proinflammation, dysfunction and 
procoagulation. These findings may shed light on a new mechanism of atherosclerosis 
in which SAA might be involved in the initial and advanced stages of atherogenesis. 
SAA could be a potential novel therapy target of CAD. SAA-lowering treatment may 
be helpful to prevent and cure CAD. 
2) Discovering the effects of SAA and celecoxib on MMP-10. MMP-10 induction by 
SAA could be alleviated by celecoxib pretreatment. This interesting finding may 
suggest that anti-inflammation therapy might be useful in CAD treatment.  
3) Investigating of the signaling pathway of the SAA effects. NFκB and MAPK 
pathway has been shown to involve in the SAA-induced proinflammation and 
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procoagulation. This finding may strengthen the hypothesis that NFκB and MAPK 
could play universal signaling roles in atherosclerosis. NFκB and MAPK may also be 
target molecules for CAD therapy.  
 
7.4 Conclusion 
This project investigates the direct impacts of SAA on atherosclerosis. SAA induces 
endothelial proinflammation, dysfunction, procoagulation and MMP-10 in cultured 
human endothelial cells. These findings may be helpful to discover a new mechanism 
of atherosclerosis in which SAA plays a role. With more studies being conducted, 
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 Endotoxin level assay by E-TOXATE kits 
Method 
Sigma’s E-TOXATE (Limulus Amebocyte Lysate) test was used to detect the 
endotoxin levels in recombined SAA protein. When exposed to minute quantities of 
endotoxin (lipopolysaccarides from the walls of gram-negative bacteria), the lysate 
increases in opacity as well as viscosity and may gel, depending on the concentration 
of endotoxin. All the procedures were carried out according to the manufactures’ 
manual. Samples, water and Endotoxin Standard Dilution were added directly to the 
bottom of 10 x 75 mm glass culture tubes. E-TOXATE Working Solution was added 
to each tubes and mixed gently. The tubes were covered with Parafilm and incubated 
for 1 h undisturbed at 37ºC. After incubation, the tubes were slowly inverted 180º to 
observe the evidence of gelation. A positive test was the formation of a Hard Gel that 
permits complete inversion of the tube without disruption of the gel. All other results 
(soft gels, turbidity, increase in viscosity, or clear liquid) were considered negative. 
To semi-quantitatively determine the endotoxin level of a sample yielding a positive 
result, a series of dilution was made for each sample to finally obtain a negative test 
result. The endotoxin level of each sample was calculated by multiplying the inverse 
of the highest dilution of sample found positive by the lowest concentration of 
Endotoxin Standard found positive.  
Results 
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For the 8 medium samples (with SAA 20µg/ml) tested, all had less than 7.6EU/ml 
endotoxin. That meant that the endotoxin levels were less than 1 EU/ µg protein in 
SAA preparation, confirming the manufacturers’ statement.   
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Appendix 2  
Detailed ABCA1 expression levels 
3a) Raw signal intensity of ABCA1 in microarray. P: present. 
SAA (20 µg/ml) treatment 
Gene Affy. ID 
C 4h 24h 48h 

















3b) SAA inhibits ABCA1 protein. Blots are representative of 4 individual 
experiments. The results of SAA (20µg/ml, 24h) treatment are comparable to those of 
TNFα (10ng/ml, 24h) treatment. 
ABCA1:  -254KDa 
β-actin:    -42KDa 






The quality of microarray study 
3a). The correlation between signal intensity datasheet from the 2 individual 
GeneChips of each group. High correlation coefficiency and low p value suggest 
good reproducibility of individual samples under a same condition.  
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y = 0.9752x + 14.555
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3b). Raw signal intensity of selected genes in microarray. Data show good calls rates 
between the 2 individual samples of each group.   
SAA (20 µg/ml) treatment 
Gene Affy. ID 








































































































































































































































































The table shows good consistency of the signal intensity between the 2 individual 




Standard Curves of ELISA 
These figures are ELISA standard curves. The standard curves are all strait lines, 
except that of TFPI which is supposed by the kit mannual to be a quantric equation. 
CV: intra-assay coefficient of variation.  
y = 0.0934x - 0.0292
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2
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y = 0.0004x + 0.0369
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Representative raw data of QRT-PCR and ELISA 
5a) Raw crossing point values of QRT-PCR for CAMs.  
 0h      
GAPD 15.23 15.66 15.04 15.04 15.23 15.05 
ICAM1 26.02 27.19  26.31 26.89 26.06 
VCAM1 26.52 27.68 26.43 27.24 27.02 26.79 
E-selectin 33.28 33.63 31.47 33.03 33.91 31.95 
 2h      
GAPD 15.76 14.54 15.16    
ICAM1 17.97 17.78 17.99    
VCAM1 17.99 17 17.75    
E-selectin 18.76 17.39 18.04    
 4h      
GAPD 16.02 15 15.27 15.02   
ICAM1 17.73 17.58 16.93 16.96   
VCAM1  16.54 16.55 17.08   
E-selectin 19.47 16.84 17.43    
 6h      
GAPD 15.54 15.47 15.95    
ICAM1 16.08 16.06 16.58    
VCAM1 16.78 15.72 16.29    
E-selectin 22.88 22.16 21.67    
 8h      
GAPD 15.2 15.28 15.22 15.22   
ICAM1 19.99 20.61 19.95    
VCAM1 21.13 19.46 20.87 20.92   
E-selectin  22.58 22.01 22.77   
 24h      
GAPD 15.55 15.51 15.2    
ICAM1 23.34 23.92 24.34    
VCAM1 24.65 24.78 24.91    
E-selectin 26.97 27.35 28.64    
 48h      
GAPD 15.95 15.84 15.96    
ICAM1 20.48 20.53 20.68    
VCAM1 22.2 22.15 22.2    
SE  26.48 26.26 26.22    
Data represent the crossing point of CAMs and the house keeping gene (GAPDH) in 
HUVECs with SAA 20µg/ml treatment for 0-48 h. The blanks represent that QRT-
PCR was not performed for this gene because of the limited RNA sample amount. 
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5b) Raw crossing points of QRT-PCR for TF.  
 C    
GAPDH 14.96 15.35 15.34  
TF 28.09 28.75 27.7  
 S1.4h    
GAPDH 15.24 15.67 15.03  
TF 23.21 23.51 23.34  
 S10.4h    
GAPDH 15.58 15.44 15.47  
TF 22.65 23.01 22.88  
 S20.4h    
GAPDH 15.93 15.27 15.2 15.18 
TF 20.61 20.62 20.24 20.81 
 S20.2h    
GAPDH 15.54 15.47 15.76  
TF 21.46 21.55 21.61  
 S20.8h    
GAPDH 15.2 15.28 15.22  
TF 21.86 21.82 22  
 S20.16h    
GAPDH 15.44 15.33 15.14  
TF 25.97 25.56 25.24  
 S20.24h    
GAPDH 15.28 15.22 15.35  
TF 27.08 27.32 28.06  
 S20.48h    
GAPDH 15.95 15.84 15.96  
TF 26.53 26.97 27.88  
Data represent the crossing point of TF and GAPDH in HUVECs with SAA 20µg/ml 
treatment for 0-48 h or SAA 0-20µg/ml treatment for 24 h.  
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5c) Raw ELISA absorbance values for TFPI.  
 Cellular TFPI 
C 0.3080 0.3020 0.3020   
S20.24h 0.2060 0.2150 0.2010   
T10.24h 0.2130 0.2055 0.1980 0.2445 0.2385 
 
 Secreted TFPI 
C 0.8810 0.8630 0.8880 
S4h 0.8620 0.8670 0.8420 
T4h 0.8720 0.8610 0.8390 
S1.24h 0.8200 0.8440 0.8320 
S10.24h 0.6310 0.6690 0.7130 
S20.24h 0.6330 0.6020 0.6140 
T10.24h 0.5450 0.5610 0.5440 
C48h 1.0670 1.0240 1.0980 
S48h 0.8890 0.8570 0.8360 
T48h 0.7120 0.7120 0.6950 
Data represent OD450/620 value in HUVECs with SAA 20µg/ml treatment for 0-48 
h or SAA 0-20µg/ml treatment for 24 h. Samples with TNFα 10ng/ml treatment for 0-
48 h are also assayed. 
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5d) Raw ELISA absorbance values for MMP-10.  
 MMP-10 
C 0.2070 0.1870 0.2100 0.2260 
S1 0.2080 0.2470 0.2680  
S10 0.6550 0.6250 0.5790  
S20 0.9820 0.9440 0.8890  
T10 0.9920 1.1410 1.1900  
Data represent OD450/540 value in HUVECs with SAA 0-20µg/ml treatment or 
TNFα 10ng/ml treatment for 24h. 
